WEST Search History

DATE: Friday, October 10, 2003


Set Name side by side	Hit Count	Hit Count Set Name result set		
DB=USPT,PGPB,JPAB,EPAB,DWPI; PLUR=YES; OP=ADJ				
L17 L16 AND v-myc	10	L17		
L16 (microglia)	1068	L16		
L15 human microglia	33	L15		
L14 (L10 AND CD11b AND CD68)	13	L14		
L13 L10 AND CD11\$	91	L13		
L12 L10 AND CD\$	805	L12		
L11 L10 AND CD11	22	L11		
L10 (microglia)	1068	L10		
L9 L8 AND microglia AND human	292	L9		
L8 ((435/325 435/363 435/366 435/368 435/456 435/)!.CCLS.)	/458 14628	L8		
L7 ((435/325)!.CCLS.)	12683	L7		
L6 (435/325,363,366,368,456,458.CCLS.)	0	L6		
L5 Kim-Seung-U.IN.	6	L5		
L4 Kim-S-U.IN.	552	L4		
L3 Kim-S.IN.	179716	L3		
L2 Kim-Seung.IN.	0	L2		
L1 (Kim.IN.)	179716	L1		

END OF SEARCH HISTORY

Entrez-PubMed Page 1 of 2







Entrez PubMed PMC Journals Shuchira Book Search PubMed for CD11 AND human AND microglia Clear Go: Limits Clipboard Preview/Index History Details About Entrez Display Show: 200 Sort Summary Sena ta Text Items 1-8 of 8 One page, Text Version 1. Kuwabara Y, Yokoyama A, Yang L. Toku K, Mori K. Takeda I, Related Articles, Links Shigekawa T, Zhang B, Maeda N, Sakanaka M, Tanaka J. Entrez PubMed Overview Two populations of microglial cells isolated from rat primary mixed glial Help | FAQ cultures. Tulorial J Neurosci Res. 2003 Jul 1;73(1):22-30. New/Noteworthy PMID: 12815705 [PubMed - indexed for MEDLINE] E-Utilifies 2: Schaecher K, Rocchini A, Dinkins J, Matzelle DD, Banik NL. Related Articles, Links **PubMed Services** Journals Database Calpain expression and infiltration of activated T cells in experimental MeSH Database allergic encephalomyelitis over time: increased calpain activity begins with Single Citation Matcher Batch Citation Matcher onset of disease. Clinical Queries J Neuroimmunol. 2002 Aug;129(1-2):1-9. LinkOut PMID: 12161014 [PubMed - indexed for MEDLINE] Cubby 3: Larsson LC, Corbascio M, Widner H, Pearson TC, Larsen CP, Related Articles Links Ekberg H. Related Resources Order Documents Simultaneous inhibition of B7 and LFA-1 signaling prevents rejection of NUM Gateway discordant neural xenografts in mice lacking CD40L. TOXNET Xenotransplantation. 2002 Jan;9(1):68-76. Consumer Health Clinical Alerts PMID: 12005106 [PubMed - indexed for MEDLINE] ClinicalTrials.gov PubMed Central 4: Mizuno T, Yoshihara Y, Inazawa J, Kagamiyama H, Mori K. Related Articles, Links cDNA cloning and chromosomal localization of the human telencephalin Privacy Policy and its distinctive interaction with lymphocyte function-associated antigen-J Biol Chem. 1997 Jan 10;272(2):1156-63. PMID: 8995416 [PubMed - indexed for MEDLINE] 5: Bo L, Peterson JW, Mork S, Hoffman PA, Gallatin WM, Ranschoff Related Articles, Links RM, Trapp BD. Distribution of immunoglobulin superfamily members ICAM-1, -2, -3, and the beta 2 integrin LFA-1 in multiple sclerosis lesions. J Neuropathol Exp Neurol. 1996 Oct;55(10):1060-72. PMID: 8858003 [PubMed - indexed for MEDLINE] 6: Becher B. Antel JP. Related Articles, Links Comparison of phenotypic and functional properties of immediately ex vivo and cultured human adult microglia. Glia. 1996 Sep;18(1):1-10. PMID: 8891687 [PubMed - indexed for MEDLINE] 7: Akiyama H, Kawamata T, Yamada T, Tooyama I, Ishii T, McGeer Related Articles, Links PL.

Expression of intercellular adhesion molecule (ICAM)-1 by a subset of astrocytes in Alzheimer disease and some other degenerative neurological

Acta Neuropathol (Berl). 1993;85(6):628-34. PMID: 8337942 [PubMed - indexed for MEDLINE] Entrez-PubMed Page 2 of 2

Brain microglia constitutively express beta-2 integrins.
J Neuroimmunol. 1990 Nov;30(1):81-93.
PMID: 1977769 [PubMed - indexed for MEDLINE]

Display Summary

Show: 200 Sort Send to Text

One page.


Write to the Help Desk
NCBI | NLM | NIH
Department of Health & Human Services
Freedom of Information Act | Disclaimer

Oct 2 2003 18:06:20

Book







of Medicine 🎎 PubMed Nucleotide Structure PMO Search PubMed for CD68 AND human AND microglia Clear Go Limits Preview/Index History Clipboard Details About Entrez Display Summary Show: 200 Sort Send to Text Items 1-103 of 103 One page. Text Version 1: Morner A. Thomas JA, Bjorling E. Munson PJ, Lucas SB, Related Articles, Links Entrez PubMed MoKnight A. Overview Productive HIV-2 infection in the brain is restricted to Help | FAQ macrophages/microglia. Tutorial AIDS. 2003 Jul 4;17(10):1451-5. New/Noteworthy E-Utilities PMID: 12824782 [PubMed - indexed for MEDLINE] 1. 2: Bukovsky A, Indrapichate K, Fujiwara H, Cekanova M, Avala ME, Belated Articles, Links Dominguez R, Caudle MR, Wimalsena J, Elder RF, Copas P, Foster PubMed Services Journals Database JS, Fernando RI, Henley DC, Upadhyaya NB. MeSH Database Single Citation Matcher Multiple luteinizing hormone receptor (LHR) protein variants, interspecies Batch Citation Matcher reactivity of anti-LHR mAb clone 3B5, subcellular localization of LHR in Clinical Queries human placenta, pelvic floor and brain, and possible role for LHR in the LinkOut Cubby development of abnormal pregnancy, pelvic floor disorders and Alzheimer's disease. Related Resources Reprod Biol Endocrinol. 2003 Jun 3;1(1):46. Epub 2003 Jun 03. Order Documents PMID: 12816543 [PubMed - as supplied by publisher] NLM Gateway TOXNET 73: Kuwabata Y. Yokoyama A. Yang L. Toku K. Mori K. Takeda I. Shigekawa T. Zhang B. Maeda N. Sakanaka M. Tanaka J. Related Articles, Links Consumer Health Clinical Alerts Two populations of microglial cells isolated from rat primary mixed glial Clinics/Trials.gov **PubMed Central** cultures. J Neurosci Res. 2003 Jul 1;73(1):22-30. Privacy Policy PMID: 12815705 [PubMed - indexed for MEDLINE] 4: Lampe JB, Schneider-Schaulies S, Aguzzi A, Related Articles, Links Expression of the interferon-induced MxA protein in viral encephalitis. Neuropathol Appl Neurobiol. 2003 Jun; 29(3):273-9. PMID: 12787324 [PubMed - indexed for MEDLINE] 5: Vallat-Decouvelacre AV, Chretien F, Gras G, Le Pavec G, Dormont Related Articles, Links D. Gray F. Expression of excitatory amino acid transporter-1 in brain macrophages and microglia of HIV-infected patients. A neuroprotective role for activated microglia? J Neuropathol Exp Neurol. 2003 May: 62(5):475-85.

Brain Pathol. 2003 Apr;13(2):144-54. PMID: 12744468 [PubMed - indexed for MEDLINE]

PMID: 12769187 [PubMed - indexed for MEDLINE] 6: Trillo-Pazos G, Diamanturos A, Rislove L, Menza T, Chao W,

Belem P. Sadiq S. Morgello S. Sharer L. Volsky DJ.

7: Deininger MH. Bekure-Nemariam K. Trautmann K. Morgalia M. Related Articles, Links Mcyermann R, Schluesener HJ.

isolated from brain tissue with HIV-1 encephalitis by laser capture

Detection of HIV-1 DNA in microglia/macrophages, astrocytes and neurons

microdissection.

Related Articles, Links

Entrez-PubMed

	Cyclooxygenase-1 and -2 in brains of patients who died of Creutzfeldt-Jakob disease. J Mol Neurosci. 2003 Feb;20(1):25-30. PMID: 12663931 [PubMed - indexed for MEDLINE]	with sporadic
□8:	Ochmichen M, Walter T, Meissner C, Friedrich HJ.	Related Articles, Links
	Time course of cortical hemorrhages after closed traumat statistical analysis of posttraumatic histomorphological at J Neurotrauma. 2003 Jan;20(1):87-103. PMID: 12614591 [PubMed - indexed for MEDLINE]	tic brain injury: Iterations.
□ 9:	Mankowski J., Queen SE, Tarwater PJ, Adams RJ, Guilarte TR.	Related Articles, Links
	Elevated peripheral benzodiazepine receptor expression i immunodeficiency virus encephalitis. J Neurovirol. 2003 Feb;9(1):94-100. PMID: 12587072 [PubMed - indexed for MEDLINE]	n simian
□10	: Petito CK, Adkins B, McCarthy M, Roberts B, Khamis I.	Related Articles, Links
	CD4+ and CD8+ cells accumulate in the brains of acqui immunodeficiency syndrome patients with human immu encephalitis. J Neurovirol. 2003 Feb;9(1):36-44. PMID: 12587067 [PubMed - indexed for MEDLINE]	red modeficiency virus
□11	Wierzba-Bobrowicz T, Gwiazda E, Kosno-Kruszewska E, Lewandowska E, Lechowicz W, Bertrand E, Szpak GM, Schmidt- Sidor B	Related Articles, Links
	Morphological analysis of active microgliarod and ram human brains affected by some neurological diseases (Sa disease and Wilson's disease). Folia Neuropathol. 2002;40(3):125-31. PMID: 12572918 [PubMed - indexed for MEDLINE]	nified microglia in SPE, Alzheimer's
□12	: Rakie S. Zecevie N.	Related Articles, Links
	Early oligodendrocyte progenitor cells in the human feta Glia. 2003 Jan 15;41(2):117-27. PMID: 12509802 [PubMed - indexed for MEDLINE]	l telencephalon.
□ 13	Chen I., Yang P. Kijlstra A.	Related Articles, Links
	Distribution, markers, and functions of retinal microglia. Ocul Immunol Inflamm. 2002 Mar;10(1):27-39. Review. PMID: 12461701 [PubMed - indexed for MEDLINE]	
□14:	Sasaki A. Shoji M. Harigaya Y. Kawarabayashi T. Ikeda M. Naito M. Matsubara F. Abe K. Nakazato Y.	Related Articles, Links
	Amyloid cored plaques in Tg2576 transgenic mice are cligiant plaques, slightly activated microglia, and the lack of filament-typed, dystrophic neurites. Virchows Arch. 2002 Oct;441(4):358-67. Epub 2002 May 01. PMID: 12404061 [PubMed - indexed for MEDLINE]	haracterized by of paired helical
□ 15:	Baker CA, Martin D, Manuelidis L.	Related Articles, Links
	Microglia from Creutzfeldt-Jakob disease-infected brains and show specific mRNA activation profiles. J Virol. 2002 Nov;76(21):10905-13. PMID: 12368333 [PubMed - indexed for MEDLINE]	s are infectious
□16:	Clements JE, Babas T, Mankowski JL, Suryanarayana K, Piatak M	Related Articles, Links

Entrez-PubMed Page 3 of 12

	The central nervous system as a reservoir for simian immunodeficiency virus (SIV): steady-state levels of SIV DNA in brain from acute through asymptomatic infection. J Infect Dis. 2002 Oct 1;186(7):905-13. Epub 2002 Sep 13. PMID: 12232830 [PubMed - indexed for MEDLINE]						
⊞17:	: Itoh M, Hayashi M, Fujioka Y, Nagashima K, Morimatsu Y, Matsuyama H. Related Articles, Links						
	Immunohistological study of globoid cell leukodystropl Brain Dev. 2002 Aug;24(5):284-90. PMID: 12142065 [PubMed - indexed for MEDLINE]	ny.					
□ 18:	Greaves DR, Gordon S.	Related Articles, Links					
	Macrophage-specific gene expression: current paradigm challenges. Int J Hematol. 2002 Jul;76(1):6-15. Review. PMID: 12138897 [PubMed - indexed for MEDLINE]	ns and future					
□ 19:	Lee YB, Nagai A, Kim SU,	Related Articles, Links					
	Cytokines, chemokines, and cytokine receptors in huma J Neurosci Res. 2002 Jul 1;69(1):94-103. PMID: 12111820 [PubMed - indexed for MEDLINE]	n microglia.					
□ 20:	Fiala M, Liu ON, Sayre J, Pop V, Brahmandam V, Graves MC, Vinters HV.	Related Articles, Links					
	Cyclooxygenase-2-positive macrophages infiltrate the Abrain and damage the blood-brain barrier. Eur J Clin Invest. 2002 May;32(5):360-71. PMID: 12027877 [PubMed - indexed for MEDLINE]	alzheimer's disease					
□ 21:	Beschorner R, Nguyen TD, Gozalan F, Pedal I, Mattern R. Schluesener HJ, Meyermann R, Schwab JM.	Related Articles, Links					
	CD14 expression by activated parenchymal microglia/m infiltrating monocytes following human traumatic brain Acta Neuropathol (Berl). 2002 Jun;103(6):541-9. Epub 2002 Jan 30 PMID: 12012085 [PubMed - indexed for MEDLINE]	iniury.					
□ 22:	Schwab JM, Beschomer R, Meyermann R, Gozalan F, Schlussener HJ.	Related Articles, Links					
	Persistent accumulation of cyclooxygenase-1-expressing and macrophages and transient upregulation by endothel brain injury. J Neurosurg. 2002 May;96(5):892-9. PMID: 12005397 [PubMed - indexed for MEDLINE]	g microglial cells ium in human					
□ 23:	Angata T, Kerr SC, Greaves DR, Varki NM, Crocker PR, Varki A.	Related Articles, Links					
firm.	Cloning and characterization of human Siglec-11. A reconsignaling that can interact with SHP-1 and SHP-2 and is tissue macrophages, including brain microglia. J Biol Chem. 2002 Jul 5;277(27):24466-74. Epub 2002 May 01. PMID: 11986327 [PubMed - indexed for MEDLINE]	ently evolved expressed by					
□ 24:	Bernal F. Graus F. Pifarre A. Saiz A. Benyahia B. Ribalta T.	Related Articles, Links					
·	Immunohistochemical analysis of anti-Hu-associated par encephalomyelitis. Acta Neuropathol (Berl). 2002 May;103(5):509-15. Epub 2002 Jan PMID: 11935268 [PubMed - indexed for MEDLINE]	_					
□ 25:	: Doininger MH, Pater S, Strik H, Meyermann R. Related Articles, Links						

	Macrophage/microglial cell subpopulations in glioblastoma multiforme relapses are differentially altered by radiochemotherapy. J Neurooncol. 2001 Dec;55(3):141-7. PMID: 11859968 [PubMed - indexed for MEDLINE]						
□ 26:	D'Aversa TG, Weidenheim KM, Berman JW.	Related Articles, Links					
	CD40-CD40L interactions induce chemokine expression microglia: implications for human immunodeficiency viand multiple sclerosis. Am J Pathol. 2002 Feb;160(2):559-67. PMID: 11839576 [PubMed - indexed for MEDLINE]	n by human irus encephalitis					
□ 27:	Nagai A, Nakagawa E, Hatori K, Choi HB, McLarnon JG, Lee MA, Kim SU.	Related Articles, Links					
	Generation and characterization of immortalized human lines: expression of cytokines and chemokines. Neurobiol Dis. 2001 Dec;8(6):1057-68. PMID: 11741401 [PubMed - indexed for MEDLINE]	microglial cell					
□ 28:	Fillebeen C, Ruchoux MM, Mitchell V, Vincent S, Benaissa M, Pierce A.	Related Articles, Links					
	Lactoferrin is synthesized by activated microglia in the l nigra and its synthesis by the human microglial CHME of upregulated by tumor necrosis factor alpha or 1-methyl- phenylpyridinium treatment. Brain Res Mol Brain Res. 2001 Nov 30;96(1-2):103-13. PMID: 11731015 [PubMed - indexed for MEDLINE]	cell line is					
□ 29:	Wang TH, Donaldson YK, Brettle RP, Bell JE, Simmonds P.	Related Articles, Links					
	Identification of shared populations of human immunod- l infecting microglia and tissue macrophages outside the system. J Virol. 2001 Dec;75(23):11686-99. PMID: 11689650 [PubMed - indexed for MEDLINE]	eficiency virus type e central nervous					
□30:	Zink MC, Coleman GD, Mankowski JL, Adams RJ, Tarwater PM, Fox K, Clements JE,	Related Articles, Links					
<u> </u>	Increased macrophage chemoattractant protein-1 in cere precedes and predicts simian immunodeficiency virus er J Infect Dis. 2001 Oct 15;184(8):1015-21. Epub 2001 Sep 10. Errat 2002 Jun 1;185(11):1696. PMID: 11574916 [PubMed - indexed for MEDLINE]	ncephalitis.					
□ 31:	Peterson JW, Bo L. Mork S, Chang A, Trapp BD.	Related Articles, Links					
	Transected neurites, apoptotic neurons, and reduced inflacortical multiple sclerosis lesions. Ann Neurol. 2001 Sep;50(3):389-400. PMID: 11558796 [PubMed - indexed for MEDLINE]	ammation in					
□ 32:	Heneka MT, Wiesinger H, Dumitresou-Ozimek L, Riederer P, Feinstein DL, Klockgether T.	Related Articles, Links					
((1)	Neuronal and glial coexpression of argininosuccinate syninducible nitric oxide synthase in Alzheimer disease. J Neuropathol Exp Neurol. 2001 Sep;60(9):906-16. PMID: 11556547 [PubMed - indexed for MEDLINE]	nthetase and					
□33:	de Groot CJ, Hulshof S. Hoozemans JJ, Veerhuis R.	Related Articles, Links					
	Establishment of microglial cell cultures derived from postmortem human adult brain tissue: immunophenotypical and functional characterization.						

Microsc Res Tech. 2001 Jul 1;54(1):34-9. PMID: 11526955 [PubMed - indexed for MEDLINE] 34: Paloneva J. Autti T. Raininko R. Partanen J. Salonen O. Puranen Related Articles, Links M. Hakola P. Haltia M. CNS manifestations of Nasu-Hakola disease: a frontal dementia with bone Neurology. 2001 Jun 12;56(11):1552-8. PMID: 11402114 [PubMed - indexed for MEDLINE] 35: Yuan L. Neufeld AH. Related Articles, Links Activated microglia in the human glaucomatous optic nerve head. J Neurosci Res. 2001 Jun 1;64(5):523-32. PMID: 11391707 [PubMed - indexed for MEDLINE] 36: Mittelbronn M. Dietz K. Schluesener HJ. Meyermann R. Related Articles, Links Local distribution of microglia in the normal adult human central nervous system differs by up to one order of magnitude. Acta Neuropathol (Berl). 2001 Mar;101(3):249-55. PMID: 11307625 [PubMed - indexed for MEDLINE] 737: Klein R, Roggendorf W. Related Articles, Links Increased microglia proliferation separates pilocytic astrocytomas from diffuse astrocytomas: a double labeling study. Acta Neuropathol (Berl). 2001 Mar; 101(3):245-8. PMID: 11307624 [PubMed - indexed for MEDLINE] 38: Kunkel P, Muller S, Schirmacher P, Stavrou D, Filibrandt R, Related Articles, Links Westphal M. Lamszus K. Expression and localization of scatter factor/hepatocyte growth factor in human astrocytomas. Neuro-oncol. 2001 Apr;3(2):82-8. PMID: 11296484 [PubMed - indexed for MEDLINE] 39: Schwab JM, Nguyen TD, Meyermann R, Schluesener HJ. Related Articles, Links Human focal cerebral infarctions induce differential lesional interleukin-16 (IL-16) expression confined to infiltrating granulocytes, CD8+ Tlymphocytes and activated microglia/macrophages. J Neuroimmunol. 2001 Mar 1;114(1-2):232-41. PMID: 11240037 [PubMed - indexed for MEDLINE] 40: Schwab JM, Schluesener HJ, Seid K, Meyermann R. Related Articles, Links IL-16 is differentially expressed in the developing human fetal brain by microglial cells in zones of neuropoesis. Int J Dev Neurosci. 2001 Feb;19(1):93-100. PMID: 11226758 [PubMed - indexed for MEDLINE] 41: Schluesener HJ, Kromsner PG, Meyermann R. Related Articles, Links Heme oxygenase-1 in lesions of human cerebral malaria. Acta Neuropathol (Berl). 2001 Jan;101(1):65-8. PMID: 11194943 [PubMed - indexed for MEDLINE] 17 42: Bornemann KD, Wiederhold KH, Pauli C, Ermini F, Stalder M. Related Articles, Links Schnell L, Sommer B. Jucker M, Staufenbiel M. Abeta-induced inflammatory processes in microglia cells of APP23 transgenic mice. Am J Pathol. 2001 Jan; 158(1):63-73.

PMID: 11141480 [PubMed - indexed for MEDLINE]

Entrez-PubMed Page 6 of 12

43	: Amold SE, Han LY, Clark CM, Grossman M, Trojanowski JQ.	Related Articles, Links
	Quantitative neurohistological features of frontotempora Neurobiol Aging. 2000 Nov-Dec;21(6):913-9, PMID: 11124442 [PubMed - indexed for MEDLINE]	l degeneration.
□44	: Yang P. Das PK, Kijlstra A.	Related Articles, Links
	Localization and characterization of immunocompetent retina. Ocul Immunol Inflamm. 2000 Sep;8(3):149-57. PMID: 11120576 [PubMed - indexed for MEDLINE]	cells in the human
□ 45	Fauser S. Deininger MH, Kremsner PG, Magdolen V, Luther T, Meyermann R, Schluesener HJ.	Related Articles, Links
	Lesion associated expression of urokinase-type plasmino receptor (uPAR, CD87) in human cerebral malaria. J Neuroimmunol. 2000 Nov 1;111(1-2):234-40. PMID: 11063844 [PubMed - indexed for MEDLINE]	ogen activator
□ 46:	Schmitt AB, Buss A, Breuer S, Brook GA, Pech K, Martin D, Schoenen J, Noth J, Love S, Schroder JM, Kreutzberg GW, Nacimiento W.	Related Articles, Links
	Major histocompatibility complex class II expression by microglia caudal to lesions of descending tracts in the hunot associated with a T cell response. Acta Neuropathol (Berl). 2000 Nov;100(5):528-36. PMID: 11045675 [PubMed - indexed for MEDLINE]	activated man spinal cord is
□ 47:	Postler E, Rímner A, Beschorner R, Schluesener HJ, Meyermann R.	Related Articles, Links
	Corrigendum to "Allograft-inflammatory-factor-1 is upre microglial cells in human cerebral infarctions". [J. Neuro 91](1)[Corrected and republished from J Neuroimmunol. (1):85-91] J Neuroimmunol. 2000 Aug 1;108(1-2):244-50. PMID: 10900360 [PubMed - indexed for MEDLINE]	immunol, 104, 85-
□ 48:	Albright AV, Shieh JT, O'Connor MJ, Gonzalez-Scarano F.	Related Articles, Links
	Characterization of cultured microglia that can be infecte J Neurovirol. 2000 May;6 Suppl 1:S53-60. PMID: 10871766 [PubMed - indexed for MEDLINE]	d by HIV-1.
□ 49:	Schwab JM, Nguyen TD, Postler E, Meyermann R, Schluesener HJ.	Related Articles, Links
	Selective accumulation of cyclooxygenase-1-expressing a cells/macrophages in lesions of human focal cerebral isch Acta Neuropathol (Berl). 2000 Jun;99(6):609-14. PMID: 10867793 [PubMed - indexed for MEDLINE]	microglial aemia.
ີ 50:	Sasaki A, Nakazato Y, Ogawa A, Sugihara S.	Related Articles, Links
	The immunophenotype of perivascular cells in the human Pathol Int. 1996 Jan;46(1):15-23. PMID: 10846545 [PubMed - indexed for MEDLINE]	ı brain.
51:	Arends YM. Duyckaerts C. Rozemuller JM. Eikelenboom P. Hauw J.J.	Related Articles, Links
لنتنا	Microglia, amyloid and dementia in alzheimer disease. A Neurobiol Aging. 2000 Jan-Feb;21(1):39-47. PMID: 10794847 [PubMed - indexed for MEDLINE]	correlative study.
	Sandmair AM, Turunen M, Tyvnela K, Loimas S, Vainio P	

□ 52:	Vanninen R, Vapalahti M, Bjerkvig R, Janne J, Yla-Herttuala S.	Related Articles, Links
	Herpes simplex virus thymidine kinase gene therapy in 6 BT4C glioma model: effect of the percentage of thymid glioma cells on treatment effect, survival time, and tissu Cancer Gene Ther. 2000 Mar;7(3):413-21. PMID: 10766347 [PubMed - indexed for MEDLINE]	ine kinase-positive
□ 53:	Postler E, Rimner A, Beschorner R, Schluesener HJ, Meyermann R.	Related Articles, Links
	Allograft-inflammatory-factor-1 is upregulated in micro human cerebral infarctions. J Neuroimmunol. 2000 Apr 3;104(1):85-91. Corrected and republis Neuroimmunol 2000 Aug 1;108(1-2):244-50. PMID: 10683518 [PubMed - indexed for MEDLINE]	
□ 54:	Kulla A. Liigant A. Piirsoo A. Rippin G. Asser T.	Related Articles, Links
	Tenascin expression patterns and cells of monocyte line human gliomas. Mod Pathol. 2000 Jan;13(1):56-67. PMID: 10658911 [PubMed - indexed for MEDLINE]	age: relationship in
□ 55:	An SF, Groves M, Giometto B, Beckett AA, Scaravilli F.	Related Articles, Links
	Detection and localisation of HIV-1 DNA and RNA in f brain by polymerase chain reaction/in situ hybridisation Acta Neuropathol (Berl). 1999 Nov;98(5):481-7. PMID: 10541871 [PubMed - indexed for MEDLINE]	
□ 56:	An SF, Groves M, Gray F, Scaravilli F.	Related Articles, Links
	Early entry and widespread cellular involvement of HIV of HIV-1 positive asymptomatic individuals. J Neuropathol Exp Neurol. 1999 Nov;58(11):1156-62. PMID: 10560658 [PubMed - indexed for MEDLINE]	'-1 DNA in brains
□ 57:	Tomlinson GS, Simmonds P, Busuttil A, Chiswick A, Bell JE.	Related Articles, Links
	Upregulation of microglia in drug users with and without HIV infection. Neuropathol Appl Neurobiol. 1999 Oct;25(5):369-79. PMID: 10564526 [PubMed - indexed for MEDLINE]	nt pre-symptomatic
□58:	Di Patre PL. Read SL, Cummings JL, Tomiyasu U, Vartavarian LM, Secor DL. Vinters HV.	Related Articles, Links
	Progression of clinical deterioration and pathological ch with Alzheimer disease evaluated at biopsy and autopsy Arch Neurol. 1999 Oct;56(10):1254-61. PMID: 10520942 [PubMed - indexed for MEDLINE]	anges in patients
□59:	Kobayashi K, Hayashi M, Fukutani Y, Miyazu K, Shiozawa M, Muramori F, Aoki T, Koshino Y.	Related Articles, Links
	KP1 expression of ghost Pick bodies, amyloid P-positive selective nigral degeneration in early onset Picks disease Clin Neuropathol. 1999 Sep-Oct;18(5):240-9. Review. PMID: 10505433 [PubMed - indexed for MEDLINE]	
⊞ 60:	Pouly S, Becher B, Blain M, Antel JP.	Related Articles, Links
	Expression of a homologue of rat NG2 on human micros Glia. 1999 Sep;27(3):259-68. PMID: 10457372 [PubMed - indexed for MEDLINE]	glia.
	Knott RM, Robertson M, Muckersie E, Folefac VA, Fairhurst FE,	Related Articles, Links
nih.gov/	/entrez/guery_fcgi?CMD=search&DR=PubMed	10/10/03

61: Wileman SM, Forrester JV. A model system for the study of human retinal angiogenesis: activation of monocytes and endothelial cells and the association with the expression of the monocarboxylate transporter type 1 (MCT-1). Diabetologia. 1999 Jul;42(7):870-7. PMID: 10440131 [PubMed - indexed for MEDLINE] 62: Rezaie P. Patel K. Male DK. Related Articles, Links Microglia in the human fetal spinal cord-patterns of distribution, morphology and phenotype. Brain Res Dev Brain Res. 1999 Jun 8:115(1):71-81. PMID: 10366704 [PubMed - indexed for MEDLINE] 63: Wagner S, Czub S, Greif M, Vince GH, Suss N, Kerkau S, Related Articles, Links Rieckmann P. Roggendorf W. Roosen K. Tonn K. Microglial/macrophage expression of interleukin 10 in human glioblastomas. Int J Cancer. 1999 Jul 2;82(1):12-6. PMID: 10360813 [PubMed - indexed for MEDLINE] 64: Ochmichen M. Theuerkauf I. Meissner C. Related Articles, Links Is traumatic axonal injury (AI) associated with an early microglial activation? Application of a double-labeling technique for simultaneous detection of microglia and AI. Acta Neuropathol (Berl). 1999 May;97(5):491-4. PMID: 10334486 [PubMed - indexed for MEDLINE] 65: Aoki T, Kobayashi K, Isaki K. Related Articles, Links Microglial and astrocytic change in brains of Creutzfeldt-Jakob disease: an immunocytochemical and quantitative study. Clin Neuropathol. 1999 Mar-Apr;18(2):51-60. PMID: 10192699 [PubMed - indexed for MEDLINE] 66: Love S, Barber R, Wilcock GK. Related Articles, Links Increased poly(ADP-ribosyl)ation of nuclear proteins in Alzheimer's disease. Brain. 1999 Feb;122 (Pt 2):247-53. PMID: 10071053 [PubMed - indexed for MEDLINE] 67: Reynolds WF, Rhees J, Maciejewski D, Paladino T, Sieburg H, Related Articles, Links Maki RA, Masliah E. Myeloperoxidase polymorphism is associated with gender specific risk for Alzheimer's disease. Exp Neurol. 1999 Jan;155(1):31-41. PMID: 9918702 [PubMed - indexed for MEDLINE] 17 68: Katsetos CD, Fincke JE, Legido A, Lischner HW, de Chadarevian Related Articles, Links JP, Kaye EM, Platsoupas CD, Oleszak EL. Angiocentric CD3(+) T-cell infiltrates in human immunodeficiency virus type 1-associated central nervous system disease in children. Clin Diagn Lab Immunol. 1999 Jan;6(1):105-14. PMID: 9874673 [PubMed - indexed for MEDLINE] 69: Zhao ML, Liu JS, He D, Dickson DW, Lee SC. Related Articles, Links Inducible nitric oxide synthase expression is selectively induced in astrocytes isolated from adult human brain. Brain Res. 1998 Dec 7;813(2):402-5.

PMID: 9838203 [PubMed - indexed for MEDLINE]

Entrez-PubMed Page 9 of 12

₹ 70:	Andjelkovic AV, Nikolic B, Pachter JS, Zecevic N.	Related Articles, Links
	Macrophages/microglial cells in human central nervous development: an immunohistochemical study. Brain Res. 1998 Dec 14;814(1-2):13-25. PMID: 9838024 [PubMed - indexed for MEDLINE]	system during
□ 71:	Schmitt AB, Brook GA, Buss A, Nacimiento W, Noth J. Kreutzberg GW.	Related Articles, Links
	Dynamics of microglial activation in the spinal cord afte infarction are revealed by expression of MHC class II an Neuropathol Appl Neurobiol. 1998 Jun;24(3):167-76. PMID: 9717181 [PubMed - indexed for MEDLINE]	r cerebral tigen.
□72:	Mesquita R. Castanos-Velez E. Biberfeld P. Trojan RM. de Siqueira MM.	Related Articles, Links
	Measles virus antigen in macrophage/microglial cells and subacute sclerosing panencephalitis. APMIS. 1998 May;106(5):553-61. PMID: 9674893 [PubMed - indexed for MEDLINE]	d astrocytes of
□73:	Zeoevic N, Andjelkovic A, Matthieu JM, Tosic M.	Related Articles, Links
	Myelin basic protein immunoreactivity in the human em Brain Res Dev Brain Res. 1998 Jan 14;105(1):97-108. PMID: 9497084 [PubMed - indexed for MEDLINE]	bryonic CNS.
□74:	Zecevic N. Andjelkovic A, Matthieu J. Tosic M.	Related Articles, Links
	Myelin basic protein immunoreactivity in the human embrain Res Dev Brain Res. 1998 Jan 14;105(1):97-108. PMID: 9473608 [PubMed - as supplied by publisher]	bryonic CNS
□75:	Kobayashi K. Muramori F. Aoki T. Havashi M. Miyazu K. Fukutani Y. Mukai M. Koshino F.	Related Articles, Links
	KP-1 is a marker for extraneuronal neurofibrillary tangle plaques in Alzheimer diseased brains. Dement Geriatr Cogn Disord. 1998 Jan-Feb;9(1):13-9. PMID: 9469259 [PubMed - indexed for MEDLINE]	s and senile
□76:	Vowinckel E. Reutens D, Becher B, Verge G, Evans A, Owens T. Antel JP.	Related Articles, Links
Ų.	PK11195 binding to the peripheral benzodiazepine recep microglia activation in multiple sclerosis and experiment encephalomyelitis. J Neurosci Res. 1997 Oct 15;50(2):345-53. PMID: 9373043 [PubMed - indexed for MEDLINE]	tor as a marker of al autoimmune
□ 77:	Dick AD, Pell M, Brew BJ, Foulcher E, Sedgwick JD.	Related Articles, Links
	Direct ex vivo flow cytometric analysis of human microg expression: examination of central nervous system biopsy HIV-seropositive patients and patients with other neurolo AIDS. 1997 Nov 15;11(14):1699-708. PMID: 9386804 [PubMed - indexed for MEDLINE]	specimens from
□ 78:	McKechnie NM, Gurr W, Braun G.	Related Articles, Links
(<u>1931)</u>	Immunization with the cross-reactive antigens Ov39 from volvulus and hr44 from human retinal tissue induces ocul activates retinal microglia. J Infect Dis. 1997 Nov;176(5):1334-43. PMID: 9359736 [PubMed - indexed for MEDLINE]	n Onchocerca ar pathology and

Entrez-PubMed Page 10 of 12

179	Roos RA.	Related Articles, Links
	Association of vascular amyloid beta and cells of the morphagocyte system in hereditary cerebral hemorrhage wit (Dutch) and Alzheimer disease. J Neuropathol Exp Neurol. 1997 Mar;56(3):273-84. PMID: 9056541 [PubMed - indexed for MEDLINE]	ononuclear th amyloidosis
□80:	Makrigeorgi-Butera M, Hagel C, Laas R, Puschel K, Stavrou D.	Related Articles, Links
	Comparative brain pathology of HIV-seronegative and Haddicts. Clin Neuropathol. 1996 Nov-Dec;15(6):324-9. PMID: 8937778 [PubMed - indexed for MEDLINE]	HIV-infected drug
□ 81:	Fox RJ, Levin MC, Jacobson S.	Related Articles, Links
	Tumor necrosis factor alpha expression in the spinal corlymphotrophic virus type I associated myelopathy/tropic paraparesis patients. J Neurovirol. 1996 Oct;2(5):323-9. PMID: 8912208 [PubMed - indexed for MEDLINE]	d of human T-cell cal spastic
□ 82:	Lue LF, Brachova L, Walker DG, Rogers J.	Related Articles, Links
	Characterization of glial cultures from rapid autopsies of control patients. Neurobiol Aging. 1996 May-Jun;17(3):421-9. PMID: 8725904 [PubMed - indexed for MEDLINE]	f Alzheimer's and
□ 83:	Hulette CM.	Related Articles, Links
	Microglioma, a histiocytic neoplasm of the central nervo Mod Pathol. 1996 Mar;9(3):316-9. PMID: 8685234 [PubMed - indexed for MEDLINE]	ous system.
≣ 84:	Provis JM, Diaz CM, Penfold PL.	Related Articles, Links
	Microglia in human retina: a heterogeneous population v ontogenies. Perspect Dev Neurobiol. 1996;3(3):213-22. Review. PMID: 8931095 [PubMed - indexed for MEDLINE]	vith distinct
≣85:	Kupinski J. Kaluza J. Kumar P. Kumar S.	Related Articles, Links
	Immunocytochemical studies of cellular reaction in hum stroke. MAB anti-CD68 stains macrophages, astrocytes a cells in infarcted area. Folia Neuropathol. 1996;34(1):17-24. PMID: 8855083 [PubMed - indexed for MEDLINE]	an ischemic brain and microglial
□ 86:	Ochmichen M. Meissner C. Reiter A. Birkholz M.	Related Articles, Links
	Neuropathology in non-human immunodeficiency virus- addicts: hypoxic brain damage after chronic intravenous Acta Neuropathol (Berl). 1996;91(6):642-6. PMID: 8781664 [PubMed - indexed for MEDLINE]	infected drug drug abuse.
□ 87:	Engel S, Wehner HD, Meyermann R.	Related Articles, Links
	Expression of microglial markers in the human CNS afte injury. Acta Neurochir Suppl (Wien). 1996;66:89-95. PMID: 8780804 [PubMed - indexed for MEDLINE]	r closed head
	Dollard SC, James HJ, Sharer LR, Epstein LG, Gelbard HA	

₩88	Dewhurst S.	Related Articles, Links
	Activation of nuclear factor kappa B in brains from chil encephalitis. Neuropathol Appl Neurobiol. 1995 Dec;21(6):518-28. PMID: 8745241 [PubMed - indexed for MEDLINE]	dren with HIV-1
T 89:	Muhleisen H, Gehrmann J, Meyermann R.	Related Articles, Links
	Reactive microglia in Creutzfeldt-Jakob disease. Neuropathol Appl Neurobiol. 1995 Dec;21(6):505-17. PMID: 8745240 [PubMed - indexed for MEDLINE]	
□ 90 :	Ranki A, Nyberg M, Ovod V, Haltia M, Elovaara I, Raininko R, Haapasalo H, Krohn K.	Related Articles, Links
	Abundant expression of HIV Nef and Rev proteins in bruvivo is associated with dementia. AIDS. 1995 Sep;9(9):1001-8. PMID: 8527071 [PubMed - indexed for MEDLINE]	ain astrocytes in
T. 91:	Janabi N, Peudenier S, Heron B, Ng KH, Tardieu M.	Related Articles, Links
	Establishment of human microglial cell lines after transficultures of embryonic microglial cells with the SV40 land Neurosci Lett. 1995 Aug 4;195(2):105-8. PMID: 7478261 [PubMed - indexed for MEDLINE]	
1 92:	Ulvestad E, Williams K, Bjerkvig R, Tiekotter K, Antel J, Matre R	Related Articles, Links
	Human microglial cells have phenotypic and functional common with both macrophages and dendritic antigen-p J Leukoe Biol. 1994 Dec;56(6):732-40. PMID: 7996050 [PubMed - indexed for MEDLINE]	
∏ 93;	Lee SC, Liu W, Brosnan CF, Dickson DW.	Related Articles, Links
	GM-CSF promotes proliferation of human fetal and adu primary cultures. Glia. 1994 Dec;12(4):309-18. PMID: 7890333 [PubMed - indexed for MEDLINE]	lt microglia in
□94:	Ulvestad E, Williams K, Mork S, Antel J, Nyland H.	Related Articles, Links
	Phenotypic differences between human monocytes/mace microglial cells studied in situ and in vitro. J Neuropathol Exp Neurol. 1994 Sep;53(5):492-501. PMID: 8083690 [PubMed - indexed for MEDLINE]	rophages and
□ 95:	Weis S, Neuhaus B, Mehraein P.	Related Articles, Links
	Activation of microglia in HIV-1 infected brains is not opresence of HIV-1 antigens. Neuroreport. 1994 Jul 21;5(12):1514-6. PMID: 7948851 [PubMed - indexed for MEDLINE]	lependent on the
5 96:	Jaspars EH. Bloomena E. Bonnet P. Scheper RJ, Kaiserling E. Meijer CJ.	Related Articles, Links
	A new monoclonal antibody (3A5) that recognises a fixed epitope on tissue macrophages and monocytes. J Clin Pathol. 1994 Mar;47(3):248-52. PMID: 7512995 [PubMed - indexed for MEDLINE]	ative resistant
□97:	Iwasaki Y, Sako K, Ohara Y, Miyazawa M, Minegishi M. Tsuchiya S, Konno T.	Related Articles, Links
	Subacute panencephalitis associated with chronic graft-	versus-host disease.

	Acta Neuropathol (Berl). 1993;85(5):566-72. PMID: 8493865 [PubMed - indexed for MEDLINE]	
□98:	Sasaki A, Hirato J, Nakazato Y.	Related Articles, Links
	Immunohistochemical study of microglia in the Creutzfi brain. Acta Neuropathol (Berl). 1993;86(4):337-44. PMID: 8256583 [PubMed - indexed for MEDLINE]	eldt-Jakob diseased
□99:	Lyman WD, Hatch WC, Pousada E, Stephney G, Rashbaum WK, Weidenheim KM.	Related Articles, Links
	Human fetal myelinated organotypic cultures. Brain Res. 1992 Dec 18;599(1):34-44. PMID: 1493548 [PubMed - indexed for MEDLINE]	
□ 100	: Lee SC, Liu W, Brosnan CF, Diokson DW.	Related Articles, Links
	Characterization of primary human fetal dissociated ce system cultures with an emphasis on microglia. Lab Invest. 1992 Oct;67(4):465-76. PMID: 1359193 [PubMed - indexed for MEDLINE]	ntral nervous
101	: Hulette CM, Downey BT, Burger PC.	Related Articles, Links
	Macrophage markers in diagnostic neuropathology. Am J Surg Pathol. 1992 May;16(5):493-9. Erratum in: Am J Surg (10):1029. PMID: 1376020 [PubMed - indexed for MEDLINE]	Pathol 1992 Oct;16
102	: Hutchins KD, Dickson DW, Rashbaum WK, Lyman WD.	Related Articles, Links
	Localization of microglia in the human fetal cervical sp Brain Res Dev Brain Res. 1992 Apr 24;66(2):270-3. PMID: 1606692 [PubMed - indexed for MEDLINE]	oinal cord.
□ 103	Penfold PL, Madigan MC, Provis JM.	Related Articles, Links
	Antibodies to human leucocyte antigens indicate subpomicroglia in human retina. Vis Neurosci. 1991 Oct;7(4):383-8. PMID: 1751423 [PubMed - indexed for MEDLINE]	pulations of
Display	Summary Show: 200 Sort Se	anato Text ☀
	Items 1-103 of 103	One page.

Write to the Help Desk NCBI | NLM | NIH Department of Health & Human Services Freedom of Information Act | Disclaimer

Oot 2 2003 18:06:20

Entrez-PubMed Page 1 of 1








***************************************			**	. 4004R 5400.	Arman and and	****	of	Medicine	2018028	
Entrez	PubMed	۸	lucleotide	Protein	Genom	9	Shuchare	PMC	Journals	Book
Search F	ubMed	fo	or viral vec	tor AND hu	man AND r	nicroglia	3	Go Cle	ar	
		:	imits	Preview	/Index	Histo	ory	Clipboard	D	etails
About Entre		Displa	y Summ	ary	Show	,: 20	Sort	¥ Ser	id to Text	*
Text Version	1		Ite	ms 1-5 of !	5				Ot	ne page.
maken m. m.		□ 1::	Cartier N.					ř	Related Articia	s, Links
Entrez Put Overview Help FAQ Tutorial			Curr Opin M	Iol Ther. 200	ies for X-l 11 Aug;3(4): led - indexed	357-61.	Review.	odystrophy	7.	
New/Notewo E-Utilities	ortny	□ 2:	Boutet A, Al	tmeyer R, H	lery C, Tardi	on M.		f	Related Article	s, Links
PubMed S Journals De McSH Date! Single Citati	tabase sase on Matcher		astrocytes AIDS. 2000	induced b Dec 1;14(17	y HIV-1-in	fected	macropha	0/41 in tox ges.	cicity to hur	nan
Batch Citation Clinical Que		□3::	van Den Pol	AN, Mocan	ki E. Saeder	up N, V	icira J. Meic	<u>r TJ.</u>	Related Article	s, Links
Canos unenes LinkOur Cubby Related Resources		₩ 🚞 .	J Neurosci. 1	999 Dec 15	1 tropism, 1 ;19(24):1094 [ed - indexed	8-65.		ene transfe	r in brain.	
Order Docui NUM Gatew		□ 4:	Bartlett JS, S	amulski RJ,	McCown T.	<u>I.</u>		F	telated Article	s, Links
TOXNET Consumer I Clinical Aler ClinicalTriak	lealin s sgov		Hum Gene T	her. 1998 M	ptake of a lay 20;9(8):1 d - indexed f	181-6.		rirus type 2	in brain.	
PubMed Ce.	าแลเ	□ 5:]	Wood MJ. B	ymes AP, P	faff DW. Ral	kin SD.	Charlton H	<u>M.</u> §	lelated Article	s, Links
Privacy Polk	y		vectors. Gene Ther. 1	994 Sep;1(5	_			NS with de	fective HS	V-1
		Displa	y Summa Itea	ary ns 1-5 of 5	Show	: 20	Sort	* Ser	d to Text Or	ne page.

Write to the Help Desk NCBI | NLM | NIH Department of Health & Human Services Freedom of Information Act | Disclaimer

Oct 2 1003 18:06: 20







PubMed Hinter Nucleotide Protein Shuchare PMO Book Search PubMed Go for human AND microglia AND myc Clear History Limits Preview/Index Clipboard Details

About Entrez

Display Summary Show: 20 Sort Sens to Text

1: Nagai A. Nakagawa E. Hatori K. Choi HB. McLarnou JG, Lee MA. Related Articles, Links

Entrez Publ/sed Overview Help | FAQ Tutorial New/Noteworthy E-Utilities

Text Version

PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Citaical Queries
LinkOut
Cubby

Related Resources Order Documents NLM Gateway TOXNET Consumer Health Clinical Alerts Clinical Triats gov PubMed Central

Privacy Policy

Generation and characterization of immortalized human microglial cell lines: expression of cytokines and chemokines.

Neurobiol Dis. 2001 Dec;8(6):1057-68.

PMID: 11741401 [PubMed - indexed for MEDLINE]

Write to the Help Desk


NCBI | NLM | NIH

Department of Health & Human Services
Freedom of Information Act | Disclaimer

Oct 2 2003 18:06:20







Search PubMed

for amphotropic AND human AND microglia
Limits Preview/Index History

Protein

Go Clear Clipboard

Structure

Details

Book

No items found.

Nucleotide

Text Version

Entrez PubMed Overview Help | FAQ Tutorial New/Noteworthy E-Utilities

PubMed Services Journals Database MeSH Database Single Citation Matcher Batch Citation Matcher Clinical Queries LinkOui Cubby

Related Resources Order Documents NLM Gateway TOXNET Consumer Health Clinical Alerte Clinical Triats gov PubMed Central

Privacy Policy

Write to the Help Desk
NCBI | NLM | NIH
Department of Health & Human Services
Freedom of Information Act | Disclaimer

Oct 2 2003 18:06:20

Connecting via Winsock to STN Welcome to STN International! Enter x:x * * * * * * * * * * Welcome to STN International * * * * * * * * * * * * FILE 'HOME' ENTERED AT 15:47:55 ON 10 OCT 2003 => file BIOSCIENCE FILE 'ADISCTI' ENTERED AT 15:48:05 ON 10 OCT 2003 COPYRIGHT (C) 2003 Adis Data Information BV FILE 'ADISINSIGHT' ENTERED AT 15:48:05 ON 10 OCT 2003 COPYRIGHT (C) 2003 Adis Data Information BV FILE 'ADISNEWS' ENTERED AT 15:48:05 ON 10 OCT 2003 COPYRIGHT (C) 2003 Adis Data Information BV FILE 'AGRICOLA' ENTERED AT 15:48:05 ON 10 OCT 2003 FILE 'ANABSTR' ENTERED AT 15:48:05 ON 10 OCT 2003 COPYRIGHT (c) 2003 THE ROYAL SOCIETY OF CHEMISTRY (RSC) FILE 'AQUASCI' ENTERED AT 15:48:05 ON 10 OCT 2003 COPYRIGHT 2003 FAO (On behalf of the ASFA Advisory Board). All rights reserved. FILE 'BIOBUSINESS' ENTERED AT 15:48:05 ON 10 OCT 2003 COPYRIGHT (C) 2003 Biological Abstracts, Inc. (BIOSIS) FILE 'BIOCOMMERCE' ENTERED AT 15:48:05 ON 10 OCT 2003 COPYRIGHT (C) 2003 BioCommerce Data Ltd. Richmond Surrey, United Kingdom. All rights reserved FILE 'BIOSIS' ENTERED AT 15:48:05 ON 10 OCT 2003 COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC.(R) FILE 'BIOTECHABS' ACCESS NOT AUTHORIZED FILE 'BIOTECHDS' ENTERED AT 15:48:05 ON 10 OCT 2003 COPYRIGHT (C) 2003 THOMSON DERWENT AND INSTITUTE FOR SCIENTIFIC INFORMATION FILE 'BIOTECHNO' ENTERED AT 15:48:05 ON 10 OCT 2003 COPYRIGHT (C) 2003 Elsevier Science B.V., Amsterdam. All rights reserved. FILE 'CABA' ENTERED AT 15:48:05 ON 10 OCT 2003 COPYRIGHT (C) 2003 CAB INTERNATIONAL (CABI) FILE 'CANCERLIT' ENTERED AT 15:48:05 ON 10 OCT 2003 FILE 'CAPLUS' ENTERED AT 15:48:05 ON 10 OCT 2003 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS) FILE 'CEABA-VTB' ENTERED AT 15:48:05 ON 10 OCT 2003 COPYRIGHT (c) 2003 DECHEMA eV FILE 'CEN' ENTERED AT 15:48:05 ON 10 OCT 2003 COPYRIGHT (C) 2003 American Chemical Society (ACS) FILE 'CIN' ENTERED AT 15:48:05 ON 10 OCT 2003 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2003 American Chemical Society (ACS) FILE 'CONFSCI' ENTERED AT 15:48:05 ON 10 OCT 2003 COPYRIGHT (C) 2003 Cambridge Scientific Abstracts (CSA)

FILE 'DDFB' ACCESS NOT AUTHORIZED

COPYRIGHT (C) 2003 THOMSON DERWENT

COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'DDFU' ACCESS NOT AUTHORIZED

FILE 'CROPB' ENTERED AT 15:48:05 ON 10 OCT 2003

FILE 'CROPU' ENTERED AT 15:48:05 ON 10 OCT 2003

```
FILE 'DGENE' ENTERED AT 15:48:05 ON 10 OCT 2003
COPYRIGHT (C) 2003 THOMSON DERWENT
FILE 'DRUGB' ENTERED AT 15:48:05 ON 10 OCT 2003
COPYRIGHT (C) 2003 THOMSON DERWENT
FILE 'DRUGLAUNCH' ENTERED AT 15:48:05 ON 10 OCT 2003
COPYRIGHT (C) 2003 IMSWORLD Publications Ltd
FILE 'DRUGMONOG2' ENTERED AT 15:48:05 ON 10 OCT 2003
COPYRIGHT (C) 2003 IMSWORLD Publications Ltd
FILE 'DRUGNL' ENTERED AT 15:48:05 ON 10 OCT 2003
COPYRIGHT (C) 2003 IMSWORLD Publications Ltd
FILE 'DRUGU' ENTERED AT 15:48:05 ON 10 OCT 2003
COPYRIGHT (C) 2003 THOMSON DERWENT
FILE 'DRUGUPDATES' ENTERED AT 15:48:05 ON 10 OCT 2003
COPYRIGHT (C) 2003 IMSWORLD Publications Ltd
FILE 'EMBAL' ENTERED AT 15:48:05 ON 10 OCT 2003
COPYRIGHT (C) 2003 Elsevier Inc. All rights reserved.
FILE 'EMBASE' ENTERED AT 15:48:05 ON 10 OCT 2003
COPYRIGHT (C) 2003 Elsevier Inc. All rights reserved.
FILE 'ESBIOBASE' ENTERED AT 15:48:05 ON 10 OCT 2003
COPYRIGHT (C) 2003 Elsevier Science B.V., Amsterdam. All rights reserved.
FILE 'FEDRIP' ENTERED AT 15:48:05 ON 10 OCT 2003
FILE 'FOMAD' ENTERED AT 15:48:05 ON 10 OCT 2003
COPYRIGHT (C) 2003 Leatherhead Food Research Association
FILE 'FOREGE' ENTERED AT 15:48:05 ON 10 OCT 2003
COPYRIGHT (C) 2003 Leatherhead Food Research Association
FILE 'FROSTI' ENTERED AT 15:48:05 ON 10 OCT 2003
COPYRIGHT (C) 2003 Leatherhead Food Research Association
FILE 'FSTA' ENTERED AT 15:48:05 ON 10 OCT 2003
COPYRIGHT (C) 2003 International Food Information Service
FILE 'GENBANK' ENTERED AT 15:48:05 ON 10 OCT 2003
FILE 'HEALSAFE' ENTERED AT 15:48:05 ON 10 OCT 2003
COPYRIGHT (C) 2003 Cambridge Scientific Abstracts (CSA)
FILE 'IFIPAT' ENTERED AT 15:48:05 ON 10 OCT 2003
COPYRIGHT (C) 2003 IFI CLAIMS(R) Patent Services (IFI)
FILE 'JICST-EPLUS' ENTERED AT 15:48:05 ON 10 OCT 2003
COPYRIGHT (C) 2003 Japan Science and Technology Corporation (JST)
FILE 'KOSMET' ENTERED AT 15:48:05 ON 10 OCT 2003 COPYRIGHT (C) 2003 International Federation of the Societies of Cosmetics Chemists
FILE 'LIFESCI' ENTERED AT 15:48:05 ON 10 OCT 2003
COPYRIGHT (C) 2003 Cambridge Scientific Abstracts (CSA)
FILE 'MEDICONF' ENTERED AT 15:48:05 ON 10 OCT 2003
COPYRIGHT (c) 2003 FAIRBASE Datenbank GmbH, Hannover, Germany
FILE 'MEDLINE' ENTERED AT 15:48:05 ON 10 OCT 2003
FILE 'NIOSHTIC' ENTERED AT 15:48:05 ON 10 OCT 2003
COPYRIGHT (C) 2003 U.S. Secretary of Commerce on Behalf of the U.S. Government
FILE 'NTIS' ENTERED AT 15:48:05 ON 10 OCT 2003
Compiled and distributed by the NTIS, U.S. Department of Commerce.
It contains copyrighted material.
All rights reserved. (2003)
FILE 'NUTRACEUT' ENTERED AT 15:48:05 ON 10 OCT 2003
```

Copyright 2003 (c) MARKETLETTER Publications Ltd. All rights reserved.

```
FILE 'OCEAN' ENTERED AT 15:48:05 ON 10 OCT 2003
COPYRIGHT (C) 2003 Cambridge Scientific Abstracts (CSA)
FILE 'PASCAL' ENTERED AT 15:48:05 ON 10 OCT 2003
Any reproduction or dissemination in part or in full,
by means of any process and on any support whatsoever is prohibited without the prior written agreement of INIST-CNRS.
COPYRIGHT (C) 2003 INIST-CNRS. All rights reserved.
FILE 'PCTGEN' ENTERED AT 15:48:05 ON 10 OCT 2003
COPYRIGHT (C) 2003 WIPO
FILE 'PHAR' ENTERED AT 15:48:05 ON 10 OCT 2003
COPYRIGHT (C) 2003 PJB Publications Ltd. (PJB)
FILE 'PHARMAML' ENTERED AT 15:48:05 ON 10 OCT 2003
Copyright 2003 (c) MARKETLETTER Publications Ltd. All rights reserved.
FILE 'PHIC' ENTERED AT 15:48:05 ON 10 OCT 2003
COPYRIGHT (C) 2003 PJB Publications Ltd. (PJB)
FILE 'PHIN' ENTERED AT 15:48:05 ON 10 OCT 2003
COPYRIGHT (C) 2003 PJB Publications Ltd. (PJB)
FILE 'PROMT' ENTERED AT 15:48:05 ON 10 OCT 2003
COPYRIGHT (C) 2003 Gale Group. All rights reserved.
FILE 'RDISCLOSURE' ENTERED AT 15:48:05 ON 10 OCT 2003
COPYRIGHT (C) 2003 Kenneth Mason Publications Ltd.
FILE 'SCISEARCH' ENTERED AT 15:48:05 ON 10 OCT 2003
COPYRIGHT 2003 THOMSON ISI
FILE 'SYNTHLINE' ENTERED AT 15:48:05 ON 10 OCT 2003
COPYRIGHT (C) 2003 Prous Science
FILE 'TOXCENTER' ENTERED AT 15:48:05 ON 10 OCT 2003
COPYRIGHT (C) 2003 ACS
FILE 'USPATFULL' ENTERED AT 15:48:05 ON 10 OCT 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)
FILE 'USPAT2' ENTERED AT 15:48:05 ON 10 OCT 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)
FILE 'VETB' ENTERED AT 15:48:05 ON 10 OCT 2003
COPYRIGHT (C) 2003 THOMSON DERWENT
FILE 'VETU' ENTERED AT 15:48:05 ON 10 OCT 2003
COPYRIGHT (C) 2003 THOMSON DERWENT
FILE 'WPIDS' ENTERED AT 15:48:05 ON 10 OCT 2003
COPYRIGHT (C) 2003 THOMSON DERWENT
FILE 'WPINDEX' ACCESS NOT AUTHORIZED
=> S human AND microglia AND CD11 AND CD68
  19 FILES SEARCHED...
  21 FILES SEARCHED...
  40 FILES SEARCHED...
  58 FILES SEARCHED...
              6 HUMAN AND MICROGLIA AND CD11 AND CD68
=> DUP REM L1
DUPLICATE IS NOT AVAILABLE IN 'ADISINSIGHT, ADISNEWS, BIOCOMMERCE, DGENE,
DRUGLAUNCH, DRUGMONOG2, DRUGUPDATES, FEDRIP, FOREGE, GENBANK, KOSMET, MEDICONF, NUTRACEUT, PCTGEN, PHAR, PHARMAML, RDISCLOSURE, SYNTHLINE'.
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
PROCESSING COMPLETED FOR L1
               6 DUP REM L1 (0 DUPLICATES REMOVED)
=> D L2 1-6
```

ANSWER 1 OF 6 USPATFULL ON STN

2003:200428 USPATFULL

L2

ΑN

```
Gene expression in monocytes and macrophages
TI
IN
         Greaves, David Robert, Oxford, UNITED KINGDOM
        Glaxo Wellcome Inc. (non-U.S. corporation)
PA
        US 2003138411
                                      20030724
PΙ
                                Α1
        US 2002-60387
ΑI
                                Α1
                                      20020201 (10)
        Continuation of Ser. No. US 1998-171802, filed on 26 Oct 1998, PENDING A 371 of International Ser. No. WO 1997-GB1209, filed on 2 May 1997,
RLI
        UNKNOWN
        GB 1996-9261
                                 19960502
PRAI
        Utility
DT
        APPLICATION
FS
LN.CNT 1391
        INCLM: 424/093.210
INCL
        INCLS: 435/069.100; 435/372.000; 435/320.100; 536/023.200; 435/226.000
NCL
        NCLM:
                 424/093.210
        NCLS:
                 435/069.100; 435/372.000; 435/320.100; 536/023.200; 435/226.000
IC
         [7]
         ICM: A61K048-00
        ICS: C07H021-04; C12N009-64; C12N005-08
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L2
      ANSWER 2 OF 6 USPATFULL on STN
AN
        2003:112548 USPATFULL
                  ***human***
TI
                                    beta2 integrin alpha subunit
IN
        Gallatin, W. Michael, Mercer Island, WA, UNITED STATES
        Van der Vieren, Monica, Seattle, WA, UNITED STATES
PA
        ICOS Corporation (U.S. corporation)
        us 2003077278
PΙ
                                      20030424
                                Α1
ΑI
        us 2001-891943
                                Α1
                                      20010626 (9)
        Division of Ser. No. US 1998-193043, filed on 16 Nov 1998, PATENTED Continuation-in-part of Ser. No. US 1997-943363, filed on 3 oct 1997, PATENTED Continuation-in-part of Ser. No. US 1996-605672, filed on 22 Feb 1996, PATENTED Continuation-in-part of Ser. No. US 1994-362652,
RLI
        filed on 21 Dec 1994, PATENTED Continuation-in-part of Ser. No. US 1994-286889, filed on 5 Aug 1994, PATENTED Continuation-in-part of Ser.
        No. US 1993-173497, filed on 23 Dec 1993, PATENTED
DT
        Utility
        APPLICATION
FS
LN.CNT 9721
INCL
        INCLM: 424/144.100
        INCLS: 435/334.000
NCL
        NCLM:
                 424/144.100
                 435/334.000
        NCLS:
IC
         [7]
        ICM: A61K039-395
        ICS: C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
      ANSWER 3 OF 6 CAPLUS COPYRIGHT 2003 ACS on STN
L2
      2002:51606 CAPLUS
AN
DN
      136:113767
                        ***human***
                                            ***microglia***
TI
      Immortalized
                                                                   cell and continuous cell
      line containing exogenous genes and uses in therapy
IN
      Kim, Seung U.
      University of British Columbia, Can.
PA
SO
      PCT Int. Appl., 46 pp.
      CODEN: PIXXD2
DT
      Patent
IΑ
      English
FAN.CNT 3
      PATENT NO.
                           KIND
                                  DATE
                                                     APPLICATION NO.
                                                                          DATE
PΙ
      wo 2002004604
                                  20020117
                           Α2
                                                     WO 2001-IB1770
                                                                          20010709
           W: AU, CA, JP
           RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
                    SE, TR
      WO 2002004618
                                  20020117
                                                     wo 2000-us18777 20000710
               AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN,
                MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ,
                                                                                          TM,
                TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU,
           RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
                DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,
```

CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

```
us 2002064877
                               20020530
                                               us 2001-855468
                                                                   20010515
                         Α1
                               20030501
                                                                   20010622
     US 2003082139
                         Α1
                                               US 2001-887145
                               20000710
PRAI WO 2000-US18777
                         W
     US 2001-855468
                               20010515
                         Α
     US 2001-887145
                         Δ
                               20010622
L2
     ANSWER 4 OF 6 USPATFULL ON STN
        2002:126365 USPATFULL
ΑN
                                              ***human***
                                                              microglial cell line
TI
       Methods of producing and using a
       Kim, Seung U., Vancouver, CANADA
ΙN
                                  20020530
       US 2002064877
PΙ
                            Α1
       US 2001-855468
                            Α1
                                  20010515 (9)
ΑI
        Continuation of Ser. No. WO 2000-US18777, filed on 10 Jul 2000, UNKNOWN
RLI
       Utility
DT
       APPLICATION
FS
LN.CNT 346
INCL
        INCLM: 435/456.000
       INCLS: 435/368.000
NCLM: 435/456.000
NCL
               435/368.000
       NCLS:
        [7]
IC
       ICM: C12N015-867
        ICS: C12N005-08
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L2
     ANSWER 5 OF 6 USPATFULL ON STN
       2002:120019 USPATFULL
ΑN
TI
                ***HUMAN***
                                BETA2 INTEGRIN ALPHA SUBUNIT
IN
        GALLATIN, W. MICHAEL, MERCER ISLAND, WA, UNITED STATES
        VAN DER VIEREN, MONICA, SEATTLE, WA, UNITED STATES
PΙ
        us 2002062008
                            Α1
                                  20020523
       US 6620915
                             B2
                                  20030916
       us 1999-350259
                                  19990708 (9)
AΙ
                            Α1
       Continuation of Ser. No. US 1998-193043, filed on 16 Nov 1998, GRANTED,
RLI
        Pat. No. US 6251395 Continuation-in-part of Ser. No. US 1997-943363,
        filed on 3 Oct 1997, GRANTED, Pat. No. US 5837478 Continuation-in-part
       of Ser. No. US 1996-605672, filed on 22 Feb 1996, GRANTED, Pat. No. US
        5817515 Continuation-in-part of Ser. No. US 1994-362652, filed on 21 Dec
       1994, GRANTED, Pat. No. US 5766850 Continuation-in-part of Ser. No. US 1994-286889, filed on 5 Aug 1994, GRANTED, Pat. No. US 5470953 Continuation-in-part of Ser. No. US 1993-173497, filed on 23 Dec 1993,
        GRANTED, Pat. No. US 5437958
DT
        Utility
        APPLICATION
FS
LN.CNT 9847
        INCLM: 530/387.300
INCL
        INCLS: 530/388.220; 530/388.730
               530/387.300
NCL
        NCLM:
        NCLS:
               530/387.100; 530/387.300; 530/388.100; 530/388.200; 530/388.220;
               530/388.700; 435/326.000; 435/328.000; 435/332.000; 435/334.000; 435/343.000; 435/343.100; 435/346.000
IC
        [7]
        ICM: C07K016-00
        ICS: G01N033-567; C12P021-08
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L2
     ANSWER 6 OF 6 EMBASE COPYRIGHT 2003 ELSEVIER INC. ALL RIGHTS RESERVED.
     on STN
ΑN
     2001212146 EMBASE
     Establishment of microglial cell cultures derived from postmortem
TI
        ***human***
                       adult brain tissue: Immunophenotypical and functional
     characterization.
ΑU
     De Groot C.J.A.; Hulshof S.; Hoozemans J.J.M.; Veerhuis R.
CS
     Dr. C.J.A. De Groot, Department of Pathology, Division of Neuropathology,
     Research Inst. Vrije Univ. Amsterdam, P.O. Box 7057, 1007 MB Amsterdam,
     Netherlands. cja.degroot@azvu.nl
SO
     Microscopy Research and Technique, (1 Jul 2001) 54/1 (34-39).
     Refs: 16
     ISSN: 1059-910X CODEN: MRTEEO
CY
     United States
DT
     Journal: Article
FS
     005
              General Pathology and Pathological Anatomy
     800
              Neurology and Neurosurgery
LA
     English
SL
     English
```

```
=> s human AND microglia
  21 FILES SEARCHED...
  47 FILES SEARCHED...
           17648 HUMAN AND MICROGLIA
=> DUP REM L3
PROCESSING COMPLETED FOR L3
             7127 DUP REM L3 (10521 DUPLICATES REMOVED)
=> S L4 AND CD11?
  10 FILES SEARCHED...
  15 FILES SEARCHED...
  25 FILES SEARCHED...
  37 FILES SEARCHED...
             196 L4 AND CD11?
\Rightarrow D L5 1-196
L5
      ANSWER 1 OF 196 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
      2003:423802
ΑN
                     BIOSIS
DN
      PREV200300423802
TI
      Anti-inflammatory drug therapy alters beta-amyloid processing and
      deposition in an animal model of Alzheimer's disease.
      Yan, Qiao; Zhang, Jianhua; Liu, Hantao; Babu-Khan, Safura; Vassar, Robert; Biere, Anja Leona; Citron, Martin (1); Landreth, Gary (1) Amgen, One Amgen Center Drive, M/S 29-2-B, Thousand Oaks, CA,
CS
      91320-1799, USA: mcitron@amgen.com USA
Journal of Neuroscience, (August 20 2003) Vol. 23, No. 20, pp. 7504-7509.
SO
      print.
      ISSN: 0270-6474.
DT
      Article
      English
L.A
L5
      ANSWER 2 OF 196 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
ΑN
      2003:327182
                     BIOSIS
      PREV200300327182
DN
TI
      ACTIVATION OF MICROGLIAL CELLS AND INDUCTION OF NEURONAL INJURY BY
      CHOLESTEROL OXIDES FOUND IN THE CEREBROSPINAL FLUID OF PATIENTS WITH
      MULTIPLE SCLEROSIS
ΑU
      Ullrich, O. (1); Diestel, A. (1); Hackel, D. (1); Haeke, I. (1); Aktas,
      O.; Zipp, F.; Nitsch, R. (1)
      (1) Dept Cell Neurobiol Inst Anat, Humboldt Univ Berlin Fac Med, Berlin,
CS
      Germany Germany
SO
      Society for Neuroscience Abstract Viewer and Itinerary Planner, (2002)
      Vol. 2002, pp. Abstract No. 799.24. http://sfn.scholarone.com.cd-rom.
      Meeting Info.: 32nd Annual Meeting of the Society for Neuroscience
      Orlando, Florida, USA November 02-07, 2002 Society for Neuroscience
DT
      Conference
      English
IΑ
      ANSWER 3 OF 196 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
L5
ΑN
      2003:326020 BIOSIS
DN
      PREV200300326020
      MECHANISMS OF AMYLOID SUPPRESSION BY IBUPROFEN AND RELATED NSAIDS.
TI
ΑU
      Morihara, T. (1); Teter, B. (1); Young, F. (1); Lim, G. (1); Chu, T. (1);
      Ubeda, O. (1); Beech, W. (1); Raymond, L. (1); Frautschy, S. (1); Cole, G.
     M. (1)
(1) Dept Med and Neurol, UCLA, North Hills, CA, USA USA

**Taget Viewer and Ttinerary | 1
CS
     Society for Neuroscience Abstract Viewer and Itinerary Planner, (2002) Vol. 2002, pp. Abstract No. 722.5. http://sfn.scholarone.com. cd-rom. Meeting Info.: 32nd Annual Meeting of the Society for Neuroscience Orlando, Florida, USA November 02-07, 2002 Society for Neuroscience
SO
DT
     Conference
      English
LA
L5
      ANSWER 4 OF 196 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
      2003:268374 BIOSIS
AN
DN
      PREV200300268374
TI
     NEURONAL GLUTAMATE TRANSPORTER EAAT4 IS EXPRESSED IN THE SPINAL CORD
```

Hu, W. H. (1); Walters, W. M. (1); Karmally, S. A. (1); Bethea, J. R. (1)

ASTROCYTES

ΑU

- (1) Miami Project Cure Paralysis, Univ Miami Sch Med, Miami, FL, USA USA CS Society for Neuroscience Abstract Viewer and Itinerary Planner, (2002) SO Vol. 2002, pp. Abstract No. 44.9. http://sfn.scholarone.com. cd-rom. Meeting Info.: 32nd Annual Meeting of the Society for Neuroscience Orlando, Florida, USA November 02-07, 2002 Society for Neuroscience
- Conference DT English LA
- ANSWER 5 OF 196 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN L5

2003:6053 BIOSIS AN PREV200300006053 DN

- Association of factor H of the alternative pathway of complement with TI agrin and complement receptor 3 in the Alzheimer's disease brain.
- Strohmeyer, Ron (1); Ramirez, Mauricio; Cole, Gregory J.; Mueller, Kyle; Rogers, Joseph
- (1) Sun Health Research Institute, P.O. Box 1278, Sun City, AZ, 85372, CS
- USA: Ronald.Strohmeyer@sunhealth.org USA
 Journal of Neuroimmunology, (October 2002, 2002) Vol. 131, No. 1-2, pp. 135-146. print. ISSN: 0165-5728.
- Article DT
- English LA
- ANSWER 6 OF 196 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN L5
- 2002:525747 BIOSIS AN
- PREV200200525747 DN
- Calpain expression and infiltration of activated T cells in experimental TI allergic encephalomyelitis over time: Increased calpain activity begins with onset of disease.
- Schaecher, K.; Rocchini, A.; Dinkins, J.; Matzelle, D. D.; Banik, N. L. ΑU
- (1) Department of Neurology, Medical University of South Carolina (MUSC), CS 96 Jonathan Lucas Street, Suite 307, Box 250606, Charleston, SC, 29425: baniknl@musc.edu USA
- S₀ Journal of Neuroimmunology, (August, 2002) Vol. 129, No. 1-2, pp. 1-9. http://www.elsevier.com/locate/jneuroim.print. ISSN: 0165-5728.
- Article DT
- English LA
- ANSWER 7 OF 196 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN L5
- AN 2002:508730 BIOSIS
- PREV200200508730 DN
- HIV-1 Tat protein and neurodegeneration: Potential interactions with TI psychostimulants and oxidative damage.
- Booze, R. M. (1); Mactutus, C. F. ($\overline{1}$); Nath, A. (1); Hasselrot, U. (1); ΑU Wu, G. (1); Aksenov, M. Y. (1)
- (1) University of Kentucky College of Medicine, Lexington, KY USA CS
- Drug and Alcohol Dependence, (1 May, 2002) Vol. 66, No. Supplement 1, pp. s18. http://www.elsevier.com/locate/drugalcdep.print. SO Meeting Info.: 64th Annual Scientific Meeting of the College on Problems of Drug Dependence Quebec City, Quebec, Canada June 08-13, 2002 ISSN: 0376-8716.
- DT Conference
- LA English
- ANSWER 8 OF 196 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN 15
- AN 2002:483668 BIOSIS
- PREV200200483668 DN
- TI Role of Fcgamma receptors in nigral cell injury induced by Parkinson disease immunoglobulin injection into mouse substantia nigra.
- ΑU
- He, Yi (1); Le, Wei-dong (1); Appel, Stanley H. (1) (1) Department of Neurology, Baylor College of Medicine, Houston, TX, CS 77030 USA
- Experimental Neurology, (August, 2002) Vol. 176, No. 2, pp. 322-327. 50 http://www.academicpress.com/en.print. ISSN: 0014-4886.
- Article DΤ
- English LA
- ANSWER 9 OF 196 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN L5
- 2002:416360 BIOSIS ΑN
- DN PREV200200416360
- Characterization of the macrophages associated with the tunica vasculosa TI lentis of the rat eye.

McMenamin, Paul G. (1); Djano, Jenny; Wealthall, Rosamund; Griffin, ΑU (1) School of Anatomy and Human Biology, The University of Western CS Australia, Crawley (Perth), 6009: mcmenamin@anhb.uwa.edu.au Australia IOVS, (July, 2002) Vol. 43, No. 7, pp. 2076-2082. http://www.iovs.org. SO print. DT Article English LA L5 ANSWER 10 OF 196 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN 2002:414804 BIOSIS AN PREV200200414804 DN ***human*** Cytokines, chemokines, and cytokine receptors in TI ***microglia*** Lee, Yong B.; Nagai, Atsushi; Kim, Seung U. (1) ΑU (1) Brain Disease Research Center, Ajou University School of Medicine, 5 San, Wonchon-Dong, Suwon, 442-721: sukim@madang.ajou.ac.kr South Korea CS Journal of Neuroscience Research, (July 1, 2002) Vol. 69, No. 1, pp. 94-103. http://www.interscience.wiley.com/jpages/0360-4012/. print. ISSN: 0360-4012. Article DT English LA L5 ANSWER 11 OF 196 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN AN 2002:145064 BIOSIS DN PREV200200145064 ***human*** Generation and characterization of immortalized microglial TI cell lines: Expression of cytokines and chemokines. Nagai, A. (1); Nakagawa, E. (1); Hatori, K. (1); Choi, H. B. (1); McLarnon, J. G.; Lee, M. A.; Kim, S. U. (1) Division of Neurology, Department of Medicine, University of British ΑU CS Columbia, Vancouver Canada Neurobiology of Disease, (December, 2001) Vol. 8, No. 6, pp. 1057-1068. SO print. ISSN: 0969-9961. DT Article LA English L5 ANSWER 12 OF 196 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN 2002:38613 BIOSIS ΑN DN PREV200200038613 TI Analysis of the role of glial cells in dopaminergic neurodegeneration using laser capture microdissection and gene microarrays. Cantuti-Castelvetri, I. (1); Keller-McGandy, C. E. (1); Korley, J. N. (1); Augood, S. J. (1); Standaert, D. G. (1) (1) Neurology Research, Massachusetts General Hospital, Charlestown, MA CS USA Society for Neuroscience Abstracts, (2001) Vol. 27, No. 2, pp. 2569. SO Meeting Info.: 31st Annual Meeting of the Society for Neuroscience San Diego, California, USA November 10-15, 2001 ISSN: 0190-5295. DT Conference English LA L5 ANSWER 13 OF 196 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN 2001:562267 BIOSIS AN DN PREV200100562267 TI Glial cell line derived neurotrophic factor inhibits MPTP-induced microglial activation in the substantia nigra of rhesus monkeys. Zhao, L. (1); Ai, Y. (1); Jin, L. (1); Zhang, Z. (1); Gash, D. M. (1); Bing, G. Y. (1) AU CS Anatomy and Neurobiology, University of Kentucky, Lexington, KY USA Society for Neuroscience Abstracts, (2001) Vol. 27, No. 2, pp. 1734. SO print. Meeting Info.: 31st Annual Meeting of the Society for Neuroscience San Diego, California, USA November 10-15, 2001 ISSN: 0190-5295. Conference DT English LA English SL L5 ANSWER 14 OF 196 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN 2001:558095 BIOSIS ΑN PREV200100558095 DN

SIV-induced abnormality in CNS evoked potentials correlates with activated

TI

CD8+ T cells in the brain. Marcondes, M. C. G. (1); Burudi, E. M. E. (1); Huitron-Resendez, S. (1); ΑU Sanchez, M. (1); Henriksen, S. J. (1); Fox, H. S. (1) (1) Department of Neuropharmacology, The Scripps Research Institute, La CS Jolla, CA, 92037 USA Journal of Medical Primatology, (August, 2001) Vol. 30, No. 4, pp. 240. SO print. Meeting Info.: 18th Annual Symposium on Nonhuman Primate Models for AIDS Madison, WI, USA October 04-07, 2000 ISSN: 0047-2565. Conference DT English LA SL English ANSWER 15 OF 196 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN L5 2001:541200 BIOSIS AN PREV200100541200 DN Immune reactivity in a mouse model of familial ALS correlates with disease TI progression. Alexianu, Maria E.; Kozovska, Milena; Appel, Stanley H. (1) (1) Department of Neurology, Baylor College of Medicine, 6501 Fannin St., NB 302, Houston, TX, 77030: sappel@bcm.tmc.edu USA Neurology, (October 9, 2001) Vol. 57, No. 7, pp. 1282-1289. print. SO ISSN: 0028-3878. Article DT English LA SL English L5 ANSWER 16 OF 196 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN ΑN 2001:503864 BIOSIS PREV200100503864 DN Marked increase in cyclooxygenase-2 in ALS spinal cord: Implications for TI Yasojima, K.; Tourtellotte, W. W.; McGeer, E. G.; McGeer, P. L. (1) ΑU (1) Kinsmen Laboratory of Neurological Research, University of British CS Columbia, 2255 Wesbrook Mall, Vancouver, BC, V6T 1Z3: mcgeerpl@interchange.ubc.ca Canada Neurology, (September 25, 2001) Vol. 57, No. 6, pp. 952-956. print. S0 ISSN: 0028-3878. DT Article English LA English SL ANSWER 17 OF 196 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN L5 2001:317148 BIOSIS PREV200100317148 DN ER-MP12+ ER-MP20- macrophage precursors repopulate multiple tissues in MPS TI VII recipients post transplant and are multipotent. ΑU Soper, Brian W. (1); Lessard, Mark D. (1); Jude, Craig D. (1); Schuldt, Adam J. (1); Barker, Jane E. (1) (1) The Jackson Laboratory, Bar Harbor, ME USA Blood, (November 16, 2000) Vol. 96, No. 11 Part 1, pp. 762a. print. CS SO Meeting Info.: 42nd Annual Meeting of the American Society of Hematology San Francisco, California, USA December 01-05, 2000 American Society of Hematology ISSN: 0006-4971. DT Conference English LΑ SL English ANSWER 18 OF 196 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN 2001:265877 BIOSIS AN DN PREV200100265877 Identification of a functional receptor for amyloid beta, the TI key-contributor to the Alzheimer's disease. Le, Ying Ying (1); Gong, Wang Hua; Tiffany, H. Lee; Tumanov, Alexei (1); Nedospasov, Sergei; Shen, Weiping (1) (1) FCRDC, National Cancer Institute, Bldg. 560, Frederick, MD, 21702-1201 FASEB Journal, (March 7, 2001) Vol. 15, No. 4, pp. A684. print. Meeting Info.: Annual Meeting of the Federation of American Societies for SO Experimental Biology on Experimental Biology 2001 Orlando, Florida, USA March 31-April 04, 2001

ISSN: 0892-6638.

Conference English

DT

LA

```
English
SL
     ANSWER 19 OF 196 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
15
     2001:88823 BIOSIS
AN
     PREV200100088823
DN
      Inflammation is more pronounced in Alzheimer disease brain than in
TI
     recognized peripheral inflammatory conditions.

Mc Geer, P. L. (1); McGeer, E. G.; Yasojima, K.

(1) Univ British Columbia, Vancouver, BC Canada

Society for Neuroscience Abstracts, (2000) Vol. 26, No. 1-2, pp. Abstract
ΑU
CS
SO
     No.-299.11. print.
     Meeting Info.: 30th Annual Meeting of the Society of Neuroscience New
     Orleans, LA, USA November 04-09, 2000 Society for Neuroscience
       ISSN: 0190-5295.
DT
      Conference
     English
LA
SL
     English
      ANSWER 20 OF 196 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
L5
AN
      2000:443525 BIOSIS
      PREV200000443525
DN
      Alzheimer disease and neuroinflammation.
TI
     McGeer, P. L. (1); McGeer, E. G.; Yasojima, K. (1) Kinsmen Laboratory of Neurological Research, University of British
ΑU
CS
      Columbia, 2255 Wesbrook Mall, Vancouver, BC, V6T 1Z3 Canada
      Journal of Neural Transmission Supplement, (2000) Vol. 59, pp. 53-57.
S<sub>0</sub>
      ISSN: 0303-6995.
      Article
DT
LA
      English
SL
      English
      ANSWER 21 OF 196 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
L5
      2000:377545 BIOSIS
ΑN
      PREV200000377545
DΝ
      Role of the phagocytic ClqR (ClqRp) in the CNS: Identification of the
TI
      signalling events following C1pRp crosslinking.
      McGreal, Eamon P. (1); Dean, Yann D. (1); van den Berg, Carmen; Morgan, B.
ΑU
      Paul (1); Gasque, Philippe (1)
CS
      (1) Brain Inflammation and Immunity Group, Medical Biochemistry
     Department, UWCM, Heath Park, Cardiff, CF14 4XN UK Immunopharmacology, (August, 2000) Vol. 49, No. 1-2, pp. 7. print.
SO
     Meeting Info.: XVIIIth International Complement Workshop Salt Lake City, Utah, USA July 23-27, 2000 ISSN: 0162-3109.
DT
      Conference
      English
LA
      English
SL
      ANSWER 22 OF 196 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
L5
      2000:362631 BIOSIS
ΑN
      PREV200000362631
DN
      Brain perivascular macrophages as the target for SIV infection: The brain
TT
      as a retroviral reservoir.
      Williams, Kenneth C.; Westmoreland, Susan V.; Pauley, Doug; Knight,
ΑU
      Heather; Lackner, Andrew A.
      Journal of Neurovirology, (May, 2000) Vol. 6, No. Supplement 1, pp. S118.
SO
      print.
      Meeting Info.: HIV and the Nervous System: Emerging Issues Bethesda,
      Maryland, USA April 14-16, 1999 National Institute of Mental Health
       ISSN: 1355-0284.
      Conference
DT
LA
      English
SL
      English
      ANSWER 23 OF 196 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
L5
      1999:335336 BIOSIS
PREV199900335336
ΑN
DN
        ***Microglia***
                             in the
                                       ***human***
                                                        fetal spinal cord-patterns of
TI
      distribution, morphology and phenotype. Rezaie, P. (1); Patel, K.; Male, D. K.
ΑU
      (1) Department of Neuropathology, Institute of Psychiatry, De Crespigny
CS
      Park, London, SE5 8JN UK
```

Developmental Brain Research, (June 8, 1999) Vol. 115, No. 1, pp. 71-81.

S₀

DT

ISSN: 0165-3806.

Article

- Enalish LA SL English
 - ANSWER 24 OF 196 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN L5
 - 1998:259656 BIOSIS ΑN
 - DN PREV199800259656
 - Phorbol ester induces differentiation of a ***human*** TI prostatic cancer cell line TSU-Pr1 into cells with characteristics of ***microglia***
- Itayasu, Tomohiro; Shimizu, Takahisa; Iizumi, Tatsuo; Oshio, Shigeru; ΑU Umeda, Takashi; Takeda, Ken (1)
- (1) Dep. Hyg. Chem., Fac. Pharm. Sci., Sci. Univ. Tokyo, 12 CS Funagawara-Machi Ichigaya, Shinjuku-ku, Tokyo 162 Japan
- Anticancer Research, (Jan.-Feb., 1998) Vol. 18, No. 1A, pp. 113-117. ISSN: 0250-7005.
- DT Article
- English LA
- L5 ANSWER 25 OF 196 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
- 1998:124275 BIOSIS AN
- PREV199800124275 DN
- Association of vascular amyloid beta and cells of the mononuclear TT phagocyte system in hereditary cerebral hemorrhage with amyloidosis (Dutch) and Alzheimer disease.
- Maat-Schieman, Marion L. C. (1); Van Duinen, Sjoerd G.; Rozemuller, ΑU Annemieke J. M.; Haan, Joost; Roos, Raymund A. C.
- (1) Dep. Neurol., K5Q 116, Leiden Univ. Hosp., PO Box 9600, 2300 RC Leiden CS Netherlands
- SO Journal of Neuropathology & Experimental Neurology, (March, 1997) Vol. 56, No. 3, pp. 273-284. ISSN: 0022-3069.
- Article DT
- English LA
- L5 ANSWER 26 OF 196 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
- ΑN 1998:34614 BIOSIS
- PREV199800034614 DN
- ***human*** Direct ex-vivo flow cytometric analysis of TI CD4 expression: Examination of central nervous system biopsy specimens from HIV-seropositive patients and patients with other neurological disease.
- Dick, Andrew D.; Pell, Malcolm; Brew, Bruce J.; Foulcher, Elena; Sedgwick, ΑU Jonathon D. (1)
- (1) Centenary Inst. Cancer Med. Cell Biol., Build. 93, Royal Prince Alfred Hosp., Missenden Road, Camperdown, Sydney, NSW 2042 Australia AIDS (London), (Nov. 15, 1997) Vol. 11, No. 14, pp. 1699-1708.
- SO ISSN: 0269-9370.
- DT Article
- LA English
- L5 ANSWER 27 OF 196 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
- AN 1997:67302 BIOSIS
- DN PREV199799366505
- ΤI Cryptococcus neoformans meningitis in the rat.
- ΑU
- Goldman, David L. (1); Casadevall, Arturo; Cho, Youngsoo; Lee, Sunhee C. (1) Div. Infectious Diseases, Dep. Pediatrics, Ullmann 1219, Albert Einstein Coll. Med., 1300 Morris Park Ave., Bronx, NY 10461 USA Laboratory Investigation, (1996) Vol. 75, No. 6, pp. 759-770. CS
- SO ISSN: 0023-6837.
- DT Article
- LA English
- L5 ANSWER 28 OF 196 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
- ΑN 1996:336575 BIOSIS
- DN PREV199699058931
- TI The immunophenotype of perivascular cells in the ***human***
- ΑU
- Sasaki, Atsushi (1); Nakazato, Yoichi; Ogawa, Akira; Sugihara, Shiro (1) Dep. Pathol., Gunma Univ. Sch. Med., 3-39-22 Showamachi, Maebashi, CS Gunma 371 Japan
- Pathology International, (1996) Vol. 46, No. 1, pp. 15-23. SO ISSN: 1320-5463.
- DT Article
- English LA
- L5 ANSWER 29 OF 196 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
- 1995:78660 BIOSIS ΑN

```
PREV199598092960
DN
       ***Human***
                     microglial cells have phenotypic and functional
     characteristics in common with both macrophages and dendritic
     antigen-presenting cells.
     Ulvestad, Elling (1); Williams, Kenneth; Bjerkvig, Rolf; Tiekotter, Kenneth; Antel, Jack; Matre, Roald
ΑU
     (1) Dep. Microbiol. Immunol., Armauer Hansen Building, N-5021 Bergen
     Norway
     Journal of Leukocyte Biology, (1994) Vol. 56, No. 6, pp. 732-740.
50
     ISSN: 0741-5400.
     Article
DT
     English
LA
     ANSWER 30 OF 196 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
L5
     1994:486945 BIOSIS
ΑN
     PREV199497499945
DN
     Phenotypic differences between
                                       ***human***
TI
                                                      monocytes/macrophages and
     microglial cells studied in situ and in vitro.
     Ulvestad, Elling (1); Williams, Kenneth; Mork, Sverre; Antel, Jack;
     Nyland, Harald
     (1) Dep. Microbiol. Immunol., Armauer Hansen Build., Univ. Bergen, N-5021
CS
     Bergen Norway
S0
     Journal of Neuropathology & Experimental Neurology, (1994) Vol. 53, No. 5,
     pp. 492-501.
     ISSN: 0022-3069.
     Article
DT
     English
LA
     ANSWER 31 OF 196 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN 1993:523547 BIOSIS
L5
ΑN
     PREV199396136954
DN
     Mitosis and apoptosis of ***microglia***
                                                    in vivo induced by an
TI
     anti-CR3 antibody which crosses the blood-brain barrier.
     Reid, D. M. (1); Perry, V. H.; Andersson, P.-B.; Gordon, S. (1) Univ. Dep. Pharmacol., Mansfield Rd., Oxford UK
ΑU
CS
     Neuroscience, (1993) Vol. 56, No. 3, pp. 529-533.
S0
     ISSN: 0306-4522.
DT
     Article
     English
LA
     ANSWER 32 OF 196 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
L5
     1993:412346 BIOSIS
ΑN
     PREV199396078071
DN
     Cell adhesion molecule expression in the regenerating rat facial nucleus.
TI
ΑU
     Moneta, Maria E.; Gehrmann, Jochen; Toepper, Rudolf; Kreutzberg, Richard
     B. Banati Andd Geore W. (1)
     (1) Dep. Neuromorphology, Max-Planck-Inst. Psychiatry, Am Klopferspitz
CS
     18A, D-8033 Martinsried Germany
S0
     Journal of Neuroimmunology, (1993) Vol. 45, No. 1-2, pp. 203-206.
     ISSN: 0165-5728.
DT
     Article
     English
LA
L5
     ANSWER 33 OF 196 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN
     1990:428177
ΑN
                  BIOSIS
DN
     BA90:88978
                                   ***HUMAN***
     MONOCYTE SUBPOPULATIONS IN
TT
                                                  GLIOMAS EXPRESSION OF FC AND
     COMPLEMENT RECEPTORS AND CORRELATION WITH TUMOR PROLIFERATION.
ΑU
     MORIMURA T; NEUCHRIST C; KITZ K; BUDKA H; SCHEINER O; KRAFT D; LASSMANN H
     NEUROLOGISCHES INSTITUT, SCHWARZSPANIERSTRASSE 17, A-1090 WIEN, AUSTRIA. ACTA NEUROPATHOL, (1990) 80 (3), 287-294.
CS
S0
     CODEN: ANPTAL. ISSN: 0001-6322.
FS
     BA; OLD
     English
LA
L5
      ANSWER 34 OF 196 BIOTECHDS COPYRIGHT 2003 THOMSON DERWENT/ISI ON STN
ΑN
      2002-09076
                  BIOTECHDS
                         ***human***
      New immortalized
                                        cell line with the characteristics of
ΤI
      Alzheimer's disease;
         vector-mediated v-myc oncogene gene transfer and expression in host
         cell for drug screening and disease therapy
ΑU
      KIM S U
```

UNIV BRITISH COLUMBIA

wo 2002004618 17 Jan 2002

PA PI

```
wo 2000-US18777 10 Jul 2000
ΑI
PRAI WO 2000-18777 10 Jul 2000
      Patent
DT
      English
LA
      WPI: 2002-154931 [20]
os
L5
      ANSWER 35 OF 196 BIOTECHDS COPYRIGHT 2003 THOMSON DERWENT/ISI ON STN
      2002-08627 BIOTECHDS
ΑN
      Genetically modified
                                ***human***
                                                  ***microglia***
TI
                                                                      cell for
      treating neurodegenerative disease, comprises demonstrable phagocytic
      properties, produces progeny in culture, presents surface antigens, and contains modified ***human*** genomic_DNA;
          glial cell encoding v-myc oncogene useful for gene therapy
      KIM<sup>-</sup>S U
ΑU
PA
      UNIV BRITISH COLUMBIA
PΙ
      WO 2002004604 17 Jan 2002
      WO 2000-IB1770 10 Jul 2000 US 2001-887145 22 Jun 2001
ΑI
PRAI
DT
      Patent
      English
LA
os
      WPI: 2002-148175 [19]
      ANSWER 36 OF 196 BIOTECHNO COPYRIGHT 2003 Elsevier Science B.V. on STN
L5
      1995:25233520 BIOTECHNO
ΑN
                          ***human***
      Establishment of
                                           microglial cell lines after transfection
ΤI
      of primary cultures of embryonic microglial cells with the SV40 large T
      antigen
ΑU
      Janabi N.; Peudenier S.; Heron B.; Ng K.H.; Tardieu M.
CS
      Laboratoire Neurovirologie, Universite Paris-Sud, UFR Kremlin-Bicetre, 67
      Rue Gabriel PERI,94276 Le Kremlin Bicetre Cedex, France. Neuroscience Letters, (1995), 195/2 (105-108) CODEN: NELED5 ISSN: 0304-3940
S0
DT
      Journal; Article
CY
      Ireland
LA
      English
SL
      English
L5
     ANSWER 37 OF 196 CANCERLIT ON STN
     2002141186
                      CANCERLIT
AN
DN
     21417959
                 PubMed ID: 11526955
     Establishment of microglial cell cultures derived from postmortem
TI
        ***human***
                       adult brain tissue: immunophenotypical and functional
      characterization.
     de Groot C J; Hulshof S; Hoozemans J J; Veerhuis R
ΑU
     Research Institute Neurosciences Vrije Universiteit Amsterdam, Department
CS
     of Pathology, University Hospital, Vrije Universiteit, The Netherlands..
     cja.degroot@azvu.nl
SO
     MICROSCOPY RESEARCH AND TECHNIQUE, (2001 Jul 1) 54 (1) 34-9.
     Journal code: 9203012. ISSN: 1059-910X.
CY
     United States
DT
     Journal; Article; (JOURNAL ARTICLE)
LA
     English
     MEDLINE; Priority Journals MEDLINE 2001484462
FS
os
EΜ
     200205
     Entered STN: 20020726
ED
     Last Updated on STN: 20020726
L5
     ANSWER 38 OF 196 CANCERLIT on STN
ΑN
     93285781
                   CANCERLIT
DN
     93285781
                 PubMed ID: 8509164
                                      ***microglia***
TI
     Lymphokine induction of rat
                                                          multinucleated giant cell
     formation.
     Lee T T; Martin F C; Merrill J E
CS
     Department of Neurology, Reed Neurological Research Center, UCLA School of
     Medicine 90024-1769.
     RO-1 NS26983 (NINDS)
RO-1 NS30768 (NINDS)
NC
SO
     GLIA, (1993 May) 8 (1) 51-61.
     Journal code: 8806785. ISSN: 0894-1491.
CY
     United States
     Journal; Article; (JOURNAL ARTICLE)
DT
LA
     MEDLINE; Priority Journals; AIDS
FS
os
     MEDLINE 93285781
```

EM

199307

```
Entered STN: 19941107
ED
     Last Updated on STN: 19941107
L5
     ANSWER 39 OF 196 CAPLUS COPYRIGHT 2003 ACS ON STN
     2003:334388 CAPLUS
ΑN
DN
     138:352740
                     ***human***
                                       ***microglia***
                                                          cell and continuous cell
TI
     Immortalized
     line for screening therapeutics for treatment of autoimmune and
     neurodegenerative diseases
     Kim, Seung U.
IN
PΑ
     can.
     U.S. Pat. Appl. Publ., 28 pp., Cont.-in-part of U.S. Ser. No. 855,468.
SO
     CODEN: USXXCO
DT
     Patent
     English
LA
FAN.CNT 3
     PATENT NO.
                       KIND
                              DATE
                                              APPLICATION NO.
                                                                 DATE
PΙ
     us 2003082139
                        Α1
                              20030501
                                              us 2001-887145
                                                                 20010622
                                              wo 2000-us18777
                                                                 20000710
     WO 2002004618
                        Α1
                              20020117
              AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,
              DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP,
              KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN,
              MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
              TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU,
              TJ, TM
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
              DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG 064877 A1 20020530 US 2001-855468 20010515
     US 2002064877
                                              WO 2001-IB1770
     wo 2002004604
                         Α2
                              20020117
                                                                 20010709
         W: AU, CA, JP RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
PT, SE, TR
PRAI WO 2000-US18777 A
                       A2
                              20000710
     US 2001-855468
                         Α2
                              20010515
     US 2001-887145
                              20010622
                         Α
L5
     ANSWER 40 OF 196 CAPLUS COPYRIGHT 2003 ACS ON STN
     2003:327238 CAPLUS
ΑN
DN
     139:83289
TI
     Specific uptake of A.beta.1-40 in rat brain occurs in astrocyte, but not
          ***microglia***
     Matsunaga, Wataru; Shirokawa, Tetsuya; Isobe, Kenichi
     Department of Basic Gerontology, National Institute for Longevity Sciences, Morioka-cho, Obu, 474-8522, Japan
CS
     Neuroscience Letters (2003), 342(1,2), 129-131
SO
     CODEN: NELED5; ISSN: 0304-3940
PB
     Elsevier Science Ltd.
DT
     Journal
     English
LA
RE.CNT 9
               THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
               ALL CITATIONS AVAILABLE IN THE RE FORMAT
L5
     ANSWER 41 OF 196 CAPLUS COPYRIGHT 2003 ACS ON STN
     2003:319354
ΑN
                  CAPLUS
     138:297688
DN
TI
     Methods and compounds for disruption of CD40R/CD40L signaling in the
     treatment of Alzheimer's disease and others
TN
     Tan, Jun; Town, Terrence C.; Mullan, Michael
PA
SO
     U.S. Pat. Appl. Publ., 26 pp., Cont.-in-part of U.S. Ser. No. 585,058.
     CODEN: USXXCO
DT
     Patent
LA
     English
FAN.CNT 2
     PATENT NO.
                        KIND
                              DATE
                                              APPLICATION NO.
                                                                 DATE
PΙ
     us 2003077667
                         Α1
                              20030424
                                              US 2002-218004
                                                                 20020812
PRAI US 1999-137016P
                        Ρ
                              19990601
     us 2000-585058
                         Α2
                              20000601
     US 2001-311115P
                              20010810
     ANSWER 42 OF 196 CAPLUS COPYRIGHT 2003 ACS ON STN
L.5
     2000:619942 CAPLUS
ΑN
     133:348621
DN
```

```
Caspase-3 activation and inflammatory responses in rat hippocampus
TI
     inoculated with a recombinant adenovirus expressing the Alzheimer amyloid
     precursor protein
     Masumura, M.; Hata, R.; Nishimura, I.; Uetsuki, T.; Sawada, T.; Yoshikawa,
ΑU
     BF Research Institute, C/O National Cardiovascular Center, Suita, Osaka,
CS
     56<u>5</u>-08<u>7</u>3, Japan
     Molecular Brain Research (2000), 80(2), 219-227
S0
     CODEN: MBREE4; ISSN: 0169-328X
PB
     Elsevier Science B.V.
     Journal
DT
     English
LA
RE.CNT 43
                THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD
                ALL CITATIONS AVAILABLE IN THE RE FORMAT
     ANSWER 43 OF 196 CAPLUS COPYRIGHT 2003 ACS on STN
L5
     1997:362543 CAPLUS
ΑN
DN
     127:93188
     Expression of adhesion molecules on
                                                 ***human***
                                                                 fetal cerebral
TT
     vessels: relationship to colonization by microglial precursors
     Rezaie, Payam; Male, David
     Dept. Neuropathology, Inst. Psychiatry, London, SE5 8AF, UK
Biochemical Society Transactions (1997), 25(2), 170S
CS
S<sub>0</sub>
     CODEN: BCSTB5; ISSN: 0300-5127
     Portland Press
PB
     Journal
DT
LA
     English
L5
     ANSWER 44 OF 196 CAPLUS COPYRIGHT 2003 ACS on STN
AN
     1991:204921 CAPLUS
DN
     114:204921
              ***microglia***
                                  constitutively express .beta.-2 integrins
TI
     Brain
     Akiyama, H.; McGeer, P. L.
ΑU
     Fac. Med., Úniv. British Columbia, Vancouver, BC, V6T 1W5, Can. Journal of Neuroimmunology (1990), 30(1), 81-93
CS
50
     CODEN: JNRIDW; ISSN: 0165-5728
     Journal
DT
LA
     English
      ANSWER 45 OF 196 DGENE COPYRIGHT 2003 THOMSON DERWENT ON STN
L5
      AAU11900 Peptide
ΑN
                                  DGENE
                                ***human***
                                                   ***microglia***
                                                                        cell for
TI
       Genetically modified
      treating neurodegenerative disease, comprises demonstrable phagocytic properties, produces progeny in culture, presents surface antigens, and contains modified ***human*** genomic DNA -
IN
       Kim S U
       (UYBR-N)
PΑ
                    UNIV BRITISH COLUMBIA.
PΙ
      WO 2002004604 A2 20020117
                                                      46p
      WO 2001-IB1770
                          20010709
AΤ
PRAI
      wo 2000-us18777
                          20000710
       us 2001-855468
                          20010515
       us 2001-887145
                          20010622
DT
       Patent
       English
LA
       2002-148175 [19]
***Human***
os
DESC
                        amyloid beta 25-35 peptide.
L5
      ANSWER 46 OF 196 DGENE COPYRIGHT 2003 THOMSON DERWENT On STN
       ABK14370 DNA
ΑN
                             DGENE
       Genetically modified
                                ***human***
                                                    ***microglia***
TI
                                                                        cell for
       treating neurodegenerative disease, comprises demonstrable phagocytic
       properties, produces progeny in culture, presents surface antigens, and contains modified ***human*** genomic DNA -
IN
       Kim S U
       (UYBR-N)
                    UNIV BRITISH COLUMBIA.
PA
PΙ
      WO 2002004604 A2 20020117
                                                      46p
ΑI
      WO 2001-IB1770
                          20010709
PRAI
      wo 2000-us18777
                          20000710
       US 2001-855468
                          20010515
       US 2001-887145
                          20010622
DT
       Patent
       English
LA
OS
       2002-148175 [19]
         ***Human***
                       G3PDH antisense PCR primer.
DESC
L5
       ANSWER 47 OF 196 DGENE COPYRIGHT 2003 THOMSON DERWENT ON STN
```

```
ABK14369 DNA
AN
                             DGENE
       Genetically modified
                               ***human***
                                                 ***microglia***
                                                                     cell for
ΤI
       treating neurodegenerative disease, comprises demonstrable phagocytic
       properties, produces progeny in culture, presents surface antigens, and contains modified ***human*** genomic DNA -
IN
       Kim S U
                    UNIV BRITISH COLUMBIA.
PA
       (UYBR-N)
       WO 2002004604 A2 20020117
PI
                                                    46p
      WO 2001-IB1770
                         20010709
ΑI
      WO 2000-US18777
                         20000710
PRAI
       US 2001-855468
                         20010515
       US 2001-887145
                         20010622
DT
       Patent
       English
LA
       2002-148175 [19]
os
         ***Human*** G3PDH sense PCR primer.
DESC
L5
       ANSWER 48 OF 196 DGENE COPYRIGHT 2003 THOMSON DERWENT ON STN
       ABK14368 DNA
ΑN
                             DGENE
                               ***human***
       Genetically modified
                                                  ***microglia***
TI
       treating neurodegenerative disease, comprises demonstrable phagocytic
      properties, produces progeny in culture, presents surface antigens, and contains modified ***human*** genomic DNA -
IN
       Kim S U
PA
       (UYBR-N)
                    UNIV BRITISH COLUMBIA.
       WO 2002004604 A2 20020117
PΙ
                                                    46p
      WO 2001-IB1770
                         20010709
ΑI
PRAI
      WO 2000-US18777
                         20000710
       US 2001-855468
                         20010515
       us 2001-887145
                         20010622
DT
       Patent
LA
       English
05
       2002-148175 [19]
         ***Human*** B7-2 antisense PCR primer.
DESC
L5
      ANSWER 49 OF 196 DGENE COPYRIGHT 2003 THOMSON DERWENT ON STN
AN
       ABK14367 DNA
                            DGENE
       Genetically modified
                               ***human***
                                                  ***microglia***
TI
       treating neurodegenerative disease, comprises demonstrable phagocytic
       properties, produces progeny in culture, presents surface antigens, and contains modified ***human*** genomic DNA -
                                            genomic DNA
ΙN
       Kim S U
PA
       (UYBR-N)
                    UNIV BRITISH COLUMBIA.
      wo 2002004604 A2 20020117
PΙ
                                                    46p
ΑI
      WO 2001-IB1770
                         20010709
      wo 2000-US18777
PRAI
                         20000710
       US 2001-855468
                         20010515
                         20010622
       US 2001-887145
DT
       Patent
LA
       English
os
       2002-148175 [19]
         ***Human*** B7-2 sense PCR primer.
DESC
L5
      ANSWER 50 OF 196 DGENE COPYRIGHT 2003 THOMSON DERWENT ON STN
ΑN
       ABK14366 DNA
                            DGENE
       Genetically modified ***human***
TI
                                                  ***microglia***
                                                                      cell for
       treating neurodegenerative disease, comprises demonstrable phagocytic
      properties, produces progeny in culture, presents surface antigens, and contains modified ***human*** genomic DNA -
                                            genomic DNA
IN
       Kim S U
PA
       (UYBR-N)
                    UNIV BRITISH COLUMBIA.
      WO 2002004604 A2 20020117
PI
                                                    46p
ΑI
      WO 2001-IB1770
                         20010709
PRAI
      wo 2000-us18777
                         20000710
      US 2001-855468
US 2001-887145
                         20010515
                         20010622
DT
       Patent
      English
LA
      2002-148175 [19]
***Human*** GFAP antisense PCR primer.
os
DESC
L5
      ANSWER 51 OF 196 DGENE COPYRIGHT 2003 THOMSON DERWENT ON STN
ΑN
      ABK14365 DNA
                               ***human***
TI
      Genetically modified
                                                  ***microglia***
                                                                      cell for
      treating neurodegenerative disease, comprises demonstrable phagocytic
```

properties, produces progeny in culture, presents surface antigens, and

```
contains modified ***human***
                                            genomic DNA -
      Kim S U
ΙN
PA
       (UYBR-N)
                   UNIV BRITISH COLUMBIA.
      WO 2002004604 A2 20020117
PΙ
                                                    46p
                         20010709
      WO 2001-IB1770
ΑI
PRAI
      WO 2000-US18777
                         20000710
      US 2001-855468
                         20010515
      US 2001-887145
                         20010622
DT
      Patent
      English
LA
os
      2002-148175 [19]
         ***Human***
DESC
                      GFAP sense PCR primer.
L5
      ANSWER 52 OF 196 DGENE COPYRIGHT 2003 THOMSON DERWENT ON STN
      ABK14364 DNA
ΑN
                            DGENE
                               ***human***
                                                 ***microglia***
TI
      Genetically modified
                                                                      cell for
      treating neurodegenerative disease, comprises demonstrable phagocytic
      properties, produces progeny in culture, presents surface antigens, and contains modified ***human*** genomic DNA -
IN
      Kim S U
       (UYBR-N)
                    UNIV BRITISH COLUMBIA.
PA
      WO 2002004604 A2 20020117
                                                    46p
PΙ
      WO 2001-IB1770
                         20010709
ΑI
      WO 2000-US18777
PRAI
                         20000710
      US 2001-855468
                         20010515
      us 2001-887145
                         20010622
DT
      Patent
      English
LA
      2002-148175 [19]
os
        ***Human*** MBP antisense PCR primer.
DESC
L5
      ANSWER 53 OF 196 DGENE COPYRIGHT 2003 THOMSON DERWENT ON STN
      ABK14363 DNA
ΑN
                            DGENE
      Genetically modified ***human***
                                                  ***microglia***
TI
      treating neurodegenerative disease, comprises demonstrable phagocytic
      properties, produces progeny in culture, presents surface antigens, and contains modified ***human*** genomic DNA -
IN
PA
                    UNIV BRITISH COLUMBIA.
       (UYBR-N)
      WO 2002004604 A2 20020117
PΙ
                                                    46p
      WO 2001-IB1770
ΑI
                         20010709
PRAI
      wo 2000-US18777
                         20000710
      US 2001-855468
                         20010515
      us 2001-887145
                         20010622
DT
      Patent
      English
LA
os
      2002-148175 [19]
         ***Human*** MBP sense PCR primer.
DESC
L5
      ANSWER 54 OF 196 DGENE COPYRIGHT 2003 THOMSON DERWENT ON STN
ΑN
      ABK14362 DNA
      Genetically modified
                               ***human***
                                                  ***microglia***
                                                                     cell for
TI
      treating neurodegenerative disease, comprises demonstrable phagocytic
      properties, produces progeny in culture, presents surface antigens, and contains modified ***human*** genomic DNA -
IN
      Kim S U
                    UNIV BRITISH COLUMBIA.
PA
       (UYBR-N)
      wo 2002004604 A2 20020117
PΙ
                                                    46p
ΑI
      WO 2001-IB1770
                         20010709
PRAI
      wo 2000-US18777
                         20000710
      us 2001-855468
                         20010515
      us 2001-887145
                         20010622
DT
      Patent
1 A
      English
os
      2002-148175 [19]
         ***Human*** NF-M antisense PCR primer.
DESC
L5
      ANSWER 55 OF 196 DGENE COPYRIGHT 2003 THOMSON DERWENT ON STN
ΑN
      ABK14361 DNA
                             DGENE
                               ***human***
TI
      Genetically modified
                                                  ***microglia***
                                                                     cell for
      treating neurodegenerative disease, comprises demonstrable phagocytic
      properties, produces progeny in culture, presents surface antigens, and contains modified ***human*** genomic DNA -
IN
      Kim S U
PΑ
                   UNIV BRITISH COLUMBIA.
       (UYBR-N)
ΡI
      WO 2002004604 A2 20020117
```

46p

```
WO 2001-IB1770
                        20010709
AΙ
      WO 2000-US18777
                        20000710
PRAI
      us 2001-855468
                        20010515
      us 2001-887145
                        20010622
DT
      Patent
      English
ΙΔ
      2002-148175 [19]
***Human*** !
OS
                     NF-M sense PCR primer.
DESC
L5
      ANSWER 56 OF 196 DGENE COPYRIGHT 2003 THOMSON DERWENT ON STN
      ABK14360 DNA
ΑN
                           DGENE
      Genetically modified
                              ***human***
                                               ***microalia***
TI
                                                                  cell for
      treating neurodegenerative disease, comprises demonstrable phagocytic
      properties, produces progeny in culture, presents surface antigens, and
                          ***human***
      contains modified
                                         genomic DNA
ΙN
      Kim S U
PΔ
      (UYBR-N)
                   UNIV BRITISH COLUMBIA.
      WO 2002004604 A2 20020117
                                                 46p
PΙ
      WO 2001-IB1770
                        20010709
ΑI
      WO 2000-US18777
PRAI
                        20000710
      US 2001-855468
                        20010515
      US 2001-887145
                        20010622
DT
      Patent
      English
LA
os
      2002-148175 [19]
        ***Human***
DESC
                     TNF-alpha antisense PCR primer.
L5
      ANSWER 57 OF 196 DGENE COPYRIGHT 2003 THOMSON DERWENT ON STN
ΑN
      ABK14359 DNA
                           DGENE
      Genetically modified ***human***
                                                                  cell for
                                               ***microglia***
TI
      treating neurodegenerative disease, comprises demonstrable phagocytic
      properties, produces progeny in culture, presents surface antigens, and
                         ***human***
      contains modified
                                          genomic DNA
IN
      Kim S U
PΑ
      (UYBR-N)
                   UNIV BRITISH COLUMBIA.
PΙ
      WO 2002004604 A2 20020117
                                                 46p
ΑI
      WO 2001-IB1770
                        20010709
PRAI
      wo 2000-us18777
                        20000710
      US 2001-855468
                        20010515
      US 2001-887145
                        20010622
DT
      Patent
LA
      English
      2002-148175 [19]
OS
        ***Human***
                       TNF-alpha sense PCR primer.
DESC
L5
      ANSWER 58 OF 196 DGENE COPYRIGHT 2003 THOMSON DERWENT ON STN
ΑN
      ABK14358 DNA
                           DGENE
      Genetically modified
TI
                              ***human***
                                               ***microglia***
                                                                  cell for
      treating neurodegenerative disease, comprises demonstrable phagocytic
      properties, produces progeny in culture, presents surface antigens, and
                          ***human***
      contains modified
                                          genomic DNA
ΤN
      Kim S U
      (UYBR-N)
                  UNIV BRITISH COLUMBIA.
PA
PΙ
      WO 2002004604 A2 20020117
                                                 46p
ΑI
      WO 2001-IB1770
                        20010709
PRAI
      WO 2000-US18777
                        20000710
      us 2001-855468
                        20010515
      US 2001-887145
                        20010622
DT
      Patent
      Enalish
LA
os
      2002-148175 [19]
        ***Human***
DESC
                      interleukin-15 antisense PCR primer.
L5
      ANSWER 59 OF 196 DGENE COPYRIGHT 2003 THOMSON DERWENT ON STN
ΑN
      ABK14357 DNA
                           DGENE
TI
      Genetically modified
                             ***human***
                                               ***microglia***
                                                                  cell for
      treating neurodegenerative disease, comprises demonstrable phagocytic
      properties, produces progeny in culture, presents surface antigens, and contains modified ***human*** genomic DNA -
IN
      Kim S U
PA
                   UNIV BRITISH COLUMBIA.
      (UYBR-N)
PI
      WO 2002004604 A2 20020117
                                                 46p
ΑI
      WO 2001-IB1770
                        20010709
PRAI
      WO 2000-US18777
                        20000710
      US 2001-855468
                        20010515
```

US 2001-887145

20010622

```
Patent
DT
      English
LA
      20Ŏ2-148175 [19]
os
         ***Human***
                       interleukin-15 sense PCR primer.
DESC
      ANSWER 60 OF 196 DGENE COPYRIGHT 2003 THOMSON DERWENT ON STN
L5
AN
      ABK14356
                 DNA
                             DGENE
      Genetically modified ***human***
                                                   ***microglia***
                                                                        cell for
TI
      treating neurodegenerative disease, comprises demonstrable phagocytic properties, produces progeny in culture, presents surface antigens, and contains modified ***human*** genomic DNA -
      Kim S U
IN
PA
       (UYBR-N)
                    UNIV BRITISH COLUMBIA.
      WO 2002004604 A2 20020117
PΙ
                                                      46p
      WO 2001-IB1770
ΑI
                          20010709
PRAI
      WO 2000-US18777
                          20000710
      US 2001-855468
                          20010515
      US 2001-887145
                          20010622
DT
      Patent
LA
      English
      2002-148175 [19]
os
         ***Human*** interleukin-13 antisense PCR primer.
DESC
L5
      ANSWER 61 OF 196 DGENE COPYRIGHT 2003 THOMSON DERWENT ON STN
      ABK14355 DNA
AN
                             DGENE
                                ***human***
      Genetically modified
                                                   ***microglia***
TI
                                                                        cell for
      treating neurodegenerative disease, comprises demonstrable phagocytic
      properties, produces progeny in culture, presents surface antigens, and
      contains modified ***human***
                                             genomic DNA
IN
      Kim S U
                    UNIV BRITISH COLUMBIA.
       (UYBR-N)
PA
      WO 2002004604 A2 20020117
PΙ
                                                      46p
ΑI
      WO 2001-IB1770
                          20010709
      WO 2000-US18777
                          20000710
PRAI
      US 2001-855468
                          20010515
      US 2001-887145
                          20010622
DT
      Patent
      English
LA
      2002-148175 [19]
os
         ***Human***
                         interleukin-13 sense PCR primer.
DESC
L5
      ANSWER 62 OF 196 DGENE COPYRIGHT 2003 THOMSON DERWENT on STN
AN
      ABK14354 DNA
                             DGENE
      Genetically modified ***human***
                                                   ***microglia***
TI
      treating neurodegenerative disease, comprises demonstrable phagocytic properties, produces progeny in culture, presents surface antigens, and contains modified ***human*** genomic DNA -
      Kim S U
ΤN
PA
       (UYBR-N)
                    UNIV BRITISH COLUMBIA.
      WO 2002004604 A2 20020117
PΙ
                                                      46p
      WO 2001-IB1770
ΑI
                          20010709
PRAI
      WO 2000-US18777
                          20000710
      US 2001-855468
                          20010515
      US 2001-887145
                          20010622
DT
      Patent
LA
      English
      2002-148175 [19]
OS
         ***Human*** interleukin-12 antisense PCR primer.
DESC
L5
      ANSWER 63 OF 196 DGENE COPYRIGHT 2003 THOMSON DERWENT ON STN
ΑN
      ABK14353 DNA
                             DGENE
      Genetically modified
                                ***human***
                                                   ***microglia***
TI
      treating neurodegenerative disease, comprises demonstrable phagocytic
      properties, produces progeny in culture, presents surface antigens, and contains modified ***human*** genomic DNA -
IN
      Kim S U
                    UNIV BRITISH COLUMBIA.
PA
       (UYBR-N)
      WO 2002004604 A2 20020117
PΙ
                                                      46p
      WO 2001-IB1770
                          20010709
ΑI
      WO 2000-US18777
PRAI
                          20000710
      US 2001-855468
                          20010515
      us 2001-887145
                          20010622
DT
      Patent
LA
      English
      2002-148175 [19]
os
         ***Human***
                        interleukin-12 sense PCR primer.
```

DESC

```
L5
      ANSWER 64 OF 196 DGENE COPYRIGHT 2003 THOMSON DERWENT ON STN
ΑN
      ABK14352 DNA
                             DGENE
      Genetically modified
                                                  ***microglia***
                                                                      cell for
                                ***human***
ΤI
      treating neurodegenerative disease, comprises demonstrable phagocytic
      properties, produces progeny in culture, presents surface antigens, and contains modified ***human*** genomic DNA -
IN
      Kim S U
       (UYBR-N)
                    UNIV BRITISH COLUMBIA.
PA
      WO 2002004604 A2 20020117
                                                    46p
ΡI
      WO 2001-IB1770
                          20010709
ΑI
      WO 2000-US18777
                         20000710
PRAI
      US 2001-855468
                         20010515
      us 2001-887145
                         20010622
DT
      Patent
      English
LA
      2002-148175 [19]
***Human*** interleukin-11 antisense PCR primer.
05
DESC
      ANSWER 65 OF 196 DGENE COPYRIGHT 2003 THOMSON DERWENT ON STN
L5
      ABK14351 DNA
ΑN
                             DGENE
                               ***human***
      Genetically modified
                                                 ***microglia***
TI
                                                                      cell for
      treating neurodegenerative disease, comprises demonstrable phagocytic
      properties, produces progeny in culture, presents surface antigens, and contains modified ***human*** genomic DNA -
IN
       (UYBR-N)
                    UNIV BRITISH COLUMBIA.
PA
      WO 2002004604 A2 20020117
PΙ
                                                    46p
ΑI
      WO 2001-IB1770
                         20010709
                         20000710
      wo 2000-us18777
PRAI
      us 2001-855468
                          20010515
      US 2001-887145
                         20010622
DT
      Patent
      English
LA
      2002-148175 [19]
0S
         ***Human***  interleukin-11 sense PCR primer.
DESC
L5
      ANSWER 66 OF 196 DGENE COPYRIGHT 2003 THOMSON DERWENT ON STN
      ABK14350 DNA
ΑN
                           DGENE
      Genetically modified ***human***
                                                 ***microglia***
TI
                                                                      cell for
      treating neurodegenerative disease, comprises demonstrable phagocytic
      properties, produces progeny in culture, presents surface antigens, and contains modified ***human*** genomic DNA -
IN
      Kim S U
                    UNIV BRITISH COLUMBIA.
PA
       (UYBR-N)
      WO 2002004604 A2 20020117
PΙ
                                                    46p
      WO 2001-IB1770
                          20010709
ΑI
                         20000710
PRAI
      WO 2000-US18777
      us 2001-855468
                         20010515
      US 2001-887145
                         20010622
DT
      Patent
      English
LA
      2002-148175 [19]
***Human*** interleukin-10 antisense PCR primer.
os
DESC
L5
      ANSWER 67 OF 196 DGENE COPYRIGHT 2003 THOMSON DERWENT ON STN
      ABK14349 DNA
ΑN
                            DGENE
      Genetically modified ***human***
                                                  ***microglia***
TI
                                                                      cell for
      treating neurodegenerative disease, comprises demonstrable phagocytic
      properties, produces progeny in culture, presents surface antigens, and contains modified ***human*** genomic DNA -
ΙN
PA
                    UNIV BRITISH COLUMBIA.
       (UYBR-N)
PΙ
      WO 2002004604 AZ 20020117
                                                    46p
ΑI
      WO 2001-IB1770
                         20010709
PRAI
      WO 2000-US18777
                         20000710
      US 2001-855468
US 2001-887145
                          20010515
                         20010622
DT
      Patent
      English
IΑ
      2002-148175 [19]
os
         ***Human*** interleukin-10 sense PCR primer.
DESC
L5
      ANSWER 68 OF 196 DGENE COPYRIGHT 2003 THOMSON DERWENT ON STN
      ABK14348 DNA
AN
                             DGENE
      Genetically modified
                                ***human***
                                                  ***microglia***
```

TI

cell for

```
treating neurodegenerative disease, comprises demonstrable phagocytic
       properties, produces progeny in culture, presents surface antigens, and
                             ***human***
       contains modified
                                             genomic DNA
IN
       Kim S U
       (UYBR-N)
                    UNIV BRITISH COLUMBIA.
PA
      WO 2002004604 A2 20020117
PΙ
                                                     46p
      WO 2001-IB1770
AΙ
                          20010709
      wo 2000-us18777
                          20000710
PRAI
       US 2001-855468
                          20010515
      US 2001-887145
                          20010622
       Patent
DT
       English
LA
       2002-148175 [19]
***Human***
os
                        interleukin-9 antisense PCR primer.
DESC
L5
      ANSWER 69 OF 196 DGENE COPYRIGHT 2003 THOMSON DERWENT ON STN
      ABK14347 DNA
ΑN
                             DGENE
       Genetically modified
                                                  ***microglia***
                                ***human***
TI
                                                                      cell for
      treating neurodegenerative disease, comprises demonstrable phagocytic properties, produces progeny in culture, presents surface antigens, and contains modified ***human*** genomic DNA -
ΙN
       Kim S U
       (UYBR-N)
                    UNIV BRITISH COLUMBIA.
PA
      WO 2002004604 A2 20020117
PI
                                                     46p
      WO 2001-IB1770
                          20010709
ΑI
      wo 2000-US18777
                         20000710
PRAI
      US 2001-855468
                          20010515
       US 2001-887145
                          20010622
DT
       Patent
       English
LA
       2002-148175 [19]
os
         ***Human*** interleukin-9 sense PCR primer.
DESC
      ANSWER 70 OF 196 DGENE COPYRIGHT 2003 THOMSON DERWENT ON STN
L5
       ABK14346 DNA
ΑN
                           DGENE
       Genetically modified ***human***
TI
                                                  ***microglia***
                                                                      cell for
       treating neurodegenerative disease, comprises demonstrable phagocytic
      properties, produces progeny in culture, presents surface antigens, and contains modified ***human*** genomic DNA -
IN
      Kim S U
       (UYBR-N)
                    UNIV BRITISH COLUMBIA.
PA
ΡI
      WO 2002004604 A2 20020117
                                                     46p
AΤ
      WO 2001-IB1770
                          20010709
      WO 2000-US18777
PRAI
                          20000710
       US 2001-855468
                          20010515
      US 2001-887145
                          20010622
DT
       Patent
LA
      English
os
       2002-148175 [19]
         ***Human*** ¯interleukin-8 antisense PCR primer.
DESC
L5
      ANSWER 71 OF 196 DGENE COPYRIGHT 2003 THOMSON DERWENT ON STN
ΑN
      ABK14345 DNA
                             DGENE
                               ***human***
ΤI
       Genetically modified
                                                  ***microglia***
                                                                      cell for
       treating neurodegenerative disease, comprises demonstrable phagocytic
      properties, produces progeny in culture, presents surface antigens, and contains modified ***human*** genomic DNA -
IN
       Kim S U
PA
       (UYBR-N)
                    UNIV BRITISH COLUMBIA.
PI
      WO 2002004604 A2 20020117
                                                     46p
ΑI
      WO 2001-IB1770
                          20010709
PRAI
      wo 2000-us18777
                          20000710
      US 2001-855468
                          20010515
      us 2001-887145
                          20010622
DT
      Patent
      English
LA
      2002-148175 [19]
***Human*** interleukin-8 sense PCR primer.
os
DESC
L5
      ANSWER 72 OF 196 DGENE COPYRIGHT 2003 THOMSON DERWENT ON STN
AN
       ABK14344 DNA
                             DGENE
TI
       Genetically modified
                                ***human***
                                                  ***microglia***
                                                                      cell for
       treating neurodegenerative disease, comprises demonstrable phagocytic
       properties, produces progeny in culture, presents surface antigens, and
                           ***human***
       contains modified
                                             genomic DNA
```

IN

Kim S U

```
(UYBR-N)
                    UNIV BRITISH COLUMBIA.
PA
      WO 2002004604 A2 20020117
ΡI
                                                     46p
ΑI
      WO 2001-IB1770
                          20010709
      WO 2000-US18777
                          20000710
PRAI
      US 2001-855468
                          20010515
      US 2001-887145
                          20010622
DT
      Patent
      English
LA
      2002-148175 [19]
os
         ***Human***
                        interleukin-7 antisense PCR primer.
DESC
      ANSWER 73 OF 196 DGENE COPYRIGHT 2003 THOMSON DERWENT ON STN
L5
ΑN
      ABK14343 DNA
                             DGENE
      Genetically modified
                                ***human***
                                                   ***microglia***
TI
      treating neurodegenerative disease, comprises demonstrable phagocytic
      properties, produces progeny in culture, presents surface antigens, and
                           ***human***
      contains modified
                                             genomic DNA
IN
      Kim S U
PA
       (UYBR-N)
                    UNIV BRITISH COLUMBIA.
      WO 2002004604 A2 20020117
PΙ
                                                     46p
      WO 2001-IB1770
                          20010709
ΑI
PRAI
      WO 2000-US18777
                          20000710
      US 2001-855468
                          20010515
      us 2001-887145
                          20010622
DT
      Patent
      English
LA
      2002-148175 [19]
os
         ***Human***
                       interleukin-7 sense PCR primer.
DESC
      ANSWER 74 OF 196 DGENE COPYRIGHT 2003 THOMSON DERWENT ON STN
L5
      ABK14342 DNA
ΑN
                             DGENE
      Genetically modified ***human***
TI
                                                   ***microalia***
                                                                       cell for
      treating neurodegenerative disease, comprises demonstrable phagocytic properties, produces progeny in culture, presents surface antigens, and contains modified ***human*** genomic DNA -
IN
      Kim S U
       (UYBR-N)
PA
                    UNIV BRITISH COLUMBIA.
      WO 2002004604 A2 20020117
PΙ
                                                     46p
      WO 2001-IB1770
ΑI
                          20010709
PRAI
      WO 2000-US18777
                          20000710
      US 2001-855468
                          20010515
      US 2001-887145
                          20010622
DT
      Patent
      English
LA
      20Ŏ2-148175 [19]
os
         ***Human*** interleukin-6 antisense PCR primer.
DESC
L5
      ANSWER 75 OF 196 DGENE COPYRIGHT 2003 THOMSON DERWENT ON STN
ΑN
      ABK14341 DNA
                             DGENE
      Genetically modified
                                ***human***
TI
                                                   ***microglia***
                                                                       cell for
      treating neurodegenerative disease, comprises demonstrable phagocytic
      properties, produces progeny in culture, presents surface antigens, and
      contains modified ***human***
                                             genomic DNA
IN
      Kim S U
PA
       (UYBR-N)
                    UNIV BRITISH COLUMBIA.
PΙ
      WO 2002004604 A2 20020117
                                                     46p
      WO 2001-IB1770
ΑI
                          20010709
      WO 2000-US18777
PRAI
                          20000710
      US 2001-855468
                          20010515
      US 2001-887145
                          20010622
DT
      Patent
LA
      English
      2002-148175 [19]
os
         ***Human***
DESC
                        interleukin-6 sense PCR primer.
L5
      ANSWER 76 OF 196 DGENE COPYRIGHT 2003 THOMSON DERWENT ON STN
AN
      ABK14340 DNA
                             DGENE
      Genetically modified
                               ***human***
TT
                                                  ***microglia***
                                                                       cell for
      treating neurodegenerative disease, comprises demonstrable phagocytic properties, produces progeny in culture, presents surface antigens, and contains modified ***human*** genomic DNA -
ΙN
      Kim S U
                    UNIV BRITISH COLUMBIA.
PA
      wo 2002004604 A2 20020117
PI
                                                     46p
      WO 2001-IB1770
ΑI
                          20010709
     wo 2000-US18777
```

PRAI

20000710

```
US 2001-855468
                         20010515
      us 2001-887145
                         20010622
DT
      Patent
      English
LA
      2002-148175 [19]
***Human*** interleukin-5 antisense PCR primer.
os
DESC
L5
      ANSWER 77 OF 196 DGENE COPYRIGHT 2003 THOMSON DERWENT ON STN
      ABK14339 DNA
AN
                            DGENE
      Genetically modified ***human***
                                                 ***microglia***
                                                                     cell for
TT
      treating neurodegenerative disease, comprises demonstrable phagocytic
      properties, produces progeny in culture, presents surface antigens, and
                            ***human***
       contains modified
                                           genomic DNA
      Kim S U
ΙN
PA
       (UYBR-N)
                   UNIV BRITISH COLUMBIA.
PΙ
      WO 2002004604 A2 20020117
                                                   46p
      WO 2001-IB1770
ΑI
                         20010709
      WO 2000-US18777
PRAI
                         20000710
      US 2001-855468
                         20010515
      US 2001-887145
                         20010622
DT
      Patent
      English
ΙΑ
      2002-148175 [19]
***Human***
OS
                      interleukin-5 sense PCR primer.
DESC
L5
      ANSWER 78 OF 196 DGENE COPYRIGHT 2003 THOMSON DERWENT ON STN
      ABK14338 DNA
ΑN
                            DGENE
      Genetically modified ***human***
ΤI
                                                 ***microglia***
                                                                    cell for
      treating neurodegenerative disease, comprises demonstrable phagocytic
      properties, produces progeny in culture, presents surface antigens, and
                           ***human***
      contains modified
                                           genomic DNA
IN
      Kim S U
       (UYBR-N)
                   UNIV BRITISH COLUMBIA.
PA
      WO 2002004604 A2 20020117
PΙ
                                                   46p
ΑI
      WO 2001-IB1770
                         20010709
PRAI
      WO 2000-US18777
                         20000710
      US 2001-855468
                         20010515
      US 2001-887145
                         20010622
DT
      Patent
LA
      English
      2002-148175 [19]
***Human*** interleukin-4 antisense PCR primer.
os
DESC
L5
      ANSWER 79 OF 196 DGENE COPYRIGHT 2003 THOMSON DERWENT ON STN
AN
      ABK14337 DNA
                            DGENE
      Genetically modified
                               ***human***
                                                 ***microglia***
TI
                                                                     cell for
      treating neurodegenerative disease, comprises demonstrable phagocytic
      properties, produces progeny in culture, presents surface antigens, and
                            ***human***
      contains modified
                                           genomic DNA
IN
      Kim S U
PA
       (UYBR-N)
                   UNIV BRITISH COLUMBIA.
      WO 2002004604 A2 20020117
PΙ
                                                   46p
      WO 2001-IB1770
                         20010709
AT
PRAI
      wo 2000-US18777
                         20000710
      us 2001-855468
                         20010515
      us 2001-887145
                         20010622
DT
      Patent
      English
LA
os
      2002-148175 [19]
         ***Human***
DESC
                      interleukin-4 sense PCR primer.
L5
      ANSWER 80 OF 196 DGENE COPYRIGHT 2003 THOMSON DERWENT ON STN
      ABK14336 DNA
AN
                            DGENE
TI
      Genetically modified
                              ***human***
                                                ***microglia***
                                                                    cell for
      treating neurodegenerative disease, comprises demonstrable phagocytic properties, produces progeny in culture, presents surface antigens, and contains modified ***human*** genomic DNA -
      Kim S U
ΙN
PA
       (UYBR-N)
                   UNIV BRITISH COLUMBIA.
PΙ
      WO 2002004604 A2 20020117
                                                   46p
ΑI
      WO 2001-IB1770
                         20010709
PRAI
      WO 2000-US18777
                         20000710
      US 2001-855468
                         20010515
      US 2001-887145
                         20010622
DT
      Patent
LA
      English
```

```
2002-148175 [19]
***Human*** interleukin-3 antisense PCR primer.
 OS
 DESC
 L5
        ANSWER 81 OF 196 DGENE COPYRIGHT 2003 THOMSON DERWENT ON STN
        ABK14335 DNA
 AN
                               DGENE
        Genetically modified ***human***
 TI
                                                     ***microglia***
                                                                           cell for
        treating neurodegenerative disease, comprises demonstrable phagocytic
        properties, produces progeny in culture, presents surface antigens, and contains modified ***human*** genomic DNA -
                                               genomic DNA
        Kim S U
IN
        (UYBR-N)
 PA
                      UNIV BRITISH COLUMBIA.
        WO 2002004604 A2 20020117
 PΙ
                                                        46p
        WO 2001-IB1770
                            20010709
ΑI
PRAI
        WO 2000-US18777
                            20000710
        US 2001-855468
                            20010515
        US 2001-887145
                            20010622
DT
        Patent
        English
LA
        2002-148175 [19]
***Human*** interleukin-3 sense PCR primer.
os
DESC
        ANSWER 82 OF 196 DGENE COPYRIGHT 2003 THOMSON DERWENT ON STN
L5
        ABK14334 DNA
AN
                               DGENE
        Genetically modified ***human***
TI
                                                     ***microglia***
                                                                           cell for
        treating neurodegenerative disease, comprises demonstrable phagocytic
       properties, produces progeny in culture, presents surface antigens, and contains modified ***human*** genomic DNA -
                                               genomic DNA
IN
       Kim S U
PA
        (UYBR-N)
                     UNIV BRITISH COLUMBIA.
       WO 2002004604 A2 20020117
ΡI
                                                        46p
ΑI
       WO 2001-IB1770
                            20010709
PRAI
       WO 2000-US18777
                           20000710
       US 2001-855468
                           20010515
       US 2001-887145
                           20010622
DT
       Patent
       English
LA
       2002-148175 [19]
os
          ***Human*** interleukin-2 antisense PCR primer.
DESC
L5
       ANSWER 83 OF 196 DGENE COPYRIGHT 2003 THOMSON DERWENT ON STN
AN
       ABK14333 DNA
                               DGENE
TI
       Genetically modified
                                 ***human***
                                                     ***microglia***
                                                                           cell for
       treating neurodegenerative disease, comprises demonstrable phagocytic properties, produces progeny in culture, presents surface antigens, and contains modified ***human*** genomic DNA -
IN
       Kim S U
PA
       (UYBR-N)
                     UNIV BRITISH COLUMBIA.
ΡI
       WO 2002004604 A2 20020117
                                                        46p
AΙ
       WO 2001-IB1770
                           20010709
PRAI
       WO 2000-US18777
                           20000710
       US 2001-855468
                           20010515
       US 2001-887145
                           20010622
DT
       Patent
LA
       English
os
       2002-148175 [19]
          ***Human*** interleukin-2 sense PCR primer.
DESC
L5
       ANSWER 84 OF 196 DGENE COPYRIGHT 2003 THOMSON DERWENT ON STN
       ABK14332 DNA
AN
                              DGENE
TI
       Genetically modified ***human***
                                                    ***microglia***
                                                                          cell for
       treating neurodegenerative disease, comprises demonstrable phagocytic properties, produces progeny in culture, presents surface antigens, and contains modified ***human*** genomic DNA -
       Kim S U
TN
PA
       (UYBR-N)
                     UNIV BRITISH COLUMBIA.
PI
       WO 2002004604 A2 20020117
                                                        46p
ΑI
       WO 2001-IB1770
                           20010709
PRAI
       WO 2000-US18777
                           20000710
       US 2001-855468
                           20010515
       US 2001-887145
                           20010622
DT
       Patent
LA
       English
       2002-148175 [19]
***Human*** interleukin-1beta antisense PCR primer.
os
DESC
L5
       ANSWER 85 OF 196 DGENE COPYRIGHT 2003 THOMSON DERWENT ON STN
```

```
ABK14331 DNA
                             DGENE
ΑN
TI
       Genetically modified ***human***
                                                  ***microglia***
                                                                      cell for
       treating neurodegenerative disease, comprises demonstrable phagocytic
       properties, produces progeny in culture, presents surface antigens, and contains modified ***human*** genomic DNA -
                                            genomic DNA
       Kim S U
IN
       (UYBR-N)
PA
                    UNIV BRITISH COLUMBIA.
       WO 2002004604 A2 20020117
ΡI
                                                    46p
ΑI
       WO 2001-IB1770
                          20010709
PRAI
      WO 2000-US18777
                          20000710
       US 2001-855468
                          20010515
       US 2001-887145
                          20010622
DT
       Patent
       English
ΙA
os
       2002-148175 [19]
         ***Human***
DESC
                        interleukin-1beta sense PCR primer.
L5
       ANSWER 86 OF 196 DGENE COPYRIGHT 2003 THOMSON DERWENT ON STN
ΑN
       ABK14330 DNA
                             DGENE
       Genetically modified
                               ***human***
TI
                                                  ***microglia***
       treating neurodegenerative disease, comprises demonstrable phagocytic
      properties, produces progeny in culture, presents surface antigens, and contains modified ***human*** genomic DNA -
                                            genomic DNA
IN
       Kim S U
       (UYBR-N)
PA
                    UNIV BRITISH COLUMBIA.
      WO 2002004604 A2 20020117
PΙ
                                                    46p
      WO 2001-IB1770
ΑI
                          20010709
PRAI
      WO 2000-US18777
                         20000710
      US 2001-855468
                          20010515
      US 2001-887145
                         20010622
DT
      Patent
      English
LA
OS
      2002-148175 [19]
         ***Human*** MCP-1 antisense PCR primer.
DESC
L5
      ANSWER 87 OF 196 DGENE COPYRIGHT 2003 THOMSON DERWENT ON STN
      ABK14329 DNA
AN
                            DGENE
TI
      Genetically modified ***human***
                                                 ***microglia***
      treating neurodegenerative disease, comprises demonstrable phagocytic
      properties, produces progeny in culture, presents surface antigens, and contains modified ***human*** genomic DNA -
                                            genomic DNA
IN
      Kim S U
PA
       (UYBR-N)
                    UNIV BRITISH COLUMBIA.
PΙ
      WO 2002004604 A2 20020117
                                                    46p
      WO 2001-IB1770
ΑI
                         20010709
PRAI
      WO 2000-US18777
                         20000710
      US 2001-855468
                         20010515
      US 2001-887145
                         20010622
DT
      Patent
      English
LA
      2002-148175 [19]
***Human*** MCP-1 sense PCR primer.
os
DESC
L5
      ANSWER 88 OF 196 DGENE COPYRIGHT 2003 THOMSON DERWENT ON STN
ΑN
      ABK14328 DNA
                            DGENE
TI
      Genetically modified ***human***
                                                 ***microglia***
                                                                     cell for
      treating neurodegenerative disease, comprises demonstrable phagocytic
      properties, produces progeny in culture, presents surface antigens, and contains modified ***human*** genomic DNA -
IN
      Kim S U
PA
      (UYBR-N)
                    UNIV BRITISH COLUMBIA.
      WO 2002004604 A2 20020117
PΙ
                                                    46p
ΑI
      WO 2001-IB1770
                         20010709
PRAI
      WO 2000-US18777
                         20000710
      US 2001-855468
                         20010515
      US 2001-887145
                         20010622
DT
      Patent
      English
LA
os
      2002-148175 [19]
        ***Human***
                      MIP-1beta antisense PCR primer.
DESC
      ANSWER 89 OF 196 DGENE COPYRIGHT 2003 THOMSON DERWENT ON STN
L5
AN
      ABK14327
                DNA
                            DGENE
      Genetically modified ***human***
TT
                                                 ***microglia***
                                                                     cell for
      treating neurodegenerative disease, comprises demonstrable phagocytic
```

properties, produces progeny in culture, presents surface antigens, and

```
contains modified
                             ***human***
                                             genomic DNA -
ΙN
       Kim S U
       (UYBR-N)
PΑ
                    UNIV BRITISH COLUMBIA.
       WO 2002004604 A2 20020117
PΙ
                                                     46p
       WO 2001-IB1770
ΑI
                          20010709
       WO 2000-US18777
PRAI
                          20000710
       US 2001-855468
                          20010515
       US 2001-887145
                          20010622
DT
       Patent
LA
       English
       2002-148175 [19]
***Human*** |
OS
DESC
                       MIP-1beta sense PCR primer.
L5
       ANSWER 90 OF 196 DGENE COPYRIGHT 2003 THOMSON DERWENT ON STN
       ABK14326 DNA
AN
                             DGENE
TI
       Genetically modified
                               ***human***
                                                 ***microglia***
       treating neurodegenerative disease, comprises demonstrable phagocytic
       properties, produces progeny in culture, presents surface antigens, and contains modified ***human*** genomic DNA -
IN
       Kim S U
       (UYBR-N)
PA
                    UNIV BRITISH COLUMBIA.
       WO 2002004604 A2 20020117
PΙ
                                                    46p
ΑI
       WO 2001-IB1770
                          20010709
      WO 2000-US18777
PRAI
                         20000710
       US 2001-855468
                          20010515
       US 2001-887145
                          20010622
DT
       Patent
       English
LA
       2002-148175 [19]
05
         ***Human*** MIP-1alpha antisense PCR primer.
DESC
L5
       ANSWER 91 OF 196 DGENE COPYRIGHT 2003 THOMSON DERWENT ON STN
       ABK14325 DNA
AN
                           DGENE
       Genetically modified ***human***
TI
                                                  ***microglia***
                                                                      cell for
       treating neurodegenerative disease, comprises demonstrable phagocytic
      properties, produces progeny in culture, presents surface antigens, and contains modified ***human*** genomic DNA -
IN
       Kim S U
PA
       (UYBR-N)
                    UNIV BRITISH COLUMBIA.
PΙ
      WO 2002004604 A2 20020117
                                                    46p
ΑI
      WO 2001-IB1770
                          20010709
PRAI
      WO 2000-US18777
                          20000710
      US 2001-855468
                          20010515
      US 2001-887145
                          20010622
DT
       Patent
LA
      English
      2002-148175 [19]
os
         ***Human***
                      MIP-1alpha sense PCR primer.
DESC
L5
      ANSWER 92 OF 196 DGENE COPYRIGHT 2003 THOMSON DERWENT ON STN
AN
      ABK14324 DNA
                             DGENE
TI
      Genetically modified
                              ***human***
                                                  ***microglia***
                                                                      cell for
      treating neurodegenerative disease, comprises demonstrable phagocytic
      properties, produces progeny in culture, presents surface antigens, and contains modified ***human*** genomic DNA -
ΙN
      Kim S U
       (UYBR-N)
                    UNIV BRITISH COLUMBIA.
PA
PΙ
      WO 2002004604 A2 20020117
                                                    46p
      WO 2001-IB1770
                         20010709
ΑI
PRAI
      WO 2000-US18777
                         20000710
      US 2001-855468
                         20010515
      US 2001-887145
                         20010622
DT
      Patent
LA
      English
      2002-148175 [19]
***Human***
os
DESC
                      CXCR4 antisense PCR primer.
L5
      ANSWER 93 OF 196 DGENE COPYRIGHT 2003 THOMSON DERWENT ON STN
ΑN
      ABK14323 DNA
                             DGENE
TT
      Genetically modified
                               ***human***
                                                  ***microglia***
      treating neurodegenerative disease, comprises demonstrable phagocytic
      properties, produces progeny in culture, presents surface antigens, and contains modified ***human*** genomic DNA -
ΙN
      Kim S U
PA
      (UYBR-N)
                   UNIV BRITISH COLUMBIA.
      wo 2002004604 A2 20020117
PI
```

46p

```
WO 2001-IB1770
 ΑI
                          20010709
 PRAI
       WO 2000-US18777
                          20000710
       US 2001-855468
                          20010515
       US 2001-887145
                          20010622
DT
       Patent
       English
 LA
       20Ŏ2-148175 [19]
os
          ***Human***
DESC
                         CXCR4 sense PCR primer.
       ANSWER 94 OF 196 DGENE COPYRIGHT 2003 THOMSON DERWENT ON STN
L5
AN
       ABK14322 DNA
                             DGENE
       Genetically modified
                                 ***human***
TI
                                                   ***microglia***
                                                                       cell for
       treating neurodegenerative disease, comprises demonstrable phagocytic
       properties, produces progeny in culture, presents surface antigens, and contains modified ***human*** genomic DNA -
ΙN
       Kim S U
       (UYBR-N)
                    UNIV BRITISH COLUMBIA.
PA
       WO 2002004604 A2 20020117
PΙ
                                                     46p
ΑI
       WO 2001-IB1770
                          20010709
       WO 2000-US18777
PRAI
                          20000710
       US 2001-855468
                          20010515
       US 2001-887145
                          20010622
DT
       Patent
       English
LA
os
       2002-148175 [19]
         ***Human*** P2Y2R antisense PCR primer.
DESC
       ANSWER 95 OF 196 DGENE COPYRIGHT 2003 THOMSON DERWENT ON STN
L5
ΑN
       ABK14321
                 DNA
                             DGENE
       Genetically modified ***human***
TI
                                                   ***microglia***
                                                                      cell for
       treating neurodegenerative disease, comprises demonstrable phagocytic
       properties, produces progeny in culture, presents surface antigens, and contains modified ***human*** genomic DNA -
IN
       Kim S U
PA
       (UYBR-N)
                    UNIV BRITISH COLUMBIA.
       WO 2002004604 A2 20020117
PΙ
                                                     46p
ΑI
       WO 2001-IB1770
                          20010709
PRAI
       WO 2000-US18777
                          20000710
       US 2001-855468
US 2001-887145
                          20010515
                          20010622
DT
       Patent
LA
       English
       2002-148175 [19]
os
         ***Human*** P2Y2R sense PCR primer.
DESC
L5
       ANSWER 96 OF 196 DGENE COPYRIGHT 2003 THOMSON DERWENT ON STN
ΑN
       ABK14320 DNA
                             DGENE
TI
       Genetically modified
                                ***human***
                                                   ***microglia***
                                                                       cell for
       treating neurodegenerative disease, comprises demonstrable phagocytic properties, produces progeny in culture, presents surface antigens, and
       contains modified ***human***
                                             genomic DNA
ΙN
       Kim S U
PA
       (UYBR-N)
                    UNIV BRITISH COLUMBIA.
PΙ
      WO 2002004604 A2 20020117
                                                     46p
AΤ
      WO 2001-IB1770
                          20010709
PRAI
      WO 2000-US18777
                          20000710
       US 2001-855468
                          20010515
       US 2001-887145
                          20010622
DT
       Patent
LA
       English
       2002-148175 [19]
os
         ***Human***
DESC
                       P2Y1R antisense PCR primer.
L5
      ANSWER 97 OF 196 DGENE COPYRIGHT 2003 THOMSON DERWENT ON STN
ΑN
      ABK14319 DNA
                             DGENE
      Genetically modified ***human***
TI
                                                  ***microglia***
                                                                      cell for
      treating neurodegenerative disease, comprises demonstrable phagocytic
      properties, produces progeny in culture, presents surface antigens, and contains modified ***human*** genomic DNA -
IN
      Kim S U
PA
       (UYBR-N)
                    UNIV BRITISH COLUMBIA.
      WO 2002004604 A2 20020117
PΙ
                                                     46p
      WO 2001-IB1770
ΑI
                          20010709
PRAI
      wo 2000-us18777
                         20000710
      US 2001-855468
                          20010515
      US 2001-887145
                         20010622
```

```
DT
      Patent
       English
LA
os
       2002-148175 [19]
         ***Human***
DESC
                      P2Y1R sense PCR primer.
      ANSWER 98 OF 196 DGENE COPYRIGHT 2003 THOMSON DERWENT ON STN
L5
      ABK14318
                DNA
                            DGENE
ΑN
      Genetically modified
                               ***human***
                                                 ***microglia***
                                                                    cell for
TI
       treating neurodegenerative disease, comprises demonstrable phagocytic
      properties, produces progeny in culture, presents surface antigens, and contains modified ***human*** genomic DNA -
      Kim S U
IN
PA
       (UYBR-N)
                   UNIV BRITISH COLUMBIA.
PΙ
      WO 2002004604 A2 20020117
                                                   46p
ΑI
      WO 2001-IB1770
                         20010709
      wo 2000-us18777
PRAI
                         20000710
      US 2001-855468
                         20010515
      US 2001-887145
                         20010622
DT
      Patent
      English
LA
      2002-148175 [19]
os
         ***Human***
DESC
                       CD68 antisense PCR primer.
L5
      ANSWER 99 OF 196 DGENE COPYRIGHT 2003 THOMSON DERWENT ON STN
                            DGENE
AN
      ABK14317
                 DNA
TI
      Genetically modified
                               ***human***
                                                ***microalia***
                                                                    cell for
      treating neurodegenerative disease, comprises demonstrable phagocytic
      properties, produces progeny in culture, presents surface antigens, and
                            ***human***
      contains modified
                                           genomic DNA
IN
      Kim S U
PA
       (UYBR-N)
                   UNIV BRITISH COLUMBIA.
PΙ
      WO 2002004604 A2 20020117
                                                   46p
      WO 2001-IB1770
ΑI
                         20010709
PRAI
      wo 2000-us18777
                         20000710
      US 2001-855468
                         20010515
      US 2001-887145
                         20010622
DT
      Patent
      English
ΙA
os
      2002-148175 [19]
        ***Human***
DESC
                       CD68 sense PCR primer.
L5
     ANSWER 100 OF 196 EMBASE COPYRIGHT 2003 ELSEVIER INC. ALL RIGHTS
     RESERVED. on STN
AN
     2003240110 EMBASE
     Cellular targets of brain inflammation in stroke.
TI
ΑU
     Han H.S.; Yenari M.A.
     M.A. Yenari, Dept. of Neurosurg. Neurol./Neurol., Stanford University
CS
     School of Medicine, 1201 Welch Road P304, Stanford, CA 94305-5487, United
     States. yenari@alum.mit.edu
     Current Opinion in Investigational Drugs, (1 May 2003) 4/5 (522-529).
SO
     Refs: 129
     ISSN: 1472-4472
                       CODEN: CIDREE
CY
     United Kingdom
DT
     Journal; General Review
FS
     800
              Neurology and Neurosurgery
     026
              Immunology, Serology and Transplantation
     037
              Drug Literature Index
     030
              Pharmacology
     029
              Clinical Biochemistry
     038
              Adverse Reactions Titles
     005
              General Pathology and Pathological Anatomy
LA.
     English
SL
     English
L5
     ANSWER 101 OF 196 EMBASE COPYRIGHT 2003 ELSEVIER INC. ALL RIGHTS
     RESERVED. on STN
     2002003335
                 EMBASE
TI
     COX-2 and ALS.
     McGeer P.L.
     P.L. McGeer, Kinsmen Lab. of Neurol. Research, University of British
     Columbia, Vancouver, BC, Canada. mcgeerpl@interchange.ubc.ca
Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, (2001) 2/3
SO
     (121-122).
     Refs: 11
     ISSN: 1466-0822 CODEN: ALSCFA
```

CY

United Kingdom

```
DT
      Journal; Editorial
FS
      800
               Neurology and Neurosurgery
      022
               Human Genetics
      029
               Clinical Biochemistry
     030
               Pharmacology
      037
               Drug Literature Index
      English
LA
L5
     ANSWER 102 OF 196 EMBASE COPYRIGHT 2003 ELSEVIER INC. ALL RIGHTS
     RESERVED. on STN
1999105367 EMBA
\Delta N
                  EMBASE
     Extracellular matrix-induced cell migration from glioblastoma biopsy
TT
      specimens in vitro.
     Mahesparan R.; Tysnes B.B.; Read T.-A.; Enger P.-O.; Bjerkvig R.;
     Lund-Johansen M.
     R. Mahesparan, Department Anatomy and Cell Biology, University of Bergen, Aarstadvollen 19, N-5009 Bergen, Norway. manrm@pki.uib.no Acta Neuropathologica, (1999) 97/3 (231-239).
CS
     Refs: 25
      ISSN: 0001-6322 CODEN: ANPTAL
     Germany
CY
DT
     Journal; Article
     005
              General Pathology and Pathological Anatomy
FS
     800
              Neurology and Neurosurgery
     016
     English
LA
     English
SL
L5
     ANSWER 103 OF 196 EMBASE COPYRIGHT 2003 ELSEVIER INC. ALL RIGHTS
     RESERVED. on STN
     92237486
                EMBASE
     1992237486
DN
     Cytokines and immunoregulatory molecules in malignant glial neoplasms.
ΤI
     Schneider J.; Hofman F.M.; Apuzzo M.L.J.; Hinton D.R.
Department of Pathology, University of Southern California, School of
ΑU
CS
     Medicine, 2011 Zonal Avenue, Los Angeles, CA 90033, United States
     Journal of Neurosurgery, (1992) 77/2 (265-273).
SO
                        CODEN: JONSAC
     ISSN: 0022-3085
     United States
CY
     Journal; Article
DT
     005
FS
              General Pathology and Pathological Anatomy
     008
              Neurology and Neurosurgery
     016
              Cancer
     026
              Immunology, Serology and Transplantation
     English
LA
SL
     English
     ANSWER 104 OF 196 EMBASE COPYRIGHT 2003 ELSEVIER INC. ALL RIGHTS
L5
     RESERVED. on STN
AN
     91096214 EMBASE
     1991096214
DN
        ***Human***
TI
                       microglial cells: Characterization in cerebral tissue and
     in primary culture, and study of their susceptibility to HIV-1 infection.
     Peudenier S.; Hery C.; Montagnier L.; Tardieu M.
ΑU
     Laboratoire de Neurovirologie, Unite INSERM, U56 Hopital de Bicetre, 94275
CS
     Le Kremlin-Bicetre, Cedex, France
     Annals of Neurology, (1991) 29/2 (152-161).
S0
     ISSN: 0364-5134 CODEN: ANNED3
     United States
CY
     Journal; Article
DT
              General Pathology and Pathological Anatomy
FS
     005
     008
              Neurology and Neurosurgery
     026
              Immunology, Serology and Transplantation
     047
              Virology
     English
SL
     English
L5
      ANSWER 105 OF 196 Elsevier BIOBASE COPYRIGHT 2003 Elsevier Science B.V.
      on STN
ΑN
      1999202350
                     ESBIOBASE
TI
      Expression of a homologue of rat NG2 on
                                                     ***human***
                                                                       ***microglia***
ΑU
      Pouly S.; Becher B.; Blain M.; Antel J.P.
      J.P. Antel, Montreal Neurological Institute, Neuroimmunology Unit, 3801
CS
      University Street, Montreal, Que. H3A 2B4, Canada.
      E-mail: mdan@musica.mcgill.ca
```

GLIA, (1999), 27/3 (259-268), 36 reference(s)

S0

```
CODEN: GLIAEJ ISSN: 0894-1491
DT
       Journal; Article
CY
       United States
       English
LA
SL
       English
      ANSWER 106 OF 196 Elsevier BIOBASE COPYRIGHT 2003 Elsevier Science B.V.
L<sub>5</sub>
       on STN
       1999152183
ΑN
                    ESBIOBASE
       Blocking OX-40/OX-40 ligand interaction in vitro and in vivo leads to
TI
       decreased T cell function and amelioration of experimental allergic
       encephalomyelitis
ΑU
      Weinberg A.D.; Wegmann K.W.; Funatake C.; Whitham R.H.
CS
      Dr. A.D. Weinberg, Earle A. Chiles Research Institute, Providence
       Portland Medical Center, 4805 NE Glisan, Portland, OR 97213, United
       States.
       E-mail: weinbera@ohsu.edu
S0
       Journal of Immunology, (01 FEB 1999), 162/3 (1818-1826), 37 reference(s)
                      ISSN: 0022-1767
       CODEN: JOIMA3
DT
       Journal: Article
      United States
CY
      English
LA
      English
SL
      ANSWER 107 OF 196 Elsevier BIOBASE COPYRIGHT 2003 Elsevier Science B.V.
L5
      on STN
       1997245335
ΑN
                    ESBIOBASE
      PK11195 binding to the peripheral benzodiazepine receptor as a marker of
TI
      microgila activation in multiple sclerosis and experimental autoimmune
      encephalomyelitis
AU
      Vowinckel E.; Reutens D.; Becher B.; Verge G.; Evans A.; Owens T.; Antel
      J.P.
      J.P. Antel, Dept. of Neurology and Neurosurgery, Montreal Neurological Inst., McGill University, 3801 University Street, Montreal, Que. H3A 2B4,
CS
      Canada.
      E-mail: mdan@musica.mcgill.ca
      Journal of Neuroscience Research, (1997), 50/2 (345-353), 37 reference(s)
SO
      CODEN: JNREDK ISSN: 0360-4012
DT
      Journal: Article
CY
      United States
LA
      English
SL
      English
      ANSWER 108 OF 196 Elsevier BIOBASE COPYRIGHT 2003 Elsevier Science B.V.
      on STN
AN
      1996165033
                    ESBIOBASE
TI
      Comparison of phenotypic and functional properties of immediately ex vivo
                                              ***microglia***
      and cultured
                      ***human***
                                     adult
ΑU
      Becher B.; Antel J.P.
      Dr. J.P. Antel, Montreal Neurological Institute, 3801 University,
CS
      Montreal, Que. H3A 2B4, Canada.
      GLIA, (1996), 18/1 (1-10)
SO
      CODEN: GLIAEJ
                     ISSN: 0894-1491
DT
      Journal; Article
CY
      United States
LA
      English
SL
      English
L5
     ANSWER 109 OF 196 FEDRIP COPYRIGHT 2003 NTIS on STN
ΑN
     2003:64868
                 FEDRIP
NR
     VA 118606
NC
     0006, 665
     NSAID Inhibition of Microglial Activation and Alzheimer Pathology
TI
     Principal Investigator: Cole, Gregory M., Ph.D.
Department of Veterans Affairs, Medical Center, Sepulveda, CA
SF
CSP
CSS
     Supported By: Department of Veterans Affairs. Research and Development
     (15), 810 Vermont Ave. N.W., Washington, D.C., 20420, United States of
     America
DB
     Jan 1, 1998
     Department of Veterans Affairs
FS
L5
     ANSWER 110 OF 196 IFIPAT COPYRIGHT 2003 IFI on STN
      10121270 IFIPAT; IFIUDB; IFICDB
ΑN
TI
      METHODS OF PRODUCING AND USING A
                                           ***HUMAN***
                                                          MICROGLIAL CELL LINE;
      GENETICALLY ENGINEERED IMMORTALIZED
                                              ***HUMAN***
                                                             AGGREGATION FOR USE
      IN TREATMENT PARKINSON'S AND ALZHEIMER'S DISEASES, SPINE DAMAGE, ATAXIA
```

```
AND ALCOHOLISM
IN
        Kim Seung U (CA)
        Unassigned Or Assigned To Individual (68000)
US 2002064877 A1 20020530
PA
PΙ
ΑI
        US 2001-855468
                                    20010515
FI
        US 2002064877
                                    20020530
        Utility; Patent Application - First Publication
DT
FS
        CHEMICAL
        APPLICATION
CLMN
        8
         1 Figure(s).
GΙ
                                                                                             ***human***
       FIGS. 1A and 1B are phase-contrast photomicrographs of live
           ***microglia***
                                   isolated from a
                                                            ***human***
                                                                               embryonic brain (FIG.
        1A) and of HM06.AI
                                     ***human***
                                                       microglial cells (FIG. 1B).
L5
       ANSWER 111 OF 196 IFIPAT COPYRIGHT 2003 IFI on STN
ΑN
        10105160 IFIPAT; IFIUDB; IFICDB
TI
        MODEL FOR ALZHEIMER'S DISEASE AND OTHER NEURODEGENERATIVE DISEASES;
        EVALUATING MODULATORS OF BRAIN DISORDERS; OBTAIN BRAIN CELLS, EXPOSE
        BRAIN CELLS TO MODULATORS, MONITOR CELLS FOR ADJUSTMENT IN BRAIN
        INFLAMMATORY REACTION
        Bi Xiaoning; Lynch Gary
Unassigned Or Assigned To Individual (68000)
IN
PA
        US 2002048746
                             A1 20020425
PΙ
ΑI
        US 2001-917789
                                    20010731
PRAI
        US 2000-222060P
                                    20000731 (Provisional)
        US 2001-283352P
                                    20010413 (Provisional)
        US 2002048746
FΙ
                                    20020425
        Utility; Patent Application - First Publication
DT
FS
        CHEMICAL
        APPLICATION
CLMN
        94
GΙ
         30 Figure(s).
       FIGS. 1A-D illustrate morphology of subicular neurons immunopositive for phosphorylated tau in cultured slices prepared from apoE-knockout mice. The slices were treated with ZPAD for six days followed by six-day washout. Panels A and B. Micrographs showing the variety of routinely
        encountered structures 1. A shrunken neuron with a dense, intracellular
        accumulation of phosphorylated tau 2. Neurons with immunopositive
        processes that appear distended (2a) or fragmented (2b, 2c) at varying distances from the cell body. 3, Cells with fibril-filled processes that
        have separated, or are about to separate, from the soma. 4 & 5, Neuronal
        remnants in which the membrane and cytoplasm are lost but labeled fibrils
        remain. Panels C and D. Higher magnification images of cells in panel B. The extended and distorted appearance of the terminal portion of the labeled process is evident for cell 2b. A similar effect accompanied by
        kinking of the neuronal process can be seen for cell 2a. A remnant neuron marked by heavy stained fibrils is present in the lower right of the
        micrograph in panel D.
       FIGS. ŽA and 2B illustrate induction of tangle-like structures in subfield
        CA1/subiculum in mouse hippocampal cultures by ZPADtreatment. Hippocampal
        slice cultures incubated with ZPAD (B) or vehicle (A) for 6 days were stained with monoclonal antibody. "AT8," that recognizes
        hyperphosphorylated tau proteins and neurofibrillary tangles in
      ***human*** tissue. Numerous immunopositive neurons are present in ZPAD treated slices, while few if any are found in control tissue (A).
FIGS. 3A and 3B illustrate ultrastructure of tangle-like formations using
       electron microscopic immunogold techniques. FIG. 3A shows a dendritic branch with accumulated organelles resembled smooth ER (arrows), rough ER (asterisks), or mitochondria (M). distorted microtubules were found passing through the abnormal inclusions. Despite these obvious pathologies, plasma membranes and synaptic apparatus were still
        distinguishable. Secondary lysosomes with variable sizes were also
        frequently encountered in ZPAD treated tissues (FIG. 3B).
       FIGS. 4A-C-illustrate immunogold analysis and shows that AT8-ir was found
        mainly over structures composed of distorted filaments located throughout
        dendrites and cell bodies. Enlarged images showed that filaments were
        often paired and twisted with axial periodicity (FIG. 4A, B). Distorted filaments were found running across each other or waving around,
        characteristics similar to early-stage neurofibrillary tangles in
      Alzheimer's disease (FIG. 4C).
FIG. 5(A and B). Levels of cathepsin D immunoreactivity in apoEdeficient
        and wild-type (WT) mice. Hippocampal slices prepared from C57BL/6J and
        C57BL/6J-apoEtmlUnc (apoE-deficient) mice at postnatal day 10 and
        cultured for 12-14 days were incubated with ZPAD or vehicle (Con) for 6
        days. Immunoblots probed with anti-cathepsin D antisera revealed three
```

major bands with apparent molecular weights of 55 kDa, 50 kDa, and 38 kDa in cultured hippocampal slices, corresponding to the inactive proenzyme, the active single chain, and the active heavy chain, respectively (A). ZPAD-treatment increased the first two isoforms in wild-type tissue, and all three isoforms in the apoE-deficient slices. Note also that the increase in cathepsin D proteins is exaggerated in the knockout compared to the wildtype mice: 145+43%, 150+29% and 84 +26% vs. 65+29%, 42+22% and 3.0+5.7% (B). Standard paired t-tests (2-tails) were used for the indicated statistical comparison.

FIG. 6. Induction of tangle-like structures in cultured hippocampal slices prepared from apoE-knockout mice. Slices were incubated with vehicle (left side) or 'ZPAD', an inhibitor of cathepsins B and L (right side) (left side) or 'ZPAD', an inhibitor of cathepsins B and L (right side), for 6 days and then processed for immunocytochemistry using a monoclonal antibody "AT8" that recognizes hyperphosphorylated tau proteins, tau fragments, and neurofibrillary tangles in ***human*** tissue. Immunopositive elements are found in the outgrowth regions of the control slice from an apoE-/-mouse but not within the hippocampus itself. In contrast, the ZPAD-treated slice has numerous, densely labeled cells in the stratum oriens of hippocampal field CA1 and in the subiculum. Note that the densely packed neurons in the s. pyramidale of field CA3 and in the s. granulosum of the dentate gyrus are not stained (4 x objective; the s. granulosum of the dentate gyrus are not stained (4 x objective;

scale bar=200 mu m).

FIG. 7. Types and distribution of phosphorylated tauimmunoreactive neurons in the CA1 region following six days of ZPAD. Shown is a vertical section that extends across most of the basal (s. oriens), and the inner third of the apical (s. radiatum), dendritic fields in field CA1 of a cultured slice that had been exposed to ZPAD for six days. The majority of the AT8 immunopositive cells were found in the basal dendritic field. The cell bodies (s. pyramidale) and apical dendrites of the pyramidal cells, by far the most numerous population of neurons in the section, were with few exceptions, unlabeled. One of these immuno-negative neurons is outlined with small circle. The stained elements were not homogeneous. The cells marked with a "1" appear to be intact neurons with immunopositive processes and dense deposits accumulating within the cell body. The labeled neuron marked as "2" had swollen and distorted dendrites. The elements marked by a "3" appeared to be remnants of neurons. (25 x objective, scale bar=50 mu m).

FIG. 8. Morphology of neurons that are stained by an antibody that recognizes neurofibrillary tangles. Upper panel. Immunopositive neurons in cultured slices prepared from apoE-/ mice. The micrographs are ordered according to a proposed sequence of pathological steps. (A) Two neurons in the subiculum with immunopositive cell bodies and primary dendritic branches (white arrows). Note that other neurons in the field are unlabeled (black arrows). (B) Neuron with a dense deposit (cap) in one pole of its cell body. (C) Neuron with pathological swelling (arrow) of a distal dendrite. (D, E) Cells with pathological dendritic expansions proximal to the cell body. (F) Exploded process attached to a dendrite containing fibrous material. Note that the dense 'cap' of immunopositive containing fibrous material. Note that the dense 'cap' of immunopositive material covers most of the cell body. (G, H) Dense caps that do not appear to be associated with somata; i.e., are likely the remnants of neurons. (100 x objective, scale bar=12.5 mu m in A, 10 mu m in B, 8 mu m in C, 15 mu m in B, 11 mu m in B, 8 mu m in C, 15 mu m in D,H; 11 mu m in E,G; and 17 mu m in F). Lower panel. Immunopositive neurons in the hippocampus from a ***human*** brai classified as being in the early stages of Alzheimer's disease. The micrographs are again arranged according to a proposed sequence of pathologies. (A) Apparently intact pyramidal neuron with a dense cap and a labeled apical dendrite. (B, C) Neurons with dendritic swellings. (D, E). Dendritic expansions proximal to the cell body. (F, G) Immunopositive caps that do not appear to be attached to intact neurons. (20 and 40 x objectives; scale bar=50 mu m in A; scale bar=45 mu m in B, D; 30 mu m in C, 18 mu m in E, 20 mu m in F, and 12.5 mu m in G). FIG. 9. Electron micrographs of CA1 neurons from apoE-/-slices that were

incubated with ZPAD for six days. (A). Survey micrograph showing the primary dendrite emerging from the cell body. Filamentous material (arrows) occupies more than half of the cross-section of the dendrite. (B). Higher power image showing the filaments that occupy the pathological region marked in panel A. (C). Micrograph from another dendrite showing that the filaments form bundles that criss-cross each other (arrows). (scale bar=2 mu m in A, 0.75 mu m in B, 0.4 mu m in C). FIG. 10. Tangle-like structures are increased in cultured hippocampal slices_by combined lysosomal dysfunction and disturbance in lipid metabolism. Hippocampal slices were prepared from 12 day old rat pups, cultured in vitro for 10 days, and incubated with vehicle only (Cont), and/or a cholesterol metabolism inhibitor mevastatin (Mev), and/or a cathepsin B and L inhibitor (ZPAD) plus mevastatin (Mev/ZPAD). Cultured

slices were stained with anti-phosphorylated tau antibody AT8.

FIG. 11. High magnification micrographs of cultured hippocampal slices that were treated with vehicle (Cont), ZPAD, mevastatin (Mev), or

mevastatin plus ZPAD (Mev/ZPAD).
FIG. 12. Generation of phosphorylated tau fragments by mevastatin and ZPAD treatment. Hippocampal slices were prepared from 12 day old rat pups, cultured in vitro for 10 days, and incubated with vehicle only (Cont), and/or_a cathepsin B and L inhibitor (ZPAD), and/or a cholesterol metabolism inhibitor mevastatin (Mev), and/or mevastatin plus ZPAD (Mev/ZPAD).

FIG. 13. Level of cdk5 regulatory unit p35 is reduced by mevastatin treatment. Hippocampal slices cultured in vitro for 12 days were treated with ZPAD, mevastatin (Mev), mevastatin plus ZPAD (Mev/ZPAD), or vehicle only for 6 days, and western blots were stained with anti-p35 antisera.

Shown are analytical data from two separate experiments.

FIGS. 14A and 14B illustrate the dose response and time course of p35 following mevastatin(diamond-suit) or mevastatin plus ZPAD (*) treatment. For the dose curve experiments, slices were subjected to mevastatin for 6 days at 0 mu M, 1 mu M, 5 mu M, 10 mu M. and 100 mu M concentrations. For the time course experiment, hippocampal cultures were incubated with 10 mu M mevastatin for 0, 2, 4, and 6 days. In the mevastatin plus ZPAD treatment, ZPAD was used at 20 mu M.

FIG. 15. Down regulation of p35 by mevastatin is blocked by the application of mevalonate. Hippocampal slices were incubated with vehicle alone/control (lane 1), mevastatin (lane 2), mevastatin plus ZPAD (lane 3), mevastatin plus EA1 (lane 4), mevastatin plus cholesterol (lane 5),

or mevastatin plus mevalonate (lane 6).

FIG. 16. Messenger RNA levels of TGF-beta and IL-10 are increased by lysosomal dysfunction and interruption of cholesterol synthesis. Messenger RNAs were extracted from cultured hippocampal slices that had been incubated with vehicle (Cont), ZPAD (20 mu M), mevastatin (Mev, 20 mu M), or mevastatin plus ZPAD respectively (each contained 12 slices) and measured by RT-PCR/northem blot techniques using a kit from Ambion Inc. Shown are representatives from three experiments. PD98 and PD98/ZPAD are groups treated with PD98059 (a mitogenactivated protein kinase

inhibitor) or PD98059 plus ZPAD respectively.
FIG. 17. Messenger RNA levels of TNF-alpha are increased by interruption of cholesterol synthesis. Messenger RNAs were extracted from cultured hippocampal slices that had been incubated with vehicle (Cont), ZPAD (20 mu M), PD98059 (50 mu M), PD98059 plus ZPAD, mevastatin (Mev, 20 mu M), or mevastatin plus ZPAD respectively (each contained 12 slices) and measured by RT-PCR/northern blot techniques using a kit from Ambion Inc. FIG. 18. Activation of MAPK is involved in lysosomal dysfunction induced microglial reaction. Brain tissue was cultured for 12 days and treated with ZPAD (20 mu M) in the presence or absence of PD98059 (50 mu M) for 6 days. Cultured explants were then sliced and stained by using monoclonal antibody ED-1 which recognizes reactive ***microglia***, a classical marker of inflammation. Note that incubation with ZPAD triggered significant reaction of ***microglia***, and this reaction w ***microglia*** , and this reaction was completely blocked by co-application of PD98059 . Inhibition of MAPK by itself did not induce evident change in ***microglia*** FIG. 19. Inhibition of cholesterol synthesis causes activation and

microglia transformation of Rat brain tissues were cultured for 10 days and incubated with vehicle (Cont), ZPAD (20 mu M), mevastatin (Mev, 20 mu M), or mevastatin plus ZPAD (Mev/ZPAD) for 6 days. Cultured brain explants were then sliced and stained by using monoclonal antibody

FIG. 20. MAPK (ERK1/2) activation by ZPAD and mevastatin treatment. Hippocampal slices were cultured for 10 days and incubated with vehicle (lane 1), ZPAD (lane 2), mevastatin (lane 3), PD98059 (lane 4), mevastatin plus ZPAD (lane 5), mevastatin plus PD98059 (lane 6) and mevastatin plus ZPAD and PD98059 (lane 7) for 6 days and processed for immunoblot with anti-active MAPK (Sigma, 1:10,000).

FIGS. 21A and 2B. Dose response and time course of MAPK following mevastatin treatment. Cultured hippocampal slices were treated with mevastatin (diamond-suit) or mevastatin plus ZPAD (*). For the dose curve experiments, slices were subjected to mevastatin for 6 days at 0 mu M, 1 mu M, 5 mu M, 10 mu M, and 100 mu M concentrations. For the time course experiment, hippocampal cultures were incubated with 10 mu M mevastatin for 0, 2, 4, and 6 days.

FIG. 22 illustrates that experimentally-induced lysosomal dysfunction

induced the conversion of p35 to p25, and that such conversion was blocked by calpain inhibitors. Hippocampal slices prepared from rats at postnatal 10 day and cultured for 12-14 days were incubated with ZPAD and/or vehicle (control) and/or a cysteine protease inhibitor for 6 days. Immunoblotting carried out using antisera that recognizes the C-terminal domain of p35 showed that the CDK5 binding protein p35 was present in

cultured hippocampal slices. Trace amount of p25, the truncated form of p35 that lacks the N-terminal domain, was also detected. A six day treatment of the brain cells, or brain tissue containing the same, with ZPAD resulted in a significant decrease in the amount of p35 polypeptide and a paralleled increase in the truncated form p25. Such conversions of p35 to p25 were significantly inhibited in the presence of calpain inhibitor I.

FIG. 23 illustrates that tau fragmentation events triggered by experimentally induced lysosomal dysfunction were blocked by calpain inhibitors. Immunoblots stained with the anti-nonphosphorylated antibody (tau 1), revealed that 6-day ZPAD treatment induced a cleavage of native tau proteins and the generation of tau fragments that migrated at approximately 40 kDa and 29 kDa (tau 29). Previous studies have shown that cathepsin D is a protease whose activation leads to the cleavage of tau and the generation of tau 29. Incubation of cathepsin D inhibitors remarkably reduced the production of tau 29 induced by ZPAD treatment, but the cathepsin D inhibitors failed to block the increase in the 40 kDa fragments. Such results suggested that another protease may be activated by the ZPAD treatment. Previous study had suggested that calpain was able to cleave tau and generate tau fragments of different length. To test whether calpain is involved in ZPAD-induced tau cleavage, levels of tau fragmentation were compared between slices incubated with and without calpain inhibitors. Results obtained from 16 slices of 2 separated experiments showed that ZPAD-induced tau 29 and tau 40 were almost completely blocked by calpain inhibitor I.

FIG. 24 illustrates that the induction of tangle-like structures by ZPAD-treatment was blocked by calpain inhibitors. Incubation of hippocampal slices with ZPAD for 6-day induced numerous tangles, in particular, in the border of subiculum and CA1 region. However, when ZPAD was applied in the presence of calpain inhibitor I, the number of tangles

was significantly reduced.

FIG. 25 illustrates that the induction of tangle-like structures by ZPAD treatment was blocked by mitogen activate kinase inhibitors. Incubation of hippocampal slices with ZPAD for 6 days induced numerous tangles, in particular, in the border of subiculum and CA1 region. However, when ZPAD was applied in the presence of a mitogen activate kinase inhibitor, the number of tangles was significantly reduced.

FIG. 26. Modulation of biological processing of amyloid precursor protein by mevastatin treatment is blocked by mevalonate. Hippocampal slices were incubated with vehicle alone/control (lane 1), mevastatin (lane 2), mevastatin plus ZPAD (lane 3), mevastatin plus EAl (lane 4), mevastatin plus cholesterol (lane 5), or mevastatin plus mevalonate (lane 6).

FIG. 27. Effects of mevastatin on APP were partially blocked by MAPKK inhibitor PD98059 but not by inhibitor SB203580 of MAPK p38. Hippocampal slices were incubated with vehicle alone/control (lane 1), mevastatin (lane 2), mevastatin plus ZPAD (lane 3), mevastatin plus PD98059 (lanes 4 and 5), mevastatin plus EA1 (lanes 6 and 7), mevastatin plus cholesterol (lane 8), mevastatin plus mevalonate (lanes 9 and 12), mevastatin plus SB203580 (lane 10), or mevastatin plus gamma-secretase inhibitor (lane 11).

FIG. 28 shows the activation of caspase 3 by lysosomal dysfunction. Hippocampal slices were cultured for 12 days and incubated with vehicle alone (CONT), ZPAD, or chloroquine (CQN; a lysosomal inhibitor) for 6 days. Cultures were then homogenized, and subjected to an ELISA assay to detect the activity of caspase 3, an apoptotic protease. ZPAD treatment caused a marked increase in the activity of caspase 3.

FIG. 29. Induction of tangle-like structures by pravastatin treatment. Shown are images taken form pravastain-treated hippocampal slices from the subiculum (A), CA1 field (B), and CA3 field (C). Also shown are higher magnification micrographs of neurons from the CA1 field (D and E). FIG. 30. Induction of microglial reactions by mevastatin and simvastatin treatments. Shown are images of hippocampal areas from one control animal and an animal treated with simvastatin. ***CD11b*** immunostaining is moderate in control tissue, while it is generally dense in simvastation treated hippocampus. Higher magnification images show that the density of

treated hippocampus. Higher magnification images show that the density of ***microglia*** is higher in simvasatin treated tissue than that in the

control tissue.!

L5 ANSWER 112 OF 196 JICST-EPlus COPYRIGHT 2003 JST on STN AN 970059223 JICST-EPlus

ΑU

SO

TI 31st symposium on the brain function. Adhesion molecules in nervous system. AxCAM and DenCAM: a novel classification of neuronal cell adhesion molecules.

YOSHIHARA YOSHIHIRO; MORI KENSAKU

CS Osaka Biosci. Inst.

Shinkei Kenkyu no Shinpo (Advances in Neurological Sciences), (1996) vol.

```
40, no. 6, pp. 937-944. Journal Code: Z0693A (Fig. 7, Ref. 38)
      ISSN: 0001-8724
CY
      Journal; General Review
DT
      Japanese
LA
STA
     New
L5
      ANSWER 113 OF 196
                               MEDLINE on STN
      2003287846
                       MEDLINE
ΑN
                 PubMed ID: 12815705
DN
      22699458
      Two populations of microglial cells isolated from rat primary mixed glial
TI
      cultures.
ΑU
      Kuwabara Yasuhide; Yokoyama Akiko; Yang Lihua; Toku Kazuko; Mori Kohji;
      Takeda Ikuko; Shigekawa Takako; Zhang Bo; Maeda Nobuji; Sakanaka Masahiro;
      Department of Physiology, School of Medicine, Ehime University, Ehime,
CS
      Japan.
      JOURNAL OF NEUROSCIENCE RESEARCH, (2003 Jul 1) 73 (1) 22-30.
SO
      Journal code: 7600111. ISSN: 0360-4012.
CY
      United States
      Journal; Article; (JOURNAL ARTICLE)
DT
      English
LA
FS
      Priority Journals
FΜ
      200309
      Entered STN: 20030620
ED
      Last Updated on STN: 20030905
      Entered Medline: 20030904
L5
       ANSWER 114 OF 196 PASCAL COPYRIGHT 2003 INIST-CNRS. ALL RIGHTS
       RESERVED. on STN
       2002-0426712
ΑN
                        PASCAL
       Copyright .COPYRGT. 2002 INIST-CNRS. All rights reserved. Characterization of the macrophages associated with the tunica vasculosa
CP
TIEN
       lentis of the rat eye
       MCMENAMIN Paul G.; DJANO Jenny; WEALTHALL Rosamund; GRIFFIN Brendan J
ΑU
       School of Anatomy and Human Biology, The University of Western Australia, Crawley (Perth), Australia; Centre for Microscopy and Microanalysis, The
CS
       University of Western Australia, Crawley (Perth), Australia
50
       Investigative ophthalmology & visual science, (2002), 43(7), 2076-2082,
       46 refs.
       ISSN: 0146-0404 CODEN: IOVSDA
DT
       Journal
BL
       Analytic
       United States
CY
LA
       English
       INIST-12095, 354000108841470030
ΑV
L5
       ANSWER 115 OF 196 PASCAL COPYRIGHT 2003 INIST-CNRS. ALL RIGHTS
       RESERVED. on STN
ΑN
       2000-0353296
                        PASCAL
      Copyright .COPYRGT. 2000 INIST-CNRS. All rights reserved. Characterization of cultured ***microglia*** that can
CP
                                         ***microglia***
TIEN
                                                                that can be infected by
       HIV-1
       HIV and the Nervous System: Emerging Issues
ΑU
       ALBRIGHT A. V.; SHIEH J. T. C.; O'CONNOR M. J.; GONZALEZ-SCARANO F.
      RAUSCH Dianne (ed.)
Department of Neurology, University of Pennsylvania School of Medicine,
Philadelphia, Pennsylvania, PA 19104-6146, United States; Department of
Microbiology, University of Pennsylvania School of Medicine,
CS
       Philadelphia, Pennsylvania, PA 19104-6146, United States; Department of
       Neurosurgery, Thomas Jefferson University, Philadelphia, Pennsylvania, PA
       19106, United States
       National Institute of Mental Health, Bethesda, MD, United States
       National Institute of Mental Health (NIMH), Bethesda, MD, United States
       (patr.); National Institute of Neurological Disorders and Stroke (NINDS),
       Bethesda, MD, United States (patr.)
SO
       Journal of neurovirology, (2000), 6(SUP1), S53-S60, refs. 1 p.1/4
       Conference: HIV and the Nervous System: Emerging Issues. Symposium,
      Washington, DC (United States), 14 Apr 1999 ISSN: 1355-0284
       Journal; Conference
DT
BL
       Analytic
       United Kingdom
CY
LA
       English
       INIST-26734, 354000082438270070
ΑV
```

```
ANSWER 116 OF 196 SCISEARCH COPYRIGHT 2003 THOMSON ISI ON STN
L5
     2001:985224 SCISEARCH
ΑN
GΑ
     The Genuine Article (R) Number: 499YX
     Caudoputamen is damaged by hypocapnia during mechanical ventilation in a
ΤI
     rat model of chronic cerebral hypoperfusion
     Miyamoto E; Tomimoto H (Reprint); Nakao S; Wakita H; Akiguchi I; Miyamoto
AU
     K; Shingu K
     Kyoto Univ, Fac Med, Dept Neurol, Sakyo Ku, Kyoto 6068507.
     (Reprint); Kansai Med Univ, Dept Anesthesiol, Osaka, Japan
CYA
     Japan
     STROKE, (DEC 2001) Vol. 32, No. 12, pp. 2920-2925.
SO
     Publisher: LIPPINCOTT WILLIAMS & WILKINS, 530 WALNUT ST, PHILADELPHIA, PA
     19106-3621 USA.
     ISSN: 0039-2499
     Article; Journal
DT
     English
LA
REC
     Reference Count: 49
     *ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS*
L5
     ANSWER 117 OF 196 SCISEARCH COPYRIGHT 2003 THOMSON ISI ON STN
     2000:931756 SCISEARCH
ΑN
     The Genuine Article (R) Number: 379XK
GA
     Intracerebral recruitment and maturation of dendritic cells in the onset
TT
     and progression of experimental autoimmune encephalomyelitis
ΑU
     Serafini B; ColumbaCabezas S; DiRosa F; Aloisi F (Reprint)
     IST SUPER SANITA, LAB ORGAN & SYST PATHOPHYSIOL, VIALE REGINA ELENA 299,
CS
     I-00161 ROME, ITALY (Reprint); IST SUPER SANITA, LAB ORGAN & SYST
     PATHOPHYSIOL, I-00161 ROME, ITALY; IST REGINA ELENA, CTR RIC SPERIMENTALE,
     LAB PATHOPHYSIOL, I-00161 ROME, ITALY
     ITALY
CYA
     AMERICAN JOURNAL OF PATHOLOGY, (DEC 2000) Vol. 157, No. 6, pp. 1991-2002. Publisher: AMER SOC INVESTIGATIVE PATHOLOGY, INC, 9650 ROCKVILLE PIKE,
SO
     BETHESDA, MD 20814-3993.
     ISSN: 0002-9440
DT
     Article; Journal
FS
     LIFE; CLIN
LA
     English
REC
     Reference Count: 62
     *ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS*
L5
     ANSWER 118 OF 196 SCISEARCH COPYRIGHT 2003 THOMSON ISI ON STN
AN
     2000:604914 SCISEARCH
     The Genuine Article (R) Number: 340TT
GΑ
TI
     IFN-gamma and LPS-mediated IL-10-dependent suppression of retinal
     microglial activation
     Broderick C; Duncan L; Taylor N; Dick A D (Reprint)
ΑU
     UNIV BRISTOL, BRISTOL EYE HOSP, DIV OPHTHALMOL, LOWER MAUDLIN ST, BRISTOL
CS
     BS1 2LX, AVON, ENGLAND (Reprint); UNIV BRISTOL, BRISTOL EYE HOSP, DIV
     OPHTHALMOL, BRISTOL BS1 2LX, AVON, ENGLAND; UNIV ABERDEEN, DEPT
     OPHTHALMOL, ABERDEEN AB9 1FX, SCOTLAND
CYA
     ENGLAND: SCOTLAND
     INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, (AUG 2000) Vol. 41, No. 9,
SO
     pp. 2613-2622.
     Publisher: ASSOC RESEARCH VISION OPHTHALMOLOGY INC, 9650 ROCKVILLE PIKE,
     BETHESDA, MD 20814-3998.
     ISSN: 0146-0404
DT
     Article; Journal
FS
     LIFE
LA
     English
REC
     Reference Count: 49
     *ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS*
L5
     ANSWER 119 OF 196 SCISEARCH COPYRIGHT 2003 THOMSON ISI ON STN
     2000:290075 SCISEARCH
ΑN
GΑ
     The Genuine Article (R) Number: 302HR
     Flow cytometric characterization of tumor-associated macrophages in
     experimental gliomas
     Badie B (Reprint); Schartner J M
CS
     UNIV WISCONSIN, SCH MED, CTR CLIN SCI H4 330, NEURO ONCOL LAB, DEPT NEUROL
     SURG, 600 HIGHLAND AVE, MADISON, WI 53792 (Reprint)
CYA
S<sub>0</sub>
     NEUROSURGERY, (APR 2000) Vol. 46, No. 4, pp. 957-961.
     Publisher: LIPPINCOTT WILLIAMS & WILKINS, 530 WALNUT ST, PHILADELPHIA, PA
```

19106-3621. ISSN: 0148-396X.

Article; Journal

DT

```
LIFE: CLIN
FS
     English
LA
REC
     Reference Count: 23
      *ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS*
L5
     ANSWER 120 OF 196 SCISEARCH COPYRIGHT 2003 THOMSON ISI on STN
     1998:402144 SCISEARCH
AN
     The Genuine Article (R) Number: ZP269
GΑ
      Central nervous system microglial cell activation and proliferation
TI
      follows direct interaction with tissue-infiltrating T cell blasts
ΑU
     Sedgwick J D (Reprint); Ford A L; Foulcher E; Airriess R
     ROYAL PRINCE ALFRED HOSP, CENTENARY INST CANC MED & CELL BIOL, BLDG 93,
CS
     MISSENDEN RD, CAMPERDOWN, NSW 2042, AUSTRALIA (Reprint)
CYA
     AUSTRALIA
     JOURNAL OF IMMUNOLOGY, (1 JUN 1998) Vol. 160, No. 11, pp. 5320-5330.
SO
     Publisher: AMER ASSOC IMMUNOLOGISTS, 9650 ROCKVILLE PIKE, BETHESDA, MD
     20814.
     ISSN: 0022-1767.
     Article; Journal
DT
FS
     LIFE
     English
LA
     Reference Count: 63
REC
      *ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS*
L5
     ANSWER 121 OF 196 USPATFULL ON STN
AN
        2003:265972 USPATFULL
TI
        Nicotinamide benzofused-heterocyclyl derivatives useful as selective
        inhibitors of pde4 isozymes
IN
        Marfat, Anthony, Mystic, CT, UNITED STATES
        Chambers, Robert James, Mystic, CT, UNITED STATES
        US 2003186989
                                   20031002
PI
                             Α1
        US 2002-181416
                             Α1
ΑI
                                   20020724 (10)
        WO 2001-IB124
                                   20010130
        US 2000-60179284
PRAI
                              20000131
DT
        Utility
FS
        APPLICATION
LN.CNT 6819
        INCLM: 514/252.020
INCL
        INCLS: 514/255.050; 514/256.000; 514/269.000; 514/332.000; 514/340.000;
                514/341.000; 514/342.000; 544/238.000; 544/295.000; 544/296.000; 544/405.000; 546/261.000; 546/262.000; 546/269.100; 546/271.400;
                546/272.100; 546/268.100; 546/268.700; 546/269.700
                514/252.020
NCL
        NCLM:
                514/255.050; 514/256.000; 514/269.000; 514/332.000; 514/340.000; 514/341.000; 514/342.000; 544/238.000; 544/295.000; 544/296.000; 544/405.000; 546/261.000; 546/262.000; 546/269.100; 546/271.400; 546/272.100; 546/268.100; 546/268.700; 546/269.700
        NCLS:
IC
        [7]
        ICM: C07D417-02
        ICS: C07D413-02; C07D043-02; C07D041-02; A61K031-513; A61K031-506;
        A61K031-497; A61K031-501; A61K031-444; A61K031-4439
L5
     ANSWER 122 OF 196 USPATFULL on STN
        2003:265957 USPATFULL
ΑN
TI
        Pyrrolyl- and imidazolyl-acid amide derivatives useful as inhibitors of
        PDE4 isozymes
ΙN
        Marfat, Anthony, UNITED STATES
        McKechney, Michael William, UNITED STATES
        US 2003186974
                                   20031002
PΙ
                             Α1
ΑI
        us 2002-300950
                                   20021120 (10)
                             Α1
        Division of Ser. No. US 2002-62145, filed on 31 Jan 2002, PENDING
RLI
                              20010131 (60)
PRAI
        US 2001-265486P
DT
        Utility
        APPLICATION
FS
LN.CNT 7140
INCL
        INCLM: 514/227.800
               514/255.050; 514/210.200; 514/235.500; 514/256.000; 514/266.200;
        INCLS:
                514/252.050; 514/263.200; 514/249.000; 514/365.000
       NCLM:
               514/227.800
NCL
       NCLS:
               514/255.050; 514/210.200; 514/235.500; 514/256.000; 514/266.200;
                514/252.050; 514/263.200; 514/249.000; 514/365.000
IC
        [7]
        ICM: A61K031-541
        ICS: A61K031-5377; A61K031-52; A61K031-501; C07D417-02
```

L5

ANSWER 123 OF 196 USPATFULL on STN

```
2003:257879 USPATFULL
AN
                  ***human***
                                   protein kinase, phosphatase, and protease family
TI
        members and uses thereof
ΙN
        Meyers, Rachel E., Newton, MA, UNITED STATES
        Olandt, Peter J., Newton, MA, UNITED STATES
        Kapeller-Libermann, Rosana, Chestnut Hill, MA, UNITED STATES
        Curtis, Rory A. J., Framingham, MA, UNITED STATES Williamson, Mark, Saugus, MA, UNITED STATES Weich, Nadine, Brookline, MA, UNITED STATES
        US 2003180930
                                     20030925
PI
                               Α1
        US 2002-170789
                                     20020613 (10)
ΑI
                               Α1
        Continuation-in-part of Ser. No. US 2001-797039, filed on 28 Feb 2001,
RLI
        PENDING Continuation-in-part of Ser. No. US 2001-882166, filed on 15 Jun
        2001, PENDING Continuation-in-part of Ser. No. US 2001-934406, filed on
        21 Aug 2001, PENDING Continuation-in-part of Ser. No. US 2001-861801,
        filed on 21 May 2001, PENDING Continuation-in-part of Ser. No. US
        2001-801267, filed on 6 Mar 2001, PENDING Continuation-in-part of Ser.
        No. US 2001-829671, filed on 10 Apr 2001, PENDING Continuation-in-part of Ser. No. US 2001-961721, filed on 24 Sep 2001, PENDING Continuation-in-part of Ser. No. US 2001-45367, filed on 7 Nov 2001,
        PENDING Continuation-in-part of Ser. No. US 2001-801275, filed on 6 Mar
        2001, PENDING
        wo 2001-us6525
PRAI
                                20010228
        wo 2001-US19269
                                20010615
        wo 2001-US26052
                                20010821
        wo 2001-us16549
                                20010521
        wo 2001-us7138
                                20010305
        wo 2001-us40483
                                20010411
        WO 2001-US29904
                                20010924
                                20010305
        wo 2001-us7074
                                20000229
        US 2000-186061P
                                           (60)
        US 2000-212078P
                                20000615
                                           (60)
        US 2000-226740P
                                20000821
                                           (60)
        US 2000-205508P
                                20000519
                                           (60)
        US 2000-187454P
                                20000307
                                           (60)
        US 2000-197508P
                                20000418
                                           (60)
        US 2000-235023P
                                20000925
                                           (60)
        US 2000-246561P
                                20001107
                                           (60)
        US 2000-187420P
                                20000307 (60)
DT
        Utility
        APPLICATION
FS
LN.CNT 45159
INCL
        INCLM: 435/194.000
        INCLS: 435/069.100; 435/325.000; 435/320.100; 536/023.200
NCL
        NCLM:
                 435/194.000
                 435/069.100; 435/325.000; 435/320.100; 536/023.200
        NCLS:
IC
        [7]
        ICM: C12N009-12
        ICS: C07H021-04; C12P021-02; C12N005-06
L5
      ANSWER 124 OF 196 USPATFULL ON STN
        2003:257841 USPATFULL
ΑN
TI
        Interleukin-20
IN
        Ebner, Reinhard, Gaithersburg, MD, UNITED STATES
        Murphy, Marianne, London, UNITED KINGDOM
        Ruben, Steven M., Brookeville, MD, UNITED STATES
        Hu, Jing-Shan, Mountain View, CA, UNITED STATES
Duan, D. Roxanne, Bethesda, MD, UNITED STATES
Florence, Kimberly A., Rockville, MD, UNITED STATES
        Rosen, Craig A., Laytonsville, MD, UNITED STATES
PA
        Human Genome Sciences, Inc., Rockville, MD, UNITED STATES, 20850 (U.S.
        corporation)
PΙ
        US 2003180892
                               Α1
                                     20030925
AΙ
        US 2002-277726
                               Α1
                                     20021023 (10)
RLI
        Division of Ser. No. US 1999-231788, filed on 15 Jan 1999, GRANTED, Pat.
        No. US 6486301 Continuation-in-part of Ser. No. US 1998-115832, filed on
        15 Jul 1998, PENDING Continuation-in-part of Ser. No. US 1998-115832, filed on 15 Jul 1998, PENDING US 1997-60140P 19970926 (60) US 1997-55952P 19970818 (60)
        US 1997-60140P
PRAI
        US 1997-55952P
        US 1997-52870P
                                19970716 (60)
        US 1997-60140P
                                19970926 (60)
        US 1997-55952P
                                19970818 (60)
        US 1997-52870P
                                19970716 (60)
DT
        Utility
```

FS

APPLICATION

```
LN.CNT 5982
        INCLM: 435/069.520
INCL
        INCLS: 435/320.100; 435/325.000; 530/351.000; 536/023.500
              435/069.520
NCL
        NCLM:
               435/320.100; 435/325.000; 530/351.000; 536/023.500
        NCLS:
        [7]
IC
        ICM: C07K014-54
        ICS: C07H021-04; C12P021-04; C12N005-06
L5
     ANSWER 125 OF 196 USPATFULL on STN
        2003:250485 USPATFULL
AN
ΤI
        Methods of regulating cytokine receptor signaling
ΙN
        Penninger, Josef, Toronto, CANADA
        US 2003175270
                                  20030918
ΡI
                            Α1
       US 2003-347051
                                 20030117 (10)
AT
                            Α1
PRAI
        US 2002-349861P
                             20020117 (60)
        Utility
DT
        APPLICATION
FS
LN.CNT 988
        INCLM: 424/141.100
INCL
        INCLS: 424/144.100
               424/141.100
NCL
       NCLM:
       NCLS:
               424/144.100
IC
        [7]
        ICM: A61K039-395
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L5
     ANSWER 126 OF 196 USPATFULL ON STN
AN
        2003:238067 USPATFULL
TI
        18232, a novel dual specificity phosphatase and uses therefor
       Meyers, Rachel A., Newton, MA, UNITED STATES
IN
       Weich, Nadine, Brookline, MA, UNITED STATES
Millennium Pharmaceuticals, Inc., a Delaware corporation (U.S.
PΑ
        corporation)
PT
       us 2003166224
                            Α1
                                  20030904
ΑI
        US 2002-165272
                            Α1
                                 20020607 (10)
        Continuation of Ser. No. US 2000-704139, filed on 1 Nov 2000, GRANTED,
RLI
       Pat. No. US 6420153
PRAI
       US 2000-185772P
                             20000229 (60)
DT
        Utility
FS
       APPLICATION
LN.CNT 4569
INCL
        INCLM: 435/196.000
        INCLS: 435/069.100; 435/320.100; 435/325.000; 536/023.200
NCL
       NCLM:
               435/196.000
       NCLS:
               435/069.100; 435/320.100; 435/325.000; 536/023.200
        [7]
TC
        ICM: C12N009-16
        ICS: C07H021-04; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L5
     ANSWER 127 OF 196 USPATFULL ON STN
       2003:237339 USPATFULL
ΑN
TI
       Humanized antibodies that recognize beta amyloid peptide
       Basi, Guriq, Palo Alto, CA, UNITED STATES Saldanha, Jose, Enfield, UNITED KINGDOM
ΙN
       Yednock, Ted, Forest Knolls, CA, UNITED STATES
       Elan Pharmaceuticals, Inc.,
PA
                                     San Francisco, CA (U.S. corporation)
                                 20030904
ΡI
       US 2003165496
                            Α1
ΑI
       US 2001-10942
                            Α1
                                 20011206 (10)
PRAI
       US 2000-251892P
                             20001206 (60)
DT
       Utility
FS
       APPLICATION
LN.CNT
       5733
INCL
       INCLM: 424/141.100
       INCLS: 530/388.150; 435/328.000
               424/141.100
NCL
       NCLM:
       NCLS:
               530/388.150; 435/328.000
IC
        [7]
       ICM: A61K039-395
       ICS: C12N005-06; C07K016-44
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L5
     ANSWER 128 OF 196 USPATFULL ON STN
       2003:232047
AN
                    USPATFULL
ΤI
       32164 protein, a novel seven transmembrane protein
```

```
IN
       Glucksmann, Maria Alexandra, Lexington, MA, UNITED STATES
       Weich, Nadine S., Brookline, MA, UNITED STATES
PΑ
       Millennium Pharmaceuticals, Inc. (U.S. corporation)
       US 2003162247
                                20030828
PΙ
                           Α1
ΑI
       US 2001-911583
                                20010724 (9)
                           Α1
       Continuation-in-part of Ser. No. US 1999-476287, filed on 30 Dec 1999,
RLI
       PENDING
PRAI
       WO 2000-US34973
                            20001222
       Utility
DT
       APPLICATION
FS
       3764
LN.CNT
       INCLM: 435/069.100
INCL
       INCLS: 530/350.000; 435/320.100; 435/325.000; 536/023.500
NCL
              435/069.100
       NCLS:
              530/350.000; 435/320.100; 435/325.000; 536/023.500
       [7]
IC
       ICM: C07K014-705
       ICS: C07H021-04; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L5
     ANSWER 129 OF 196 USPATFULL ON STN
ΑN
       2003:231634 USPATFULL
       Methods and compositions for treating or preventing skin disorders using
ΤI
       binding agents specific for prostate specific membrane antigen
IN
       Bander, Neil, New York, NY, UNITED STATES
PI
       US 2003161832
                           Α1
                                20030828
ΑI
       US 2002-160506
                           Α1
                                20020530 (10)
PRAI
       US 2001-324100P
                            20010920 (60)
       US 2002-362612P
                            20020308 (60)
       Utility
DT
FS
       APPLICATION
LN.CNT 7532
INCL
       INCLM: 424/155.100
NCL
       NCLM: 424/155.100
IC
       [7]
       ICM: A61K039-395
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L5
     ANSWER 130 OF 196 USPATFULL ON STN
ΑN
       2003:231619 USPATFULL
TI
       Pluripotent embryonic-like stem cells, compositions, methods and uses
       thereof
IN
       Young, Henry E., Macon, GA, UNITED STATES
       Lucas, Paul A., Poughkeepsie, NY, UNITED STATES
       US 2003161817
PΙ
                           Α1
                                20030828
       US 2001-820320
ΑI
                           Α1
                                20010328 (9)
       Utility
DT
       APPLICATION
FS
LN.CNT 10419
       INCLM: 424/093.210
INCL
       INCLS: 435/366.000
NCL
       NCLM:
              424/093.210
       NCLS:
              435/366.000
IC
       [7]
       ICM: A61K048-00
       ICS: C12N005-08
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L5
     ANSWER 131 OF 196 USPATFULL ON STN
       2003:225758 USPATFULL
AN
       Diagnostic and therapeutic compositions and methods related to G
TI
       protein-coupled receptor (GPCR) anaphylatoxin C3a receptor
IN
       Burmer, Glenna C., Seattle, WA, UNITED STATES
       Morningstar, Douglas A., Enumclaw, WA, UNITED STATES
       Roush, Christine L., Seattle, WA, UNITED STATES
       Brown, Joseph P., Seattle, WA, UNITED STATES
       us 2003157570
PT
                                20030821
                           Α1
       US 2002-206395
AΤ
                           Α1
                                20020726 (10)
       wo 2001-US45220
PRAI
                            20011129
       US 2001-330036P
                            20011017 (60)
       Utility
DT
FS
       APPLICATION
LN.CNT 4412
       INCLM: 435/007.200
INCL
       NCLM: 435/007.200
NCL
IC
       [7]
```

```
ICM: G01N033-53
         ICS: G01N033-567
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
      ANSWER 132 OF 196 USPATFULL ON STN 2003:220233 USPATFULL
L5
                       USPATFULL
ΑN
        Methods for inhibiting ocular processes
Hinton, David R., Venice, CA, UNITED STATES
He, Shikun, Temple City, CA, UNITED STATES
ΤI
ΙN
        Oliver, Noelynn A., Los Altos, CA, UNITED STATES
PI
         US 2003153524
                                     20030814
                              Α1
ΑI
        US 2002-317390
                               Α1
                                     20021211 (10)
PRAI
        US 2001-339547P
                                20011211 (60)
        Utility
DT
FS
        APPLICATION
LN.CNT 2796
INCL
         INCLM: 514/044.000
         INCLS: 424/145.100; 514/001.000
                 514/044.000
NCL
        NCLM:
        NCLS:
                 424/145.100; 514/001.000
         [7]
TC
        ICM: A61K048-00
        ICS: A61K031-00: A61K039-395
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L5
      ANSWER 133 OF 196 USPATFULL on STN
AN
        2003:207939 USPATFULL
TI
        Pyrimidine carboxamides useful as inhibitors of pde4 isozymes
IN
        Magee, Thomas Victor, Mystic, CT, UNITED STATES
        Marfat, Anthony, Mystic, CT, UNITED STATES
Chambers, Robert James, Mystic, CT, UNITED STATES
PT
        us 2003144300
                                     20030731
                               Α1
        US 2002-181417
ΑI
                               Α1
                                     20020724 (10)
        WO 2001-IB125
                                     20010130
DT
        Utility
FS
        APPLICATION
LN.CNT 5944
INCL
        INCLM: 514/256.000
        INCLS: 514/269.000; 544/314.000; 544/326.000; 544/328.000
NCL
        NCLM:
                 514/256.000
        NCLS:
                 514/269.000; 544/314.000; 544/326.000; 544/328.000
IC
        ICM: A61K031-513
        ICS: A61K031-506
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L5
      ANSWER 134 OF 196 USPATFULL on STN
ΑN
        2003:200905 USPATFULL
TI
        Novel G protein-coupled receptor family members.
                                                                     ***human***
        thioredoxin family members, members, and ***human***
                                            ***human***
                                                            leucine-rich repeat family
                                          ringfinger family member
ΙN
        Glucksmann, Maria Alexandra, Lexington, MA, UNITED STATES
        Silos-Santiago, Inmaculada, Jamaica Plain, MA, UNITED STATES
        Galvin, Katherine M., Jamaica Plain, MA, ÚNITÉD STATES
Weich, Nadine, Brookline, MA, UNITED STATES
        Curtis, Rory A. J., Framingham, MA, UNITED STATES
Bandaru, Rajasekhar, Watertown, MA, UNITED STATES
Kapeller-Libermann, Rosana, Chestnut Hill, MA, UNITED STATES
ΡI
                                     20030724
        us 2003138890
                              Α1
ΑI
        US 2002-145586
                                     20020514 (10)
                               Α1
        Continuation-in-part of Ser. No. US 2001-796338, filed on 28 Feb 2001,
RLI
        PENDING Continuation-in-part of Ser. No. WO 2001-US6543, filed on 28 Feb
        2001, PENDING
WO 2001-US6057
PRAI
                                20010223
        WO 2001-US23152
                                20010723
        wo 2001-us40476
                                20010409
        WO 2001-US7139
                                20010305
        wo 2001-us19544
                                20010615
        wo 2001-US29967
                                20010925
        wo 2001-US9470
                                20010323
        wo 2001-US10380
                                20010330
        wo 2001-us29968
                                20010925
        US 2000-186059P
                                20000229 (60)
        US 2000-220042P
                                20000721 (60)
        US 2000-187447P
                                20000307 (60)
        US 2000-211673P
                                20000615 (60)
```

```
US 2000-235049P
                            20000925 (60)
       US 2000-191863P
                            20000324 (60)
       US 2000-193919P
                             20000331 (60)
          2000-235032P
                            20000925 (60)
DT
       Utility
       APPLICATION
FS
LN.CNT 51652
INCL
       INCLM: 435/069.100
       INCLS: 435/320.100; 435/325.000; 530/350.000; 536/023.500
               435/069.100
NCL
       NCLS:
               435/320.100; 435/325.000; 530/350.000; 536/023.500
IC
       171
       ICM: C07K014-705
       ICS: C12P021-02; C12N005-06; C07H021-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L5
     ANSWER 135 OF 196 USPATFULL on STN
       2003:200428
ΑN
                    USPATFULL
TI
       Gene expression in monocytes and macrophages
       Greaves, David Robert, Oxford, UNITED KINGDOM
IN
PA
       Glaxo Wellcome Inc. (non-U.S. corporation)
       US 2003138411
                                 20030724
PΙ
                           Α1
                                20020201 (10)
ΑI
       US 2002-60387
                           A1
       Continuation of Ser. No. US 1998-171802, filed on 26 Oct 1998, PENDING A
RLI
       371 of International Ser. No. WO 1997-GB1209, filed on 2 May 1997,
       UNKNOWN
PRAI
       GB 1996-9261
                            19960502
DT
       Utility
FS
       APPLICATION
LN.CNT 1391
       INCLM: 424/093.210
INCL
       INCLS: 435/069.100; 435/372.000; 435/320.100; 536/023.200; 435/226.000
              424/093.210
NCL
       NCLM:
       NCLS:
              435/069.100; 435/372.000; 435/320.100; 536/023.200; 435/226.000
IC
       [7]
       ICM: A61K048-00
       ICS: C07H021-04; C12N009-64; C12N005-08
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L5
     ANSWER 136 OF 196 USPATFULL on STN
ΑN
       2003:197032 USPATFULL
TI
       Prevention and treatment of amyloid-associated disorders
IN
       Hyslop, Paul Andrew, Indianapolis, IN, United States
       Miller, Foy Dean, Camby, IN, United States
Higgins, Linda S., Palo Alto, CA, United States
       Catalano, Rosanne, Hayward, CA, United States
       Cordell, Barbara, Palo Alto, CA, United States
       Puchacz, Elizbieta, Pleasanton, CA, United States
PA
       Scios Inc., Sunnyvale, CA, United States (U.S. corporation)
       Eli Lilly and Company, Indianapolis, IN, United States (U.S.
       corporation)
       us 6596474
PΙ
                                20030722
                           B1
ΑI
       US 2000-608640
                                20000630 (9)
       US 1999-142175P
PRAI
                            19990701 (60)
       Utility
DT
       GRANTED
FS
LN.CNT 1226
INCL
       INCLM: 435/004.000
       INCLS: 435/070.300; 435/347.000; 435/374.000; 424/562.000
NCL
              435/004.000
              424/562.000; 435/070.300; 435/347.000; 435/374.000
       NCLS:
IC
       [7]
       ICM: C12Q001-00
       ICS: C12P021-04; C12N005-06; C12N005-00; A61K035-55
       424/562; 435/4; 435/70.3; 435/373; 435/347
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 137 OF 196 USPATFULL on STN
L5
       2003:188461 USPATFULL
ΑN
       oxazolyl-acid amide derivatives useful as inhibitors of PDE4 isozymes
TI
       Marfat, Anthony, UNITED STATES
ΙN
       McKechney, Michael William, UNITED STATES
       us 2003130254
PΙ
                           Α1
                                20030710
       us 2002-300959
ΑI
                           Α1
                                20021120 (10)
       Division of Ser. No. US 2002-62145, filed on 31 Jan 2002, PENDING
RLI
       US 2001-265486P
PRAI
                            20010131 (60)
```

```
Utility
DT
FS
        APPLICATION
LN.CNT 7168
INCL
        INCLM: 514/210.200
        INCLS: 514/227.800; 514/235.500; 514/249.000; 514/248.000; 514/263.200; 514/266.200; 514/256.000; 514/255.050; 514/252.050; 514/365.000;
                514/314.000
514/210.200
NCL
        NCLM:
        NCLS:
                514/227.800; 514/235.500; 514/249.000; 514/248.000; 514/263.200;
                514/266.200; 514/256.000; 514/255.050; 514/252.050; 514/365.000;
                514/314.000
        [7]
IC
        ICM: A61K031-541
        ICS: A61K031-5377; A61K031-506; A61K031-52; A61K031-517; A61K031-4709;
        A61K031-427; C07D417-02
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L5
     ANSWER 138 OF 196 USPATFULL ON STN
AN
        2003:187401 USPATFULL
        Complement pathway inhibitors binding to C5 and C5a without preventing
ΤI
        formation of C5b
IN
        Fung, Michael, Houston, TX, UNITED STATES
        Lu, Meisheng, Houston, TX, UNITED STATES
        Sun, William N.C., Shanghai, CHINA
        Sun, Cecily R.Y., Shanghai, CHINA
PA
        Tanox, Inc. (U.S. corporation)
        us 2003129187
ΡI
                                   20030710
                             Α1
        US 2002-222464
                                   20020817 (10)
AΤ
                             Α1
                              20010817 (60)
PRAI
        US 2001-313137P
DT
        Utility
FS
        APPLICATION
LN.CNT 1012
        INCLM: 424/144.100
INCL
        INCLS: 435/334.000; 530/388.220; 424/141.100; 530/388.150
NCL
                424/144.100
        NCLM:
               435/334.000; 530/388.220; 424/141.100; 530/388.150
        NCLS:
IC
        [7]
        ICM: A61K039-395
        ICS: C12N005-06; C07K016-28
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 139 OF 196 USPATFULL on STN 2003:180797 USPATFULL
L5
ΑN
ΤI
        Diagnostic and therapeutic compositions and methods related to chemokine
        (C motif ) XC receptor 1 (CCXCR1), a G protein-coupled receptor (GPCR) Burmer, Glenna C., Seattle, WA, UNITED STATES
IN
        Woodward, Madeline L., Mercer Island, WA, UNITED STATES
        Roush, Christine L., Seattle, WA, UNITED STATES
        Brown, Joseph P., Seattle, WA, UNITED STATES
        us 2003124627
PΙ
                                   20030703
                             Α1
       US 2002-206401
ΑI
                             Α1
                                   20020726 (10)
PRAI
       WO 2001-US45218
                              20011129
        Utility
DT
FS
        APPLICATION
LN.CNT 4499
INCL
        INCLM: 435/007.230
        INCLS: 514/012.000; 530/350.000
               435/007.230
NCL
        NCLM:
               514/012.000; 530/350.000
        NCLS:
IC
        [7]
        ICM: G01N033-574
        ICS: C07K014-715; A61K038-17
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L5
     ANSWER 140 OF 196 USPATFULL ON STN
AN
        2003:166521 USPATFULL
       Methods of treating or preventing cell, tissue, and organ damage using
TI
          ***human***
                         myeloid progenitor inhibitory factor-1 (MPIF-1)
        Li, Haodong, Gaithersburg, MD, UNITED STATES
IN
       Ruben, Steven M., Olney, MD, UNITED STATES
Grzegorzewski, Krzysztof J., Gaithersburg, MD, UNITED STATES
Rosen, Craig A., Laytonsville, MD, UNITED STATES
       Patel, Vikram, Germantown, MD, UNITED STATES
       Gentz, Reinder L., Rockville, MD, UNITED STATES
       Human Genome Sciences, Inc. (U.S. corporation)
PA
PΙ
       US 2003114379
                            Α1
                                  20030619
```

```
ΑI
        us 2002-261950
                                    20021002 (10)
                              Α1
        Division of Ser. No. US 2000-689693, filed on 13 Oct 2000, GRANTED, Pat.
RLI
        No. US 6495129 Division of Ser. No. US 2000-571013, filed on 15 May
        2000, PENDING Division of Ser. No. US 1999-334951, filed on 17 Jun 1999,
        GRANTED, Pat. No. US 6451562 Continuation of Ser. No. US 1996-722723
        filed on 30 Sep 1996, ABANDONED Continuation of Ser. No. US 1996-722719,
        filed on 30 Sep 1996, GRANTED, Pat. No. US 6001606 Continuation-in-part of Ser. No. US 1995-465682, filed on 6 Jun 1995, ABANDONED Continuation-in-part of Ser. No. US 1995-446881, filed on 5 May 1995,
        ABANDONED Continuation of Ser. No. US 1994-208339, filed on 8 Mar 1994,
        GRANTED, Pat. No. US 5504003
PRAI
        US 1999-159362P
                               19991014 (60)
        US 1999-164059P
                               19991108 (60)
        US 1999-172063P
                               19991223 (60)
        US 2000-189048P
                               20000314 (60)
        US 2000-199142P
                               20000424 (60)
        US 2000-211458P
                               20000613
                                         (60)
        US
           2000-212658P
                               20000619
                                          (60)
        US
           1996-27299P
                               19960930
                                         (60)
        US 1996-27300P
                               19960930 (60)
        Utility
DT
FS
        APPLICATION
LN.CNT 14465
INCL
        INCLM: 514/012.000
NCL
        NCLM:
                514/012.000
IC
        [7]
        ICM: A61K038-17
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 141 OF 196 USPATFULL on STN 2003:165951 USPATFULL
L5
ΑN
TI
        Function homology screening
IN
        Berg, Ellen L., Palo Alto, CA, UNITED STATES
        Butcher, Eugene C., Portola Valley, CA, UNITED STATES
        Melrose, Jennifer, La Honda, CA, UNITED STATES
PI
        US 2003113807
                             Α1
                                   20030619
ΑI
        us 2001-800605
                              Α1
                                   20010306 (9)
                               20000306 (60)
        US 2000-186976P
PRAI
        US 2000-195672P
                               20000407 (60)
        Utility
DT
FS
        APPLICATION
LN.CNT 4315
INCL
        INCLM: 435/007.200
        INCLS: 702/019.000
NCL
                435/007.200
        NCLM:
        NCLS:
                702/019.000
        [7]
IC
        ICM: G01N033-53
        ICS: G01N033-567; G06F019-00; G01N033-48; G01N033-50
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L5
     ANSWER 142 OF 196 USPATFULL ON STN
        2003:165472 USPATFULL
AN
TI
        Reducing myelin-mediated inhibition of axon regeneration
ΤN
        He, Zhigang, Boston, MA, UNITED STATES
       Wang, Kevin C., Boston, MA, UNITED STATES
Koprivica, Vuk, Boston, MA, UNITED STATES
Kim, Jieun A., Boston, MA, UNITED STATES
        Children's Medical Center Corporation (U.S. corporation)
PA
PΙ
        US 2003113326
                             Α1
                                   20030619
ΑI
        US 2002-127058
                             Α1
                                   20020419 (10)
RLI
        Continuation of Ser. No. US 2001-6002, filed on 3 Dec 2001, PENDING
DT
        Utility
FS
        APPLICATION
LN.CNT
       1071
INCL
        INCLM: 424/146.100
        INCLS: 435/007.200
                424/146.100
NCL
        NCLM:
                435/007.200
        NCLS:
IC
        [7]
        ICM: G01N033-53
        ICS: G01N033-567; A61K039-395
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L5
     ANSWER 143 OF 196 USPATFULL ON STN
```

ΑN

2003:165471 USPATFULL

```
TI
        Reducing myelin-mediated inhibition of axon regeneration
 IN
        He, Zhigang, Boston, MA, UNITED STATES
        Wang, Kevin C., Boston, MA, UNITED STATES
Koprivica, Vuk, Boston, MA, UNITED STATES
        Kim, Jieun A., Boston, MA, UNITED STATES
 PΙ
        US 2003113325
                            Α1
                                  20030619
 ΑI
        US 2001-6002
                            Α1
                                  20011203 (10)
        Utility
 DT
 FS
        APPLICATION
 LN.CNT
        1220
 INCL
        INCLM: 424/146.100
        INCLS: 435/007.200
NCL
               424/146.100
        NCLM:
        NCLS:
               435/007.200
        [7]
 TC
        ICM: A61K039-395
        ICS: G01N033-53; G01N033-567
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L5
      ANSWER 144 OF 196 USPATFULL ON STN
        2003:153329 USPATFULL
AN
TI
        Multi-lineage directed induction of bone marrow stromal cell
        differentiation
IN
        Black, Ira B., Skillman, NY, UNITED STATES
        Woodbury, Dale, Piscataway, NJ, UNITED STATES
        US 2003104997
PΙ
                                  20030605
                            Α1
ΑI
        US 2001-946325
                            Α1
                                  20010905 (9)
DT
        Utility
FS
        APPLICATION
LN.CNT 2016
INCL
        INCLM: 514/012.000
        INCLS: 435/372.000; 514/044.000
NCL
        NCLM:
               514/012.000
        NCLS:
               435/372.000; 514/044.000
IC
        [7]
        ICM: A61K038-18
        ICS: A61K048-00; C12N005-08
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 145 OF 196 USPATFULL ON STN
L5
ΑN
        2003:152692 USPATFULL
       Diagnosis methods based on microcompetition for a limiting GABP complex
TI
ΙN
        Polansky, Hanan, Rochester, NY, UNITED STATES
PI
       US 2003104358
                            Α1
                                 20030605
ΑI
       US 2002-219649
                            Α1
                                 20020815 (10)
       Continuation-in-part of Ser. No. US 2000-732360, filed on 7 Dec 2000,
RLI
       PENDING
DT
       Utility
FS
       APPLICATION
LN.CNT 14430
INCL
       INCLM: 435/005.000
       INCLS: 435/006.000
NCL
       NCLM:
               435/005.000
       NCLS:
               435/006.000
IC
        [7]
       ICM: C12Q001-70
       ICS: C12Q001-68
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L5
     ANSWER 146 OF 196 USPATFULL ON STN
ΑN
       2003:146361 USPATFULL
ΤI
       Compositions and methods for generating differentiated
                                                                    ***human***
       cells
ΙN
       Peschle, Cesare, Rome, ITALY
PA
       Thomas Jefferson University, Philadelphia, PA, UNITED STATES (non-U.S.
       corporation)
PΙ
       US 2003100107
                           Α1
                                 20030529
ΑI
       us 2001-7574
                           Α1
                                 20011109 (10)
       Continuation-in-part of Ser. No. US 1999-322352, filed on 28 May 1999,
RLI
       PENDING
PRAI
                            19980529 (60)
       US 1998-87153P
DT
       Utility
FS
       APPLICATION
LN.CNT 3085
INCL
       INCLM: 435/372.000
```

INCLS: 435/007.210

```
NCL
        NCLM:
                435/372.000
        NCLS:
                435/007.210
IC
        [7]
        ICM: C12N005-08
        ICS: G01N033-567
CAS INDEXING IS AVAILABLE FOR THIS PATENT,
L5
      ANSWER 147 OF 196 USPATFULL ON STN
        2003:140112 USPATFULL
AN
        Multi-organ engraftment with a single bone marrow-derived stem cell
TI
IN
        Krause, Diane S., Hamden, CT, UNITED STATES
        Theise, Neil D., New York, NY, UNITED STATES
        Collector, Michael I., Baltimore, MD, UNITED STATES
        Sharkis, Saul J., Towson, MD, UNITED STATES US 2003095952 A1 20030522
PΙ
        US 2002-165533
ΑI
                             Α1
                                  20020607 (10)
        US 2001-297927P
PRAI
                              20010613 (60)
        Utility
DT
FS
        APPLICATION
LN.CNT 1313
INCL
        INCLM: 424/093.700
        INCLS: 435/372.000
NCL
        NCLM:
               424/093.700
        NCLS:
               435/372.000
IC
        [7]
        ICM: A61K045-00
        ICS: C12N005-08
      ANSWER 148 OF 196 USPATFULL ON STN
L5
        2003:130039 USPATFULL
AN
TI
        Perlecan transgenic animals and methods of identifying compounds for the
        treatment of amyloidoses
IN
        Snow, Alan D., Lynnwood, WA, United States
        Fukuchi, Ken-Ichiro, Birmingham, AL, United States
        Hassell, John, Tampa, FL, United States
PA
        University of Washington, Seattle, WA, United States (U.S. corporation)
PΙ
        us 6563016
                                  20030513
                             В1
        US 2000-536231
ΑI
                                  20000327 (9)
        Continuation of Ser. No. US 1997-870987, filed on 6 Jun 1997, now
RLI
        abandoned
        US 1996-17830P
Utility
PRAI
                              19960606 (60)
DT
FS
        GRANTED
LN.CNT 2931
INCL
        INCLM: 800/012.000
        INCLS: 800/008.000; 800/009.000; 800/003.000; 800/014.000; 800/018.000;
               800/021.000; 800/022.000; 800/025.000; 435/320.100; 435/325.000;
               435/455.000
        NCLM:
NCL
               800/012.000
        NCLS:
               435/320.100; 435/325.000; 435/455.000; 800/003.000; 800/008.000;
               800/009.000; 800/014.000; 800/018.000; 800/021.000; 800/022.000;
               800/025.000
IC
        [7]
        ICM: A01K067-00
        ICS: A01K067-027; C12N015-00; C12N005-00
       800/3; 800/12; 800/14; 800/18; 800/21; 800/22; 800/8; 800/9; 800/25; 435/320.1; 435/325; 435/455; 536/23.1; 536/23.5
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L5
     ANSWER 149 OF 196 USPATFULL ON STN
        2003:127035 USPATFULL
ΑN
ΤI
       Diagnosis and treatment of inflammation and hyperactive immune
       conditions
       Kumamoto, Tadashi, Tsu, JAPAN
Mizumoto, Norikatsu, Irving, TX, UNITED STATES
IN
       Takashima, Akira, Coppell, TX, UNITED STATES US 2003087247 A1 20030508
PΙ
ΑI
       US 2002-74220
                            Α1
                                  20020212 (10)
PRAI
       US 2001-273212P
                             20010301 (60)
       US 2001-334618P
                             20011101 (60)
       Utility
DT
       APPLICATION
FS
       3955
LN.CNT
       INCLM: 435/006.000
INCL
       INCLS: 435/004.000
NCL
       NCLM:
               435/006.000
```

```
NCLS: 435/004.000
 IC
         [7]
         ICM: C12Q001-68
        ICS: C12Q001-00
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
      ANSWER 150 OF 196 USPATFULL on STN
15
        2003:120776 USPATFULL
ΑN
        Cryptococcal mannoproteins or equivalents thereof for use in modulating
TI
        neutrophil migration
IN
        Hoepelman, IIja Mohandas, Utrecht, NETHERLANDS
        us 2003083260
                                   20030501
PΙ
                              Α1
ΑI
        US 2002-238908
                              Α1
                                   20020909 (10)
RLI
        Continuation of Ser. No. WO 2001-NL192, filed on 8 Mar 2001, UNKNOWN
        EP 2000-200826
Utility
PRAI
                               20000308
DT
        APPLICATION
FS
LN.CNT 560
INCL
        INCLM: 514/012.000
        INCLS: 514/008.000
                514/012.000
NCL
        NCLM:
        NCLS:
                514/008.000
IC
        [7]
        ICM: A61K038~16
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L5
      ANSWER 151 OF 196 USPATFULL ON STN
AN
        2003:112894
                      USPATFULL
        20685, 579, 17114, 23821, 33894 and 32613, novel
TI
                                                                  ***human***
        transporters
ΙN
        Glucksmann, Maria Alexandra, Lexington, MA, UNITED STATES
        Silos-Santiago, Inmaculada, Jamaica Plain, MA, UNITED STATES
        Millennium Pharmaceuticals, Inc. (U.S. corporation)
PA
PΙ
        US 2003077626
                                   20030424
                              A1
ΑI
        US 2002-199485
                             Α1
                                    20020718 (10)
        Continuation-in-part of Ser. No. US 2001-795693, filed on 28 Feb 2001,
RLI
        PENDING
PRAI
        US 2000-185906P
                               20000229 (60)
        Utility
DT
FS
        APPLICATION
LN.CNT 8163
INCL
        INCLM: 435/006.000
        INCLS: 530/350.000; 536/023.100
NCL
        NCLM:
                435/006.000
                530/350.000; 536/023.100
        NCLS:
IC
        [7]
        ICM: C12Q001-68
        ICS: C07H021-02; C07H021-04; C07K001-00; C07K014-00; C07K017-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L5
     ANSWER 152 OF 196 USPATFULL ON STN
ΑN
        2003:112548 USPATFULL
                 ***human***
TT
                                beta2 integrin alpha subunit
        Gallatin, W. Michael, Mercer Island, WA, UNITED STATES
IN
        Van der Vieren, Monica, Seattle, WA, UNITED STATES
PA
        ICOS Corporation (U.S. corporation)
ΡI
        US 2003077278
                             Α1
                                   20030424
ΑI
        US 2001-891943
                             Α1
                                   20010626 (9)
RLI
        Division of Ser. No. US 1998-193043, filed on 16 Nov 1998, PATENTED
        Continuation-in-part of Ser. No. US 1997-943363, filed on 3 Oct 1997
        PATENTED Continuation-in-part of Ser. No. US 1996-605672, filed on 22
       Feb 1996, PATENTED Continuation-in-part of Ser. No. US 1994-362652, filed on 21 Dec 1994, PATENTED Continuation-in-part of Ser. No. US 1994-286889, filed on 5 Aug 1994, PATENTED Continuation-in-part of Ser. No. US 1994-286889, Filed on 5 Aug 1994, PATENTED Continuation-in-part of Ser.
        No. US 1993-173497, filed on 23 Dec 1993, PATENTED
        Utility
DT
        APPLICATION
LN.CNT 9721
        INCLM: 424/144.100
INCL
        INCLS: 435/334.000
NCL
        NCLM:
               424/144.100
               435/334.000
        NCLS:
IC
        [7]
        ICM: A61K039-395
        ICS: C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
```

```
L5
      ANSWER 153 OF 196 USPATFULL ON STN
        2003:105826 USPATFULL
ΑN
TI
        Tissue protective cytokines for the protection, restoration, and
        enhancement of responsive cells, tissues and organs Brines, Michael, Woodbridge, CT, UNITED STATES
TN
        Cerami, Antony, Croton On Hudson, NY, UNITED STATES
        Cerami, Carla, Sleepy Hollow, NY, UNITED STATES
        US 2003072737
PΙ
                            Α1
                                 20030417
ΑI
        US 2002-188905
                            Α1
                                 20020703 (10)
        Continuation-in-part of Ser. No. US 2000-753132, filed on 29 Dec 2000,
RLI
        PENDING Continuation-in-part of Ser. No. wo 2001-US49479, filed on 28
        Dec 2001, PENDING
        US 2000-259245P
Utility
PRAI
                             20001229 (60)
DT
        APPLICATION
FS
LN.CNT 3417
INCL
        INCLM: 424/085.100
        INCLS: 530/351.000
NCL
        NCLM:
               424/085.100
        NCLS:
               530/351.000
IC
        L7 I
        ICM: A61K038-19
        ICS: C07K014-52
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L5
     ANSWER 154 OF 196 USPATFULL on STN 2003:100088 USPATFULL
AN
        Treatment methods based on microcompetition for a limiting GABP complex
TI
IN
        Polansky, Hanan, Rochester, NY, UNITED STATES
PΙ
        US 2003069199
                                 20030410
                            Α1
ΑI
        US 2002-219334
                            Α1
                                 20020815 (10)
        Continuation-in-part of Ser. No. US 2000-732360, filed on 7 Dec 2000,
RLI
        PENDING
DT
       Utility
       APPLICATION
FS
LN.CNT 14837
INCL
        INCLM: 514/044.000
        INCLS: 424/093.200; 424/186.100
               514/044.000
NCL
       NCLM:
       NCLS:
               424/093.200; 424/186.100
        [7]
IC
       ICM: A61K048-00
       ICS: A61K039-12
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L5
     ANSWER 155 OF 196 USPATFULL ON STN
       2003:99511 USPATFULL
AN
TI
       Drug discovery assays based on microcompetition for a limiting GABP
       complex
ΙN
       Polansky
                 Hanan, Rochester, NY, UNITED STATES
PΙ
       US 2003068616
                                 20030410
                           Α1
       US 2002-223050
ΑI
                           A1
                                 20020814 (10)
       Continuation-in-part of Ser. No. US 2000-732360, filed on 7 Dec 2000,
RLI
       PENDING
       Utility
DT
FS
       APPLICATION
LN.CNT 14981
INCL
       INCLM: 435/005.000
       INCLS: 435/007.210; 435/456.000; 435/320.100; 435/325.000; 435/366.000
NCL
       NCLM:
               435/005.000
               435/007.210; 435/456.000; 435/320.100; 435/325.000; 435/366.000
       NCLS:
TC
       [7]
       ICM: C12Q001-70
       ICS: G01N033-567; C12N015-86; C12N005-08
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L5
     ANSWER 156 OF 196 USPATFULL ON STN
ΑN
       2003:52389 USPATFULL
TT
       Novel nucleic acid sequences encoding a
                                                    ***human***
                                                                   ubiquitin
       protease, lipase, dynamin, short chain dehydrogenase, and ADAM-TS
       metalloprotease and uses therefor
       Glucksmann, Maria Alexandra, Lexington, MA, UNITED STATES
IN
       Kapeller-Libermann, Rosana, Chestnut Hill, MA, UNITED STATES
       Meyers, Rachel E., Newton, MA, UNITED STATES
       Rudolph-Owen, Laura A., Jamaica Plain, MA, UNITED STATES
```

```
PΑ
        Millennium Pharmaceuticals, Inc. (U.S. corporation)
PΙ
        US 2003037350
                                    20030220
                              Α1
ΑI
        us 2002-163547
                              Α1
                                    20020605 (10)
        Continuation-in-part of Ser. No. US 1999-407356, filed on 29 Sep 1999,
RLI
        PENDING Continuation-in-part of Ser. No. US 2000-704918, filed on 2 Nov
        2000, PENDING Continuation-in-part of Ser. No. US 1999-435311, filed on 5 Nov 1999, PENDING Continuation-in-part of Ser. No. US 2001-796100, filed on 28 Feb 2001, PENDING Continuation-in-part of Ser. No. US
        2001-781598, filed on 12 Feb 2001, PENDING Continuation-in-part of Ser.
        No. US 2001-782952, filed on 14 Feb 2001, PENDING Continuation-in-part
        of Ser. No. US 2000-496005, filed on 1 Feb 2000, PENDING
        US 2000-185503P
PRAI
                               20000228 (60)
                               20000211 (60)
        US 2000-182009P
        US 2000-182408P
                               20000214 (60)
DT
        Utility
FS
        APPLICATION
LN.CNT 23031
        INCLM: 800/008.000
INCL
        INCLS: 435/069.100; 435/320.100; 435/325.000; 435/183.000; 536/023.200
                800/008.000
NCL
        NCLM:
        NCLS:
                435/069.100; 435/320.100; 435/325.000; 435/183.000; 536/023.200
IC
        [7]
        ICM: A01K067-00
        ICS: C07H021-04; C12N009-00; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L5
      ANSWER 157 OF 196 USPATFULL on STN
        2003:51117 USPAIFULL
Novel nucleic acid sequences encoding ***human**

atpace molecule, a ***human***
AN
        2003:51117
                     USPATFULL
TI
                                                     ***human***
                                                                      transporters, a
        ***human*** atpase molecule, a ***h
hydrolase-like_molecule, a ***human***
                                                                 ubiquitin
                                                          ubiquitin conjugating
        enzyme-like molecule, and uses therefor
        Glucksmann, Maria Aléxandra, Lexington, MA, UNITED STATES
Kapeller-Libermann, Rosanna, Chestnut Hill, MA, UNITED STATES
IN
PA
        Millennium Pharmaceuticals, Inc. (U.S. corporation)
PΙ
        US 2003036074
                                    20030220
                              Α1
ΑI
        us 2002-156239
                                    20020524 (10)
                              Α1
        Continuation-in-part of Ser. No. US 2001-795693, filed on 28 Feb 2001,
RLI
        PENDING Continuation-in-part of Ser. No. US 2001-809557, filed on 15 Mar
        2001, PENDING Continuation-in-part of Ser. No. US 2001-808568, filed on
        14 Mar 2001, PENDING Continuation-in-part of Ser. No. US 2001-808767, filed on 15 Mar 2001, PENDING US 2000-185906P 20000229 (60)
PRAI
        US 2000-192018P
                               20000324 (60)
        US 2000-191790P
                               20000324 (60)
        US 2000-191781P
                               20000324 (60)
DT
        Utility
FS
        APPLICATION
LN.CNT 19568
INCL
        INCLM: 435/006.000
        INCLS: 435/069.100; 435/226.000; 435/199.000; 435/320.100; 435/325.000;
                530/350.000; 536/023.200
NCL
        NCLM:
                435/006.000
        NCLS:
                435/069.100; 435/226.000; 435/199.000; 435/320.100; 435/325.000;
                530/350.000; 536/023.200
        [7]
IC
        ICM: C12Q001-68
        ICS: C07H021-04; C12N009-22; C12N009-64; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 158 OF 196 USPATFULL ON STN
L5
ΑN
        2003:44875 USPATFULL
TI
        Method of making a homogeneous preparation of hematopoietic stem cells
ΙN
        Sharkis, Saul J., Towson, MD, UNITED STATES
        Collector, Michael I., Baltimore, MD, UNITED STATES
        US 2003032185
PΙ
                              Α1
                                    20030213
        US 2002-132695
ΑI
                              Α1
                                    20020426 (10)
        US 2001-288084P
PRAI
                               20010503 (60)
DT
        Utility
        APPLICATION
FS
LN.CNT 1217
        INCLM: 435/372.000
INCL
        NCLM: 435/372.000
NCL
IC
        ICM: C12N005-08
```

```
ANSWER 159 OF 196 USPATFULL on STN
              2003:38351 USPATFULL
 ΑN
             Novel genes encoding proteins having prognostic, diagnostic, preventive,
 TI
             therapeutic, and other uses
             Holtzman, Douglas A., Jamaica Plain, MA, UNITED STATES
 ΙN
             Barnes, Thomas M., Brookline, MA, UNITED STATES US 2003027998 A1 20030206
 PΙ
 ΑI
             us 2001-796753
                                              Α1
                                                       20010301 (9)
             Continuation-in-part of Ser. No. US 1998-183175, filed on 30 Oct 1998
 RLI
             ABANDONED Continuation-in-part of Ser. No. US 2000-599596, filed on 22 Jun 2000, ABANDONED Division of Ser. No. US 1998-223546, filed on 30 Dec
             1998, ABANDONED Division of Ser. No. US 1999-471179, filed on 23 Dec
             1999, PENDING Continuation-in-part of Ser. No. US 1998-223546, filed on
            1999, PENDING CONTINUATION-IN-part of Ser. No. US 1998-223546, Tiled on 30 Dec 1998, ABANDONED Continuation-in-part of Ser. No. US 1999-474072, filed on 29 Dec 1999, PENDING Continuation-in-part of Ser. No. US 1998-224246, filed on 30 Dec 1998, ABANDONED Continuation-in-part of Ser. No. US 1999-474071, filed on 29 Dec 1999, ABANDONED Continuation-in-part of Ser. No. US 1998-223094, filed on 30 Dec 1998, ABANDONED Continuation-in-part of Ser. No. US 2000-514010, filed on 25 Feb 2000, ABANDONED Continuation-in-part of Ser. No. US 1999-259388, filed on 26 Feb 1999, ABANDONED Continuation-in-part of Ser. No. US 2000-516745, filed on 1 Mar 2000, ABANDONED Continuation-in-part of Ser.
             2000-516745, filed on 1 Mar 2000, ABANDONED Continuation-in-part of Ser.
             No. US 2000-597993, filed on 19 Jun 2000, PENDING Continuation-in-part
             of Ser. No. US 1999-336536, filed on 18 Jun 1999, PENDING
             Continuation-in-part of Ser. No. US 2000-630334, filed on 31 Jul 2000, PENDING Continuation-in-part of Ser. No. US 1999-365164, filed on 30 Jul
             1999, ABANDONED Continuation-in-part of Ser. No. US 2000-665666, filed
            on 20 Sep 2000, PENDING Continuation—in—part of Ser. No. US 1999–399723, filed on 20 Sep 1999, ABANDONED Continuation—in—part of Ser. No. US 2000–667751, filed on 21 Sep 2000, PENDING Continuation—in—part of Ser. No. US 1999–409634, filed on 30 Sep 1999, ABANDONED Continuation—in—part of Ser. No. US 2000–572002, filed on 15 May 2000, PENDING Continuation—in—part of Ser. No. US 1999–312359, filed on 14 May 1999, ABANDONED Continuation—in—part of Ser. No. US 1999–312359, filed on 14 May 1999, ABANDONED Continuation—in—part of Ser. No. US 2000–606565, filed on 20
             ABANDONED Continuation-in-part of Ser. No. US 2000-606565, filed on 29
             Jun 2000, PENDING Continuation-in-part of Ser. No. US 1999-342687, filed
            on 29 Jun 1999, ABANDONED Continuation-in-part of Ser. No. US 2000-606317, filed on 29 Jun 2000, PENDING Continuation-in-part of Ser. No. US 1999-345464, filed on 30 Jun 1999, ABANDONED
PRAI
            US 1999-122458P
                                               19990301 (60)
DT
            Utility
FS
            APPLICATION
LN.CNT 22222
INCL
            INCLM: 536/023.100
NCL
            NCLM:
                        536/023.100
IC
             [7]
            ICM: C07H021-02
            ICS: C07H021-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L5
         ANSWER 160 OF 196 USPATFULL ON STN 2003:38198 USPATFULL
ΑN
TI
            Ether derivatives useful as inhibitors of PDE4 isozymes
            Marfat, Anthony, Mystic, CT, UNITED STATES
Chambers, Robert J., Mystic, CT, UNITED STATES
Magee, Thomas V., Mystic, CT, UNITED STATES
Pfizer Inc. (U.S. corporation)
IN
PΑ
ΡI
            US 2003027845
                                           A1
                                                     20030206
ΑI
            US 2002-66503
                                            Α1
                                                     20020131 (10)
PRAI
            US 2001-265304P
                                              20010131 (60)
DT
            Utility
FS
            APPLICATION
LN.CNT 8073
INCL
            INCLM: 514/340.000
            INCLS: 514/345.000; 546/268.100; 546/298.000
                        514/340.000
NCL
            NCLM:
                        514/345.000; 546/268.100; 546/298.000
            NCLS:
IC
            [7]
            ICM: A61K031-4439
            ICS: A61K031-44; C07D213-78
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L5
        ANSWER 161 OF 196 USPATFULL ON STN
ΑN
           2003:30210 USPATFULL
TI
           Methods of producing a library and methods of selecting polynucleotides
            of interest
IN
           Zauderer, Maurice, Pittsford, NY, UNITED STATES
```

L5

```
Smith, Ernest S., Ontario, NY, UNITED STATES
        University of Rochester (Ú.S. corporation)
 PA
 PΙ
        US 2003022157
                                  20030130
                            Αl
 ΑI
        US 2001-818991
                                  20010328 (9)
                            Α1
                             20000328 (60)
 PRAI
        US 2000-192586P
        US 2000-203343P
                              20000510 (60)
        US 2001-263226P
                              20010123 (60)
        US 2001-271426P
                              20010227 (60)
        Utility
 DT
 FS
        APPLICATION
 LN.CNT
        10535
        INCLM: 435/005.000
 INCL
        INCLS: 435/069.100; 435/456.000; 435/235.100
        NCLM:
NCL
               435/005.000
        NCLS:
               435/069.100; 435/456.000; 435/235.100
 IC
        [7]
        ICM: C12Q001-70
        ICS: C12N007-00; C12P021-02; C12N015-863
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L5
      ANSWER 162 OF 196 USPATFULL on STN
ΑN
        2003:17888 USPATFULL
TI
        Integrin linked kinase modulation of leukocyte trafficking
IN
        Kojic, Ljiljana, Vancouver, CANADA
        Kalmar, Gabe, Richmond, CANADA
Moran, David M., Woking, UNITED KINGDOM
        US 2003013640
PΙ
                                  20030116
                            Α1
ΑI
        US 2002-163385
                                  20020604 (10)
                            Α1
PRAI
        US 2001-296262P
                             20010605 (60)
DT
        Utility
FS
        APPLICATION
LN.CNT 858
INCL
        INCLM: 514/002.000
NCL
        NCLM: 514/002.000
IC
        [7]
        ICM: A61K038-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 163 OF 196 USPATFULL ON STN
L5
ΑN
        2002:338241 USPATFULL
        Nicotinamide biaryl derivatives useful as inhibitors of PDE4 isozymes
ΤI
IN
        Chambers, Robert J., Mystic, CT, UNITED STATES
       Marfat, Anthony, Mystic, CT, UNITED STATES
       Magee, Thomas V., Mystic, CT, UNITED STATES
PA
        Pfizer Inc. (U.S. corporation)
PΙ
        US 2002193612
                            Α1
                                 20021219
ΑI
        US 2002-62813
                            Α1
                                 20020131 (10)
       US 2001-265492P
PRAI
                             20010131 (60)
       Utility
DT
FS
        APPLICATION
LN.CNT
       7001
INCL
       INCLM: 549/200.000
NCL
       NCLM:
              549/200.000
IC
        [7]
       ICM: C07D321-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L5
     ANSWER 164 OF 196 USPATFULL ON STN
ΑN
       2002:336861 USPATFULL
TI
       Novel uses of mammalian OX2 protein and related reagents
ΙN
       Hoek, Robert M., Mountain_View, CA, UNITED STATES
       Sedgwick, Jonathan D., Palo Alto, CA, UNITED STATES
       Schering Corporation, a New Jersey corporation (U.S. corporation) US 2002192215 A1 20021219
PA
PΙ
ΑI
       US 2002-86972
                                 20020301 (10)
                           Α1
       Division of Ser. No. US 2000-547432, filed on 12 Apr 2000, ABANDONED
RLI
PRAI
       US 1999-129124P
                            19990413 (60)
DT
       Utility
FS
       APPLICATION
LN.CNT
       885
INCL
       INCLM: 424/144.100
       INCLS: 514/012.000
NCL
               424/144.100
       NCLM:
              514/012.000
       NCLS:
IC
       [7]
       ICM: A61K039-395
```

```
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L5
      ANSWER 165 OF 196 USPATFULL ON STN
         2002:311025 USPATFULL
 ΑN
 TI
         Interleukin-20
 IN
         Ebner, Reinhard, Gaithersburg, MD, United States
        Murphy, Marianne, Richmond, UNITED KINGDOM
        Ruben, Steven M., Olney, MD, United States
        Hu, Jing-Shan, Sunnyvale, CA, United States
        Duan, D. Roxanne, Bethesda, MD, United States
        Florence, Kimberly A., Rockville, MD, United States
        Rosen, Craig A., Laytonsville, MD, United States
 PA
        Human Genome Sciences, Inc., Rockville, MD, United States (U.S.
        corporation)
 PΙ
        US 6486301
                                  20021126
                             В1
        US 1999-231788
 ΑI
                                  19990115
        Continuation-in-part of Ser. No. US 1998-115832, filed on 15 Jul 1998
 RLI
                              19970716 (60)
 PRAI
        US 1997-52870P
        US 1997-60140P
                              19970926 (60)
        US 1997-55952P
                              19970818 (60)
        Utility
 DT
 FS
        GRANTED
 LN.CNT
        5643
        INCLM: 530/351.000
 INCL
        INCLS: 424/085.100
 NCL
        NCLM:
                530/351.000
               424/085.100
        NCLS:
 IC
        [7]
        ICM: C07K014-475
        ICS: A61K038-19
EXF
        530/351; 424/85.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L.5
      ANSWER 166 OF 196 USPATFULL ON STN
ΑN
        2002:300827
                     USPATFULL
ΤI
        Methods and compositions for treating secondary tissue damage and other
        inflammatory conditions and disorders
ΙN
        McDonald, John R., Calgary, AB, UNITED STATES
        Coggins, Philip J., Calgary, AB, UNITED STATES US 2002168370 A1 20021114
PΙ
ΑI
        US 2001-792793
                                  20010222 (9)
                            A1
        Division of Ser. No. US 1999-453851, filed on 2 Dec 1999, PENDING Division of Ser. No. US 1999-360242, filed on 22 Jul 1999, PENDING
RLI
        Continuation of Ser. No. US 1998-120523, filed on 22 Jul 1998, ABANDONED
PRAI
        WO 1999-CA659
                             19990721
        US 1998-155186P
                             19980722 (60)
DT
        Utility
FS
        APPLICATION
LN.CNT 7972
INCL
        INCLM: 424/178.100
        INCLS: 514/012.000; 530/389.100; 536/023.530; 435/069.100; 435/320.100;
               435/325.000
NCL
               424/178.100
        NCLM:
               514/012.000; 530/389.100; 536/023.530; 435/069.100; 435/320.100;
        NCLS:
               435/325.000
IC
        [7]
        ICM: A61K039-395
        ICS: C07H021-04; C12P021-02; C12N005-06; C07K016-46
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L5
     ANSWER 167 OF 196 USPATFULL ON STN
AN
        2002:300807
                     USPATFULL
       Methods for treating disorders of neuronal deficiency with bone
TI
       marrow-derived cells
IN
       Brazelton, Timothy R., Cupertino, CA, UNITED STATES
       Blau, Helen M., Menlo Park, CA, UNITED STATES
PI
       US 2002168350
                                 20021114
                            Α1
       US 2001-993045
ΑI
                                 20011113 (9)
                            Α1
PRAI
       US 2000-247128P
                             20001110 (60)
DT
       Utility
FS
       APPLICATION
LN.CNT 1696
INCL
       INCLM: 424/093.210
       INCLS: 424/093.700
NCL
       NCLM: 424/093.210
```

ICS: A61K038-17

```
NCLS: 424/093.700
        [7]
 IC
        ICM: A61K048-00
      ANSWER 168 OF 196 USPATFULL ON STN
 L5
 ΑN
        2002:251234 USPATFULL
TI
        14087, a novel serine protease molecule and uses therefor
 TN
        Meyers, Rachel, Newton, MA, UNITED STATES
 PI
        US 2002137181
                                 20020926
                            Α1
        US 2001-910151
ΑI
                            Α1
                                 20010718 (9)
        US 2000-219022P
PRAI
                             20000718 (60)
        Utility
DT
FS
        APPLICATION
LN.CNT 4064
        INCLM: 435/226.000
INCL
        INCLS: 435/006.000; 435/091.200; 435/069.100; 435/325.000; 435/320.100;
               536/023.200
NCL
        NCLM:
               435/226.000
        NCLS:
               435/006.000; 435/091.200; 435/069.100; 435/325.000; 435/320.100;
               536/023.200
IC
        [7]
        ICM: C12Q001-68
        ICS: C07H021-04; C12N009-64; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L5
     ANSWER 169 OF 196 USPATFULL on STN
        2002:228358 USPATFULL
AN
        Thiazolyl-, oxazolyl-, pyrrolyl-, and imidazolyl-acid amide derivatives useful as inhibitors of PDE4 isozymes
TI
       Marfat, Anthony, Mystic, CT, UNITED STATES
IN
       McKechney, Michael William, Fairport, NY, UNITED STATES
PΑ
        Pfizer Inc. (U.S. corporation)
PI
       US 2002123520
                           A1
                                 20020905
        US 6559168
                           B2
                                 20030506
        US 2002-62145
ΑI
                                 20020131 (10)
                           Α1
PRAI
       US 2001-265486P
                            20010131 (60)
       Utility
DT
FS
       APPLICATION
LN.CNT 6963
       INCLM: 514/365.000
INCL
       INCLS: 514/398.000; 548/188.000; 548/323.100; 514/341.000; 514/342.000;
               546/269.700; 546/272.700
NCL
       NCLM:
               514/338.000
               514/342.000; 514/369.000; 514/370.000; 546/269.700; 548/188.000;
       NCLS:
               548/195.000; 548/196.000
IC
        [7]
       ICM: A61K031-4439
       ICS: A61K031-426; C07D417-02; C07D043-02
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 170 OF 196 USPATFULL on STN
L5
       2002:228311 USPATFULL
AN
TI
       LENTIVIRUS BASED VECTOR AND VECTOR SYSTEM
ΙN
       UBERLA, KLAUS, MOEHRENDORF, GERMANY, FEDERAL REPUBLIC OF
PT
       US 2002123471
                                 20020905
                           Α1
ΑI
       US 1999-380323
                           Α1
                                 19991122
                                          (9)
       WO 1998-EP1191
                                 19980303
       DK 1997-238
PRAI
                            19970603
DT
       Utility
FS
       APPLICATION
LN.CNT 999
INCL
       INCLM: 514/044.000
       INCLS: 424/093.100; 435/456.000; 435/320.100; 435/235.100; 536/023.100
              514/044.000
NCL
       NCLM:
              424/093.100; 435/456.000; 435/320.100; 435/235.100; 536/023.100
       NCLS:
IC
       [7]
       ICM: A61K048-00
       ICS: A01N063-00; C12N015-86; C12N007-01; C12N007-01; C07H021-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L5
     ANSWER 171 OF 196 USPATFULL ON STN
ΑN
       2002:206794 USPATFULL
TI
       Nicotinamide acids, amides, and their mimetics active as inhibitors of
       PDE4 isozymes
TN
       Magee, Thomas Victor, Mystic, CT, UNITED STATES
       Marfat, Anthony, Mystic, CT, UNITED STATES
```

```
Chambers, Robert James, Mystic, CT, UNITED STATES
 PA
         Pfizer Inc. (U.S. corporation)
 ΡI
         US 2002111495
                              Α1
                                    20020815
         US 2002-62811
 ΑI
                              Α1
                                    20020131 (10)
                                20010131 (60)
 PRAI
         US 2001-265240P
         US 1997-43403P
                                19970404 (60)
         US 1998-105120P
                                19981021 (60)
 DT
         Utility
         APPLICATION
 FS
 LN.CNT 7710
 INCL
         INCLM: 546/291.000
         INCLS:
                 546/298.000; 546/315.000
 NCL
         NCLM:
                 546/291.000
         NCLS:
                 546/298.000; 546/315.000
         [7]
 IC
         ICM: C07D213-78
         ICS: C07D213-63
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
      ANSWER 172 OF 196 USPATFULL ON STN
 L5
        2002:201650 USPATFULL
 AN
 TI
        Methods of inhibiting locomotor damage following spinal cord injury with
         .alpha. D-specific antibodies
 IN
        Gallatin, W. Michael, Mercer Island, WA, United States
        Van der Vieren, Monica, Snohomish, WA, United States ICOS Corporation, Bothell, WA, United States (U.S. corporation)
 PA
PΙ
        US 6432404
                              В1
                                    20020813
ΑI
        US 2000-688307
                                    20001013 (9)
        Continuation-in-part of Ser. No. US 1999-350259, filed on 8 Jul 1999
RLI
        Continuation of Ser. No. US 1998-193043, filed on 16 Nov 1998, now
        patented, Pat. No. US 6251395, issued on 26 Jun 2001
        Continuation-in-part of Ser. No. US 1997-943363, filed on 3 Oct 1997,
        now patented, Pat. No. US 5837478, issued on 17 Oct 1998
        Continuation-in-part of Ser. No. US 1996-605672, filed on 22 Feb 1996,
        now patented, Pat. No. US 5817515, issued on 6 Oct 1998
        Continuation-in-part of Ser. No. US 1994-362652, filed on 21 Dec 1994,
        now patented, Pat. No. US 5766850, issued on 16 Jun 1998 Continuation-in-part of Ser. No. US 1994-286889, filed on 5 Aug 1994,
        now patented, Pat. No. US 5470953, issued on 28 Nov 1995
Continuation-in-part of Ser. No. US 1993-173497, filed on 23 Dec 1993,
        now patented, Pat. No. US 5437958, issued on 1 Aug 1995
DT
        Utility
FS
        GRANTED
LN.CNT 10229
INCL
        INCLM: 424/144.100
        INCLS: 424/130.100; 424/141.100; 424/143.100; 424/153.100; 424/154.100;
                424/173.100; 530/387.100; 530/388.100; 530/388.200; 530/388.220;
                530/388.700; 530/388.730; 530/388.750
NCL
                424/144.100
        NCLM:
                424/130.100; 424/141.100; 424/143.100; 424/153.100; 424/154.100; 424/173.100; 530/387.100; 530/388.100; 530/388.200; 530/388.200; 530/388.750
        NCLS:
IC
        Γ71
        ICM: A61K039-395
        ICS: C07K016-28
EXF
        424/130.1; 424/141.1; 424/153.1; 424/143.1; 424/144.1; 424/154.1;
        424/173.1; 530/387.1; 530/388.22; 530/388.75; 530/388.1; 530/388.2; 530/388.7; 530/388.73
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L5
      ANSWER 173 OF 196 USPATFULL ON STN
ΑN
        2002:193026
                     USPATFULL
        METHOD FOR IDENTIFYING ALZHEIMER'S DISEASE THERAPEUTICS USING TRANSGENIC
TI
        ANIMAL MODELS
IN
        GAMES, KATE DORA, BELMONT, CA, UNITED STATES
        SCHENK, DALE BERNARD, BURLINGAME, CA, UNITED STATES
        MCCONLÓGUE, LISA CLAIRE, SAN FRANCISCO, CA, UNITED STATES
        SEUBERT, PETER ANDREW, SAN FRANCISCO, CA, UNITED STATES
        RYDEL, RUSSELL E., BELMONT, CA, UNITED STATES
        US 2002104104
PΙ
                             Α1
                                   20020801
ΑI
        US 1998-149718
                             Α1
                                   19980908 (9)
        Continuation-in-part of Ser. No. US 1996-660487, filed on 7 Jun 1996,
RLI
        ABANDONED Continuation-in-part of Ser. No. US 1995-480653, filed on 7
        Jun 1995, ABANDONED Continuation-in-part of Ser. No. US 1996-659797, filed on 7 Jun 1996, ABANDONED Continuation-in-part of Ser. No. US
        1995-486538, filed on 7 Jun 1995, ABANDONED
```

```
DT
         Utility
         APPLICATION
 FS
 LN.CNT
        4514
 INCL
         INCLM: 800/003.000
         INCLS: 435/354.000; 435/029.000; 800/012.000; 800/018.000
 NCL
                 800/003.000
                435/354.000; 435/029.000; 800/012.000; 800/018.000
         NCLS:
 IC
         [7]
         ICM: A01K067-027
         ICS: C12Q001-02
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L5
      ANSWER 174 OF 196 USPATFULL ON STN
 AN
         2002:191516 USPATFULL
        Diagnostics and therapeutics for ocular disorders Hageman, Gregory S., Coralville, IA, UNITED STATES Mullins, Robert F., Coralville, IA, UNITED STATES
 TI
 IN
 ΡI
         US 2002102581
                              Α1
                                    20020801
         US 2001-949261
 ΑI
                                    20010906 (9)
                              Α1
         Continuation-in-part of Ser. No. US 2000-510230, filed on 22 Feb 2000,
 RLI
         PENDING Continuation-in-part of Ser. No. US 2001-845745, filed on 30 Apr
         2001, PENDING
US 1999-120822P
PRAI
                               19990219 (60)
        US 1999-120668P
                               19990219 (60)
        US 1999-123052P
                               19990305 (60)
        US 2000-200698P
                               20000429 (60)
        Utility
DT
        APPLICATION
FS
LN.CNT 5644
        INCLM: 435/006.000
INCL
        INCLS: 435/007.200; 435/040.500
NCL
        NCLM:
                435/006.000
        NCLS:
                435/007.200; 435/040.500
IC
         [7]
        ICM: C12Q001-68
        ICS: G01N033-53; G01N033-567
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
      ANSWER 175 OF 196 USPATFULL on STN
L5
        2002:185609 USPATFULL
ΑN
TI
        Method and marker for the isolation of
                                                      ***human***
                                                                      multipotent
        hematopoietic stem cells
        Bonnet, Dominique, Finsbury, UNITED KINGDOM
Danet, Guenahel H., Philadelphia, PA, UNITED STATES
IN
        US 2002098521
PI
                             Α1
                                   20020725
ΑI
        US 2001-982473
                                   20011018 (9)
                             Α1
        US 2000-241253P
PRAI
                              20001018 (60)
DT
        Utility
FS
        APPLICATION
LN.CNT 713
INCL
        INCLM: 435/007.200
        INCLS: 435/372.000
NCL
               435/007.200
        NCLM:
        NCLS:
               435/372.000
TC
        [7]
        ICM: G01N033-53
        ICS: G01N033-567; C12N005-08
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L5
     ANSWER 176 OF 196 USPATFULL ON STN
ΑN
        2002:185271 USPATFULL
TI
        Pharmaceutical combinations
IN
        Brearley, Christopher John, Sandwich, UNITED KINGDOM
        Butler, Paul, Sandwich, UNITED KINGDÓM
        Chahwala, Suresh Babubhai, Sandwich, UNITED KINGDOM
        Chopp, Michael, Sandwich, UNITED KINGDOM
        Krams, Michael, Sandwich, UNITED KINGDOM
        Looby, Michael, Sandwich, UNITED KINGDOM
        MacIntyre, Fiona, Sandwich, UNITED KINGDOM
        McElroy, Andrew Brian, Sandwich, UNITED KINGDOM
       McHarg, Aileen Dorothy, Sandwich, UNITED KINGDOM US 2002098179 A1 20020725
PΙ
                                   20020725
ΑI
       US 2001-969271
                                   20011001 (9)
                             Α1
PRAI
       GB 2000-25473
                              20001017
       US 2000-253847P
                              20001129 (60)
DT
       Utility
```

```
APPLICATION
 LN.CNT 3309
 INCL
        INCLM: 424/094.640
        INCLS: 514/012.000
 NCL
                424/094.640
        NCLM:
        NCLS:
                514/012.000
        [7]
 IC
        ICM: A61K038-48
        ICS: A61K038-17
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L5
      ANSWER 177 OF 196 USPATFULL ON STN
 ΑN
        2002:174981 USPATFULL
 TI
        18232, a novel dual specificity phosphatase and uses therefor
        Meyers, Rachel A., Newton, MA, United States
Weich, Nadine, Brookline, MA, United States
 IN
        Millennium Pharmaceuticals, Inc., Cambridge, MA, United States (U.S.
 PA
        corporation)
PI
        US 6420153
                                  20020716
        US 2000-704139
AΙ
                                  20001101 (9)
PRAI
        US 2000-185772P
                             20000229 (60)
        Utility
DT
FS
        GRANTED
LN.CNT
        4450
        INCLM: 435/196.000
INCL
        INCLS: 435/252.300; 435/320.100; 435/325.000; 536/023.200; 536/023.100;
                536/024.100
NCL
        NCLM:
               435/196.000
        NCLS:
               435/252.300; 435/320.100; 435/325.000; 536/023.100; 536/023.200;
               536/024.100
IC
        [7]
        ICM: C12N009-16
        ICS: C12N001-20; C12N005-00; C07H021-02; C07H021-04
EXF
        435/196; 435/252.3; 435/320.1; 435/325; 536/23.2; 536/23.1; 536/24.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L5
     ANSWER 178 OF 196 USPATFULL ON STN
AN
        2002:148641 USPATFULL
TI
                          ***human***
        40322, a novel
                                         dynamin
IN
        Meyers, Rachel, Newton, MA, UNITED STATES
ΡI
        US 2002076784
                                  20020620
                           A1
ΑI
        us 2001-796100
                            Α1
                                 20010228 (9)
PRAI
        US 2000-185503P
                             20000228 (60)
DT
       Utility
       APPLICATION
FS
LN.CNT 4407
INCL
        INCLM: 435/195.000
        INCLS: 435/006.000; 435/007.100; 435/069.100; 435/325.000; 536/023.200
NCL
               435/195.000
       NCLM:
       NCLS:
               435/006.000; 435/007.100; 435/069.100; 435/325.000; 536/023.200
IC
        [7]
       ICM: C12N009-14
        ICS: C12Q001-68; G01N033-53; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L5
     ANSWER 179 OF 196 USPATFULL ON STN
       2002:133852 USPATFULL
ΑN
TI
       20685, 579, 17114, 23821, 33894 and 32613, novel
                                                              ***human***
       transporters
ΙN
       Glucksmann, Maria Alexandra, Lexington, MA, UNITED STATES
PA
       Millennium Pharmaceuticals, Inc. (U.S. corporation) US 2002068710 A1 20020606
PΙ
ΑI
       us 2001-795693
                                 20010228 (9)
                            Α1
PRAI
       US 2000-185906P
                             20000229 (60)
DT
       Utility
FS
       APPLICATION
LN.CNT 8073
       INCLM: 514/044.000
INCL
       INCLS: 514/012.000; 424/139.100
NCL
       NCLM:
               514/044.000
               514/012.000; 424/139.100
       NCLS:
IC
       [7]
       ICM: A61K031-70
       ICS: A01N043-04; A61K038-00; A61K039-395; A61K039-40; A61K039-42
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
```

```
ANSWER 180 OF 196 USPATFULL ON STN 2002:120019 USPATFULL
 L5
 ΑN
                  ***HUMAN***
 TI
         NOVEL
                                  BETA2 INTEGRIN ALPHA SUBUNIT
         GALLATIN, W. MICHAEL, MERCER ISLAND, WA, UNITED STATES
 IN
         VAN DER VIEREN, MONICA, SEATTLE, WA, UNITED STATES
 PΙ
         US 2002062008
                               Α1
                                     20020523
         US 6620915
                               В2
                                     20030916
         US 1999-350259
 ΑI
                               Α1
                                     19990708 (9)
         Continuation of Ser. No. US 1998-193043, filed on 16 Nov 1998, GRANTED,
 RLI
         Pat. No. US 6251395 Continuation-in-part of Ser. No. US 1997-943363,
         filed on 3 Oct 1997, GRANTED, Pat. No. US 5837478 Continuation-in-part
         of Ser. No. US 1996-605672, filed on 22 Feb 1996, GRANTED, Pat. No. US
         5817515 Continuation-in-part of Ser. No. US 1994-362652, filed on 21 Dec
        1994, GRANTED, Pat. No. US 5766850 Continuation-in-part of Ser. No. US 1994-286889, filed on 5 Aug 1994, GRANTED, Pat. No. US 5470953 Continuation-in-part of Ser. No. US 1993-173497, filed on 23 Dec 1993,
         GRANTED, Pat. No. US 5437958
DT
         Utility
FS
         APPLICATION
LN.CNT 9847
         INCLM: 530/387.300
INCL
         INCLS: 530/388.220; 530/388.730
NCL
         NCLM:
                 530/387.300
                530/387.100; 530/387.300; 530/388.100; 530/388.200; 530/388.220; 530/388.700; 435/326.000; 435/328.000; 435/332.000; 435/334.000; 435/343.000; 435/343.000;
IC
         [7]
        ĬCM: C07K016-00
        ICS: G01N033-567; C12P021-08
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L5
      ANSWER 181 OF 196 USPATFULL on STN
        2002:48008 USPATFULL
AN
TI
        Neuroprotective, antithrombotic and anti-inflammatory uses of activated
        protein C (APC)
IN
        Griffin, John H., Del Mar, CA, UNITED STATES
        Zlokovic, Berislav Y., Rochester, NY, UNITED STATES
PΙ
        US 2002028199
                              Α1
                                    20020307
ΑI
        US 2001-777484
                                    20010205 (9)
                              Α1
        US 2000-180227P
PRAI
                               20000204 (60)
        Utility
DT
        APPLICATION
FS
LN.CNT 1433
INCL
        INCLM: 424/094.630
        INCLS: 514/258.000; 514/165.000
NCL
        NCLM:
                424/094.630
        NCLS:
                514/258.000; 514/165.000
IC
        [7]
        ICM: A61K038-48
        ICS: A61K031-60; A61K031-519
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 182 OF 196 USPATFULL on STN
L5
        2002:13912 USPATFULL
AN
          ***Human***
TI
                          cell lines
IN
        Stringer, Bradley Michael John, Cardiff, UNITED KINGDOM
        CellFactors plc, Cambridge, UNITED KINGDOM (non-U.S. corporation)
PA
        US 6340592
US 2000-694203
PI
                              В1
                                    20020122
ΑI
                                    20001023 (9)
        Division of Ser. No. US 1999-390161, filed on 3 Sep 1999, now patented,
RLI
        Pat. No. US 6197585 Continuation of Ser. No. US 836440, now abandoned
PRAI
        GB 1994-22523
                               19941108
        GB 1995-10555
                               19950524
DT
        Utility
FS
        GRANTED
LN.CNT 932
INCL
        INCLM: 435/372.000
        INCLS: 435/325.000; 435/366.000; 435/375.000; 435/440.000; 435/455.000;
                435/467.000; 536/023.100; 536/023.700; 536/023.720
NCL
        NCLM:
                435/372.000
                435/325.000; 435/366.000; 435/375.000; 435/440.000; 435/455.000; 435/467.000; 536/023.100; 536/023.700; 536/023.720
        NCLS:
IC
        ICM: C12N015-85
        ICS: C12N015-00; C12N015-11; C07H021-04
        435/6; 435/69.1; 435/91.1; 435/440; 435/455; 435/467; 435/325; 435/366;
EXF
```

```
435/368; 435/372; 435/375; 435/320.1; 536/23.1; 536/23.7; 536/23.72
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 183 OF 196 USPATFULL ON STN
L5
       2002:12239 USPATFULL
ΑN
                                     ***human***
       Methods for using 20893, a
                                                    protein kinase
ΤI
       Galvin, Katherine M., Jamaica Plain, MA, UNITED STATES
IN
       Kapeller-Libermann, Rosana, Chestnut Hill, MA, UNITED STATES
       Weich, Nadine S., Brookline, MA, UNITED STATES
       us 2002006618
                                20020117
                           Α1
PI
       US 2001-780949
US 2000-181690P
                                20010209 (9)
                           Α1
AΙ
                            20000209 (60)
PRAI
       Utility
DT
       APPLICATION
FS
LN.CNT 4723
       INCLM: 435/006.000
INCL
       INCLS: 435/004.000
              435/006.000
NCL
       NCLM:
       NCLS:
              435/004.000
       [7]
IC
       ICM: C12Q001-68
       ICS: C12Q001-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L5
     ANSWER 184 OF 196 USPATFULL ON STN
       2001:223926 USPATFULL
AN
         ***Human***
ΤI
                        cell-lines
       Stringer, Bradley Michael John, Cyncoed, Great Britain
ΙN
PΙ
       US 2001049143
                                20011206
                           Α1
AΙ
       us 2001-837561
                           Α1
                                20010418 (9)
       Continuation of Ser. No. US 2000-693597, filed on 20 Oct 2000, PENDING
RLI
                            19941108
PRAI
       GB 1994-22523
       GB 1995-10555
                            19950524
       Utility
DT
FS
       APPLICATION
LN.CNT 928
INCL
       INCLM: 435/455.000
       INCLS: 435/456.000; 435/366.000
              435/455.000
NCL
       NCLM:
              435/456.000; 435/366.000
       NCLS:
       [7]
IC
       ICM: C12N015-86
       ICS: C12N005-08
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 185 OF 196 USPATFULL ON STN
L5
       2001:212136 USPATFULL
ΑN
       39406 protein, a novel seven transmembrane protein
ΤI
       Glucksmann, Maria Alexandra, Lexington, MA, United States
IN
       Galvin, Katherine M., Jamaica Plain, MA, United States
       Millennium Pharmaceuticals, Inc (U.S. corporation) US 2001044130 A1 20011122
PA
PΙ
       US 2001044130
                           Α1
       us 2001-779239
ΑI
                           Α1
                                20010208 (9)
PRAI
       US 2000-180912P
                            20000208 (60)
DT
       Utility
FS
       APPLICATION
LN.CNT 4199
INCL
       INCLM: 435/069.100
       INCLS: 435/325.000; 536/023.500; 530/350.000
NCL
       NCLM:
              435/069.100
              435/325.000; 536/023.500; 530/350.000
       NCLS:
IC
       ICM: C12P021-02
       ICS: C12N005-06; C07H021-04; C07K014-705
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 186 OF 196 USPATFULL on STN
L5
       2001:40462 USPATFULL
ΑN
TT
       Pharmaceutical preparations of glutathione and methods of administration
       thereof
IN
       Demopoulos, Harry B., Scarsdale, NY, United States
       Seligman, Myron L., Fairfield, CT, United States
PA
       Antioxidant Pharmaceuticals Corp., Elmsford, NY, United States (U.S.
       corporation)
PT
       us 6204248
                           В1
                                20010320
       us 1999-457642
ΑI
                                19991209 (9)
```

```
Continuation of Ser. No. US 331947 Continuation of Ser. No. US 1997-2100, filed on 31 Dec 1997, now abandoned US 1996-34101P 19961231 (60)
 RLI
 PRAI
         Utility
 DT
 FS
         Granted
 LN.CNT 5144
         INCLM: 514/021.000
 INCL
         INCLS: 514/018.000
 NCL
         NCLM:
                 514/021.000
         NCLS:
                 514/018.000
         [7]
         ICM: A61K031-00
         514/21; 514/18
 EXF
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
      ANSWER 187 OF 196 USPATFULL ON STN
 L5
 AN
         2001:33082
                      USPATFULL
           ***Human***
 TI
                           cell-lines
 IN
         Stringer, Bradley Michael John, Cardiff, United Kingdom
 PA
         CellFactors plc, Cambridge, United Kingdom (non-U.S. corporation)
         US 6197585
US 1999-390161
 PΙ
                              в1
                                    20010306
 ΑI
                                    19990903 (9)
         Continuation of Ser. No. US 836440, now abandoned
 RLI
         GB 1994-22523
 PRAI
                                19941108
         GB 1995-10555
                                19950524
         Utility
 DT
         Granted
 FS
 LN.CNT
        934
 INCL
         INCLM: 435/368.000
         INCLS: 435/325.000; 435/366.000; 435/375.000; 435/440.000; 435/455.000;
                 435/467.000; 536/023.100; 536/023.700; 536/023.720
NCL
        NCLM:
                 435/368.000
                 435/325.000; 435/366.000; 435/375.000; 435/440.000; 435/455.000;
        NCLS:
                 435/467.000; 536/023.100; 536/023.700; 536/023.720
IC
         ICM: C12N015-85
        ICS: C12N015-00; C12N015-11; C07H021-04
435/6; 435/69.1; 435/91.1; 435/440; 435/455; 435/325; 435/366; 435/368;
435/372; 435/375; 435/320.1; 435/467; 536/23.1; 536/23.72; 536/23.7
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L.5
      ANSWER 188 OF 196 USPATFULL ON STN
AN
        2001:21755 USPATFULL
TI
        Cancer immunotherapy with semi-allogeneic cells
IN
        Cohen, Edward P., Chicago, IL, United States
        Research Corporation Technologies, Inc., Tucson, AZ, United States (U.S.
PA
        corporation)
PΤ
        US 6187307
                              в1
                                    20010213
ΑТ
        US 1998-16528
                                    19980130 (9)
        US 1997-36620P
PRAI
                               19970131 (60)
DT
        Utility
FS
        Granted
LN.CNT
        2184
        INCLM: 424/093.210
INCL
        INCLS: 424/093.710; 435/455.000; 435/372.000; 435/366.000; 435/325.000;
                536/023.500
NCL
                424/093.210
        NCLM:
        NCLS:
                424/093.710; 435/325.000; 435/366.000; 435/372.000; 435/455.000;
                536/023.500
IC
        [7]
        ICM: C12N005-10
        ICS: C12N005-08; A01N063-00
        435/325; 435/455; 435/366; 435/372; 424/93.21; 424/93.71; 536/23.5
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L5
     ANSWER 189 OF 196 USPATFULL ON STN
AN
        1999:142115 USPATFULL
TI
        Stem cell proliferation factor
ΙN
        Lawman, Michael J. P., Gainesville, FL, United States
        Lawman, Patricia D., Gainesville, FL, United States
        Denslow, Nancy D., Gainesville, FL, United States
University of Florida, Gainesville, FL, United States (U.S. corporation)
PA
PΙ
        US 5981708
                                   19991109
ΑI
        US 1997-889228
                                   19970708 (8)
       Division of Ser. No. US 1994-319165, filed on 6 Oct 1994, now patented,
RLI
        Pat. No. US 5650299 which is a continuation-in-part of Ser. No. US
```

```
1993-132994, filed on 6 Oct 1993, now abandoned
 DT
         Utility
 FS
         Granted
 LN.CNT 2476
 INCL
         INCLM: 530/351.000
         INCLS: 530/300.000; 435/069.100; 435/325.000
 NCL
                 530/351.000
                435/069.100; 435/325.000; 530/300.000
         NCLS:
         [6]
 IC
         ICM: C07K014-52
 EXF
         530/350; 530/351; 530/300; 435/69.1; 435/325
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 L5
      ANSWER 190 OF 196 USPATFULL ON STN
 ΑN
         1999:96476
                     USPATFULL
         Methods of treating inflammation and compositions therefor
 TI
 IN
         McFadden, D. Grant, Edmonton, Canada
         Lucas, Alexandra, Edmonton, Canada
 PA
        Viron Therapeutics, Inc., London, Canada (non-U.S. corporation)
ΡI
        US 5939525
                                    19990817
        US 1995-411043
ΑI
                                    19950327 (8)
        Utility
DT
FS
        Granted
LN.CNT
        2356
        INCLM: 530/324.000 INCLS: 514/021.000
INCL
                530/324.000
NCL
        NCLM:
IC
         [6]
        ICM: A61K038-16
EXF
         514/21; 530/324
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L5
      ANSWER 191 OF 196 USPATFULL ON STN
        1999:75756 USPATFULL
AN
        Modified hookworm neutrophil inhibitors
ΤI
ΙN
        Moyle, Matthew, Escondido, CA, United States
        Foster, David L., Brighton, MA, United States
PA
        Corvas International, Inc., San Diego, CA, United States (U.S.
        corporation)
PΙ
        US 5919900
                                    19990706
ΑI
        US 1995-450497
                                   19950526 (8)
        Division of Ser. No. US 1993-173510, filed on 23 Dec 1993 which is a continuation-in-part of Ser. No. US 1993-151064, filed on 10 Nov 1993
RLI
        which is a continuation-in-part of Ser. No. US 1993-60433, filed on 11 May 1993 which is a continuation-in-part of Ser. No. US 1992-996972,
        filed on 24 Dec 1992 which is a continuation-in-part of Ser. No. US
        1992-881721, filed on 11 May 1992, now abandoned
        Utility
DT
FS
        Granted
LN.CNT
        5740
INCL
        INCLM: 530/350.000
        INCLS: 435/069.100; 435/172.100
                530/350.000
NCL
        NCLM:
               435/069.100
        NCLS:
IC
        [6]
        ICM: C07K014-435
        ICS: C12N015-01
EXF
        435/69.1; 435/172.1; 530/350
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
     ANSWER 192 OF 196 USPATFULL ON STN
L5
ΑN
        1999:72706 USPATFULL
        Methods of treating inflammation and compositions therefor McFadden, D. Grant, Edmonton, Canada
TI
ΙN
        Lucas, Alexandra, Edmonton, Canada
PA
        Viron Therapeutics, Inc., London, Canada (non-U.S. corporation)
                                   19990629
PΙ
        us 5917014
ΑI
        us 1995-468865
                                   19950606 (8)
RLI
        Continuation of Ser. No. US 1995-411043, filed on 27 Mar 1995
        Utility
DT
        Granted
LN.CNT 2074
INCL
        INCLM: 530/324.000
               514/021.000
        INCLS:
NCL
               530/324.000
        NCLM:
TC
        [6]
```

```
ICM: A61K038-16
514/21; 530/324
 EXF
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
       ANSWER 193 OF 196 USPATFULL ON STN
          1998:162339 USPATFULL
 ΑN
 TI
          Murine and humanizer 23F2G antibodies and cell lines expressing said
          antibodies
 IN
          Rose, Lynn M., Seattle, WA, United States
 PA
          ICOS Corporation, Bothell, WA, United States (U.S. corporation)
          Board of Regents of the University of Washington, Seattle, WA, United
          States (U.S. corporation)
 PΙ
          US 5854070
                                         19981229
          US 1997-785571
 ΑI
                                         19970121 (8)
          Continuation of Ser. No. US 1995-396089, filed on 28 Feb 1995, now
 RLI
          abandoned which is a continuation of Ser. No. US 1993-94535, filed on 16
          Jul 1993, now abandoned which is a continuation-in-part of Ser. No. US
          1993-60699, filed on 10 May 1993, now abandoned which is a continuation of Ser. No. US 1992-915068, filed on 16 Jul 1992, now abandoned
 DT
          Utility
 FS
          Granted
 LN.CNT 1524
          INCLM: 435/343.200
 INCL
         INCLS: 435/343.000; 435/343.100; 435/326.000; 435/328.000; 435/346.000; 435/358.000; 435/334.000; 530/387.100; 530/387.300; 530/388.100; 530/388.200; 530/388.220; 530/388.700; 530/388.730; 530/388.750
NCL
                  435/326.000; 435/328.000; 435/334.000; 435/343.000; 435/343.100; 435/346.000; 435/358.000; 530/387.100; 530/387.300; 530/388.100; 530/388.200; 530/388.200; 530/388.700; 530/388.730; 530/388.750
         NCLS:
IC
          [6]
          ICM: C07K016-18
         ICS: C07K016-28; C12N005-12
EXF
         435/70.21; 435/172.2; 435/334; 435/343.2; 530/387.1; 530/388.2;
          530/388.73
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
L5
       ANSWER 194 OF 196 USPATFULL ON STN
ΑN
         1998:147225
                         USPATFULL
TI
         Methods for enriching specific cell-types by density gradient
         centrifugation
         Van Vlasselaer, Peter, Sunnyvale, CA, United States
Activated Cell Therapy, Inc., Mountain View, CA, United States (U.S.
ΙN
PA
         US 5840502
PΙ
                                        19981124
ΑI
         US 1994-299467
                                        19940831 (8)
         Utility
DT
FS
         Granted
LN.CNT
         2018
INCL
         INCLM: 435/007.210
         INCLS: 210/781.000; 210/782.000; 435/002.000; 435/007.230; 435/007.240; 435/803.000; 436/514.000; 436/518.000; 436/527.000; 436/824.000; 422/072.000; 422/101.000; 422/102.000
NCL
         NCLM:
                  435/007.210
                  210/781.000; 210/782.000; 422/072.000; 422/101.000; 422/102.000; 435/002.000; 435/007.230; 435/007.240; 435/803.000; 436/514.000;
         NCLS:
                  436/518.000; 436/527.000; 436/824.000
IC
         [6]
         ICM: G01N033-567
         ICS: B01L011-00
         210/781; 210/782; 435/2; 435/7.21; 435/7.23; 435/7.24; 435/803; 436/514; 436/518; 436/527; 436/824; 422/72; 422/101; 422/102
FXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
      ANSWER 195 OF 196 USPATFULL ON STN
L5
AN
         1998:48215 USPATFULL
         Method of detecting neutophil inhibitory factor mimics
TI
         Moyle, Matthew, Escondido, CA, United States
TN
         Foster, David L., Brighton, MA, United States
         Vlasuk, George P., Carlsbad, CA, United States
         Corvas International, Inc., San Diego, CA, United States (U.S.
PA
         corporation)
         us 5747296
PT
                                        19980505
         US 1993-173510
ΑI
                                        19931223 (8)
        Continuation-in-part of Ser. No. US 1993-151064, filed on 10 Nov 1993
RLI
        which is a continuation-in-part of Ser. No. US 1993-60433, filed on 11
```

```
May 1993 which is a continuation-in-part of Ser. No. US 1992-996972,
         filed on 24 Dec 1992 which is a continuation-in-part of Ser. No. US
         1992-881721, filed on 11 May 1992, now abandoned
DT
         Utility
         Granted
FS
LN.CNT 5069
INCL
         INCLM: 435/072.000
         INCLS: 435/007.100; 435/007.900; 435/007.920; 424/851.000; 424/327.000; 424/527.000; 514/002.000; 514/008.000; 530/351.000; 530/355.000
         NCLM:
                  435/007.200
NCL
                  424/085.100; 435/007.100; 435/007.900; 435/007.920; 514/002.000; 514/008.000; 530/351.000; 530/355.000
         NCLS:
         [6]
IC
         ICM: G01N033-53
         ICS: A61K039-002; C07K014-44
         424/85.1; 424/327; 424/527; 514/2; 514/8; 530/351; 530/395; 435/7.1; 435/7.9; 435/7.92; 435/7.2
EXF
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
      ANSWER 196 OF 196 USPATFULL ON STN
L5
         97:63902 USPATFULL
AN
         Cells producing stem cell proliferation factor
Lawman, Michael J. P., Orlando, FL, United States
ΤI
ΙN
         Lawman, Patricia D., Orlando, FL, United States
         Denslow, Nancy D., Gainesville, FL, United States
The University of Florida, Gainesville, FL, United States (U.S.
PΑ
         corporation)
         US 5650299
                                        19970722
PΙ
```

STN INTERNATIONAL LOGOFF AT 16:05:05 ON 10 OCT 2003